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Vascular endothelial dysfunction plays a major role in the pathogenesis of 
atherosclerosis. As such, the study of endothelial cells has sought to identify causal 
pathways and novel therapeutic approaches to promote vascular repair. Induced 
pluripotent stem (iPS) cell technology may be a particularly useful tool, and could be 
used to derive endothelial cells and their progenitors from individuals with 
endothelial dysfunction to explore these pathways and develop novel strategies for 
vascular regeneration. Whilst iPS cells are conventionally obtained from the 
reprogramming of dermal fibroblasts, it was hypothesised that endothelial cells could 
also be reprogrammed, and that these pluripotent cells would have enhanced capacity 
for endothelial differentiation and vascular regeneration. 
Objectives:  
To generate iPS cells from human fibroblasts and endothelial cells and to assess their 
potential for endothelial differentiation and vascular regeneration. 
Methods and Results:  
A) Reprogramming: Dermal fibroblasts and endothelial outgrowth cells from blood 
were obtained from healthy donors (n=5) and transfected with episomal vectors 
containing six reprogramming factors: Sox2, Klf4, Oct3/4, L-Myc, Lin28 and Shp53. 
Successfully reprogrammed fibroblast-derived iPS (fiPS) and endothelial cell-
derived iPS (eiPS) arose as colonies, and were isolated and expanded. 
Reprogrammed cells expressed pluripotency markers SSEA3, SSEA4, TRA 1 60, 
Oct3/4 and NANOG, and developed into all three germ layers following embryoid 
body formation. B) Endothelial differentiation: iPS and ES cell lines were 
aggregated into embryoid bodies in stem cell growth media containing mesoderm-
inducing cytokines. Embryoid bodies were then disaggregated and cultured in 
endothelial medium supplemented with VEGF. After seven days, a population of 
CD31+ cells was isolated and further cultured. Mature endothelial cell antigen 
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expression was confirmed by flow cytometry. CD31+ cells were similar to mature 
endothelial cells in functional assays of proliferation, migration, nitric oxide 
production and angiogenesis. C) Comparison of fiPS versus eiPS: eiPS differentiated 
into endothelial cells with greater efficiency than fiPS (21±3% versus 3±2%, P<0.05). 
fiPS-derived endothelial cells and eiPS-derived endothelial cells expressed similar 
levels of endothelial markers CD146, CD31, VEFGR2 and CD34 compared to 
control endothelial cells. When grown on Matrigel, they formed tubule-like 
structures with a similar number of vessel connections. In vivo, endothelial cells 
derived from fiPS and eiPS increased neovasculogenesis in a nude mouse model: 
vessel density was increased after implantation of endothelial cells from fiPS and 
eiPS by 3.50 vessel counts (P≤0.001) and 3.47 vessel counts (P≤0.001) respectively, 
when compared to controls. By comparison control endothelial cells did not increase 
vessel density compared to control (P>0.05). 
Conclusions:  
Endothelial cells can be isolated from blood and reprogrammed to form pluripotent 
stem cells with enhanced capacity to differentiate into endothelial cells than those 
derived from dermal fibroblasts. Endothelial cells derived from both sources promote 
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The genetic factors predisposing individuals to atherosclerosis, a major cause of 
coronary heart disease, are poorly understood. Deficiencies in endothelial cell 
function play a role in the genetic basis of coronary artery disease. Studies of the 
endothelium from patients with premature atherosclerosis (occurring before age is 
considered a risk factor: men under 45 and women under 55; National Heart Lung 
and Blood Institute) include ‘non-invasive clinical investigations’, for example flow-
mediated dilation of the brachial artery in response to endothelium-dependent 
vasoactive factors, or detection of biomarkers in peripheral blood (Wong, 2012). 
However, whilst informative, these techniques give little insight into the molecular 
and cellular mechanisms behind endothelial dysfunction. Studies of endothelial cells 
in vitro allow more in depth phenotypic, genomic and functional analyses. The scope 
of in vitro endothelial cell research has been expanded by the generation of 
endothelial cells from pluripotent stem cells (both embryonic and induced), which 
provide a long-term, renewable, expandable and bankable source of endothelial cells 
(Reed et al., 2013). Induced pluripotent stem cell technology has the potential to 
generate patient-specific endothelial cells for in vitro disease modelling, with the 
hope of elucidating genetic causes of endothelial cell dysfunction. Moreover, it 
represents a population of cells with the potential for novel vascular regenerative 




1.2 The role of endothelial dysfunction in atherosclerosis  
 
The most common cause of premature death in the UK is coronary heart disease, 
responsible for 74,000 deaths per year (British Heart Foundation). In the majority of 
cases, coronary heart disease is preceded by atherosclerosis, a complex multi-
factorial condition involving inflammation and plaque formation in arterial blood 
vessels (Hansson, 2005). Multiple environmental risk factors for atherosclerosis are 
well characterised, including smoking, hypertension, exposure to pollution, and a 
cholesterol-rich diet. However, individuals not exposed to these factors, but with a 
first degree relative who has coronary artery disease are also at risk of developing the 
condition, indicating a hereditary component (Mayer et al., 2007). Though this is less 
well understood than the environmental risk factors, genome wide association studies 
suggest that pathogenesis of the disease could be potentiated in part by defects in 
endothelial cell function (reviewed by Damani and Topol, 2007). 
 
1.2.1  Vascular endothelium 
 
The endothelium, a monolayer of cells lining blood vessels, plays a critical role in 
vascular health. It was initially considered an interface between the blood and 
surrounding connective tissue (Florey, 1966), but its importance in the regulation and 
maintenance of vascular homeostasis has since been realised. The endothelium 
releases vasoactive factors for dilation or constriction of the vessel in response to 
changes in blood flow, shear stress or circulating humoral factors (Cines et al, 1998). 
A key endothelial vasodilator is nitric oxide, which has multiple ‘anti-atherogenic’ 
effects. Nitric oxide (NO) regulates vessel wall permeability, inhibits platelet 
aggregation and adhesion of leukocytes to the vessel wall, and prevents smooth 
muscle cell proliferation (Kawashima, 2004). The endothelium also regulates 
inflammatory processes (e.g., the expression of surface adhesion molecules on 
activated endothelial cells attract leukocytes) and thrombogenesis (the production of 
prostaglandins to prevent platelet aggregation and clot formation) (Deanfield et al., 
2007). The post-natal endothelium is typically quiescent in mature adults, with little 
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cell turnover (Cines et al., 1998), although it retains an ability to undergo 
remodelling in response to changing functional demand, through the formation of 
new vessels (neovasculogenesis), and the growth of new vessels from pre-existing 
ones (angiogenesis) (Davis et al., 2011).  
Various factors threaten endothelial health, for example exposure to free radicals 
caused by cigarette smoking, elevated circulating low-density lipoprotein (LDL) or 
plasma homocysteine concentrations, hypertension, and/or genetic alterations (Ross, 
1999). The integrity of the endothelium depends, not only on the extent of injury, but 
also on its capacity for regeneration and repair. Persistent endothelial cell injury can 
lead to increased expression of adhesion molecules and synthesis of pro-
inflammatory or pro-thrombotic factors; this disrupts endothelial homeostasis and 
can ultimately manifest as vascular disease (Widlansky et al., 2003).  
 
1.2.2  Pathophysiology of atherosclerosis 
 
It is widely accepted that endothelial cell dysfunction following chronic endothelial 
injury is one of the earliest events in the pathogenesis of atherosclerosis (Davignon et 
al., 2004; Celermajer et al., 1997). A major effect of endothelial dysfunction is loss 
of endothelium-dependent dilation, due in part to decreased nitric oxide synthesis 
(Sitia et al., 2010). Due to its diverse physiological functions, a decrease in NO 
bioavailability has widespread effects. For example, one of the consequences of 
reduced NO bioavailability is increased permeability of the vessel wall, an 
attenuation of NO’s actions to decrease permeability of the endothelium (John et al, 
2001; Wever et al., 1998). It has been theorised that this allows infiltration of low-
density lipoprotein (LDL) particles into the vessel intima (Cardona-Sanclemente and 
Born, 1995). These particles become oxidised by factors released from the 
endothelium, prompting a local inflammatory response (Hansson and Libby, 2006). 
Platelets adhere to ‘activated’ endothelial cells, which attract circulating monocytes 
that diffuse into the intima. The latter develop into macrophages which digest 
oxidised LDL and are gradually converted into large lipid-rich foam cells 
(Choudhury et al., 2005). Meanwhile, smooth muscle cells proliferate and migrate 
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from the media to the intima in response to cytokines secreted by the endothelium, 
where they form a fibrous cap over the fibro-fatty atheroma, made up of lipid debris 
and migrated inflammatory cells (Gomez and Owens, 2012). The inflammatory 
response is propagated by apoptosis of foam cells, which can form a necrotic core. If 
plaque growth continues over time, the artery becomes occluded, and can be prone to 
rupture depending of the stability of the fibrous cap (Newby and Zaltsman, 1999). 
This can lead to complete arterial occlusion, preventing blood flow to the areas of the 
heart supplied by that vessel, leading to myocardial ischaemia and infarction. 
 
1.2.3  Genetic basis of atherosclerosis  
 
Atherosclerosis can develop in the absence of environmental risk factors, suggesting 
there is likely to be a hereditary component to the disease. Indeed, a history of 
premature coronary artery disease in a first degree relative is an independent risk 
factor for coronary heart disease (Shea et al., 1984; Myers et al., 1990; Grech et al., 
1992). A group of individuals whose only major cardiovascular risk factor was 
family history were found to have dysfunctional endothelium (indicated by impaired 
endothelium-dependent flow mediated dilation) in a study by Clarkson et al. (1997). 
These patients likely had genetic risk factors predisposing them to subsequent arterial 
disease, and may have an inherited abnormality of the vessel wall, or increased 
vulnerability to circulating risk factors. 
Genome wide association studies, which identify DNA sequence variations 
associated with risk of disease development, show that atherosclerosis is a polygenic 
condition, as there are multiple candidate genes that contribute to disease 
susceptibility (Lusis et al., 2012). Though the genetic causes of atherosclerosis are 
poorly understood, these candidate genes provide insight into the molecular 
pathways which, if dysfunctional, lead to the pathogenesis of atherosclerosis. Some 
of these pathways are those involved in lipid metabolism, vascular homeostasis, 
coagulation of inflammatory factors, thrombolysis and endothelial cell function 
(Alavantic and Djuric, 2006; Damani and Topol, 2007). Genetic influence can also 
be subject to significant modulation by environmental factors, complicating an 
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individual’s atherogenic predisposition. Defective genes which lead to endothelial 
cell dysfunction (one of the earliest events in the onset of atherosclerosis) include 
those involved in NO production and release, interactions between inflammatory and 
endothelial cells, and permeability of the endothelium permitting infiltration of 
plasma constituents (Damani and Topol, 2007).  
A key pathogenic feature of atherosclerosis is impaired endothelium-dependent 
relaxation, often caused by disturbances in NO production. NO is constitutively 
produced by the endothelium from the conversion of L-arginine to L-citrulline, a 
reaction driven by the enzymatic activity of endothelial nitric oxide synthase (eNOS) 
(Cannon, 1998). Therefore, defective eNOS, leading to a reduction in NO levels, can 
result in impairment of endothelium-dependent relaxation and acceleration of lesion 
formation in atherosclerotic vessels. Meta-analyses have sought to define the 
association between polymorphisms in the eNOS gene with occurrence of 
cardiovascular disease. A polymorphism in the eNOS gene on chromosome 7, 
G894T, has been identified and results in a non-synonymous Glu298Asp substitution 
which causes decreased NO plasma levels, and therefore a reduction in NO’s 
beneficial anti-atherosclerotic effects (Casas et al., 2006). Individuals homozygous 
for this mutation have a slightly increased risk of ischaemic heart disease. Other 
studies report an association of this polymorphism with coronary artery disease 
(Zhang et al., 2012a) and with myocardial infarction (Luo et al., 2014); although this 
association only manifests in the Asian population, indicating the role of ethnicity in 
this association. Further large-scale studies are needed to elucidate this association.   
Given the variety of functions of the endothelium, and the multiple genes which 
orchestrate these functions, genome-wide association studies have identified 
candidate genes in pathways other than eNOS which if mutated have the potential to 
cause endothelial cell dysfunction. For example, defects in the thrombospondin (TSP) 
family of matrix proteins are linked to cardiovascular disease (Topol et al., 2001; 
Wessel et al., 2004). A base pair substitution in TSP 4 variant (A387P) alters the 
tertiary structure of the protein and disrupts the calcium binding site; this is 
associated with a significant reduction in the proliferative capacity of the 
endothelium, thus severely decreasing the endothelium’s capacity for repair and 
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regeneration following minor injury. This polymorphism correlates with an increased 
risk of premature myocardial infarction (Stenina et al., 2003). 
Another cause of endothelial cell dysfunction is thought to be due to a defect in the 
gene encoding for connexin 37 (Yamada et al., 2002), specifically the C1019T single 
nucleotide polymorphism (SNP; Guo et al., 2014). In its normal state, connexin 37 is 
an endothelial gap junction protein, which aids the integration of endothelial cell and 
smooth muscle cell function, and is involved in endothelium-dependent 
hyperpolarising factor (EDHF)-mediated vasodilation (Söhl & Willecke, 2004). In 
general, EDHF-mediated reactions increase intracellular calcium levels, leading to 
the opening of calcium-activated potassium channels of small and intermediate 
conductance, and the hyperpolarisation of endothelial cells. This prompts 
hyperpolarisation and relaxation of the smooth muscle cells (Feletou and Vanhoutte, 
2006), causing vasodilation. When mutated, connexin 37 has an abnormal tertiary 
structure and, therefore, formation of endothelial-smooth muscle cell gap junctions is 
altered and normal endothelial functions are compromised. Dysfunctional connexin 
37 has also been associated with an increased risk of myocardial infarction (Yamada 
et al., 2002). 
The polygenic nature of endothelial cell dysfunction, in combination with its 
variability between affected individuals, indicates the complexity of the hereditary 
component of atherosclerosis. Further research is required to elucidate these 
mutations and the mechanisms by which they cause endothelial cell dysfunction on 
an individual basis.  
 
1.2.4  Assessment of endothelial cell function 
 
Endothelial dysfunction in the brachial artery is closely correlated with dysfunction 
in the coronary circulation (Anderson et al., 1995), demonstrating the systemic 
nature of endothelial dysfunction. Thus the vessels of the forearm are used for 
clinical assessment of endothelial function. A popular clinical assessment of 
endothelial function is flow-mediated vasodilation (measured by ultrasound or 
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angiography), which is predictive of cardiovascular morbidity and mortality (Wong 
et al., 2012). Acetylcholine infusion of the brachial artery causes endothelium-
dependent vasodilation in healthy vessels, whilst in unhealthy vessels, smooth 
muscle-mediated vasoconstriction occurs (Langrish et al., 2012). This finding is 
based on the pivotal studies by Furchgott (Furchgott and Zawadzki, 1980), in which 
rabbit aorta strips denuded of endothelial cells constricted in response to 
acetylcholine, whilst healthy (non-denuded) vessels demonstrated acetylcholine-
induced relaxation. Further investigations confirmed that this phenomenon is due to 
stimulation of muscarinic acetylcholine receptors, triggering NO synthesis by eNOS 
(Kamimura et al., 2003). Venous occlusion plethysmography is another method used 
to measure vasomotor responses of the brachial artery to vasoactive factors. 
Endothelial function can also be measured by quantification of levels of circulating 
biomarkers - for example soluble adhesion molecules, which are increased due to 
vascular inflammation or endothelial activation, or endothelial progenitor cells, 
which are reduced in patients with cardiovascular risk factors (Burger et al., 2012). 
Endothelial cell biopsies have also been used for immunohistochemical and genetic 
single cell analyses (Lehle et al., 2010). However, there are limitations to these 
approaches, either due to limited numbers of endothelial cells or the invasive nature 
of the techniques, and they have yet to provide novel molecular insight into 
endothelial cell biology.  
The primary culture of endothelial cells in vitro was developed over forty years ago 
(Jaffe et al., 1973) and has greatly increased understanding of endothelial cell 
biology through phenotypic, genomic and functional studies. However, primary cell 
lines have limited capacity to expand in vitro, thus the range of these studies have 
been enhanced by use of endothelial cells derived from pluripotent stem cells, both 
embryonic (ES) and induced (iPS). These immortal cell lines are capable of 
differentiating into all types of cardiovascular lineages: endothelial cells, vascular 
mural cells, smooth muscle cells and cardiomyocytes (Narazaki et al., 2008; Yoshida 
and Yamanaka, 2010), opening up new avenues for cardiac and vascular regeneration 




1.3 Pluripotent stem cells 
 
Human embryonic stem (ES) cells are derived from the inner cell mass of the pre-
implantation blastocyst, and were first derived in James Thomson’s laboratory in the 
University of Wisconsin in 1998 (Thomson et al., 1998). Donated human embryos 
produced by in vitro fertilisation were cultured for approximately five days until they 
became blastocysts, consisting of the outer trophoectoderm (the cells providing 
nutrients to the embryo) and the inner cell mass (the cells from which the fetus 
develops). The inner cell masses were isolated, and from them ES cells were derived 
as described by Thomson et al., 1995. In culture, these cells cluster together as 
colonies- they are small and rounded and have a high nucleus-to-cytoplasm ratio. 
Activity of telomerase is high in ES cells (Thomson et al., 1998). Telomerase is a 
ribonucleoprotein that maintains chromosome length by adding telomere repeats to 
the ends of chromosomes and has a significant effect on cell life span (Shay and 
Wright, 2005). This accounts for the ability of ES cells to proliferate and remain 
undifferentiated for long periods in culture (Rosler et al., 2004). ES cells express 
many markers associated with pluripotency- for example the stage specific 
embryonic antigens 3 and 4 (SSEA3 and SSEA4) and stem cell specific markers Tra-
1-60 and Tra-1-81. In addition, ES cells form teratomas when injected into 
immunocompromised mice, which contain derivative cells from all three primary 
germ layers: mesoderm, ectoderm and endoderm, demonstrating their pluripotent 
potential (Zhang et al., 2012b). 
Human ES cells can be differentiated into endothelial cells in vitro (Vittet et al., 
1996; Yamashita et al., 2000; Levenberg et al., 2002). Though they represent a 
useful source for the derivation of many cell types, ethical and immunological issues 
have hampered their use in research. These issues may be avoided by the use of an 
alternative stem cell type: induced pluripotent stem cells.   
 
1.3.1  Induced pluripotent stem cells 
 
Induced pluripotent stem (iPS) cells were first produced in 2006, by Yamanaka and 
Takahashi, at Kyoto University (Takahashi et al., 2006). Pluripotency was induced in 
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murine somatic fibroblasts, by ectopic expression of four transcription factors: 
octamer-binding transcription factor-3/4 (Oct 3/4), SRY-related-high-mobility-group 
(HMG)-box protein-2 (Sox2), Kruppel-like factor 4 (Klf4) and c-myc, a process 
called cellular reprogramming. These four transcription factors act in concert in 
cellular reprogramming. Firstly, c-myc acetylates specific histones, leading to 
chromatin remodelling. This allows greater access of Oct3/4 and Sox2 (which both 
target oncogenes) to their respective binding sites, promoting cellular proliferation. 
Usually, this would induce apoptosis through tumour suppression mechanisms, 
however the presence of Klf4 (another oncogene) results in suppression of p53 and 
upregulation of Nanog, the result of which inhibits cell death. Transcription factors 
Oct and Sox also activate other critical embryonic genes and recruit chromatin-
remodelling complexes that promote reprogramming (Buganim et al., 2013). A year 
after the generation of murine iPS cells, this process was replicated using human 
fibroblasts, generating the first human iPS cells (Takahashi et al., 2007; Yu et al., 
2007). Human iPS cells are strikingly similar to human ES cells: they replicate via 
mitotic division whilst maintaining an undifferentiated state (in theory, indefinitely), 
and they have the potential to differentiate into all somatic cell types when provided 
with the necessary stimuli. Through directed differentiation systems, hepatocytes 
(Sullivan et al, 2010), adipocytes (Tashiro et al, 2009), motor neurons (Dimos et al, 
2008), osteoblasts (Bilousova et al 2011), and pancreatic insulin-producing cells 
(Zhang et al., 2009) have all been derived from iPS cells, to name a few examples. 
iPS cells can also differentiate to all lineages of the cardiovascular system: 
endothelial cells, vascular mural cells, smooth muscle cells and cardiomyocytes 
(Narazaki et al., 2008; Tulloch et al., 2008). 
Avoiding the ethical and immunological issues that typically hamper ES cell research, 
the arrival of iPS cell technology marked the start of an exciting new dimension of 
stem cell research, expanding the potential of regenerative cell medicine. iPS cells 
are patient-specific and can be used for the modelling of monogenic and polygenic 
human disease phenotypes, in vitro and in vivo. They could also be applied to the 
screening of novel drugs and toxicology studies. In time, iPS cell technology may 
prove to be a reliable and renewable source of cells for autologous cellular therapy. 
In the case of polygenic diseases, such as atherosclerosis, in which the genetic 
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predisposition may vary between individuals, patient-specific iPS cell technology 
can offer personalised strategies for the study of endothelial cell dysfunction for 
elucidation of genetic causes. 
 
1.3.2  Cellular reprogramming methods 
 
Cellular reprogramming methods can be categorised based upon whether or not the 
delivery systems cause genetic modifications to the donor cell. Cellular transfection 
with viral vectors, transposons, or transfer of linear DNA involves the integration of 
exogenous genetic material, whilst transfection with transient episomal plasmids, 
RNA or protein does not. Initially, retroviral vectors were used to deliver the 
reprogramming transcription factors (Takahashi et al., 2007). Whilst effective, via 
this method the retroviral vector backbone and transgenes are permanently and 
randomly integrated into the genome, and therefore have the potential to cause 
mutations. Transgene expression can also influence specific lineage differentiation 
(Yu et al., 2007), or may result in tumourigenesis (Okita et al., 2007). Aside from 
this, viral vectors pose risks to the user, especially when containing the oncogene c-
myc. Proper facilities and equipment are required for handling viruses, and they are 
not appropriate for the production of clinical grade cells. Cre/LoxP recombination 
methods were developed as an attempt to excise integrated transgenes (Soldner et al., 
2009), however these can still leave behind residual vector sequences. As an 
alternative to viral approaches to iPS cell generation, non-integrating methods of 
delivery of reprogramming factors have been promoted. Episomal plasmids are only 
present in the cell transiently; once pluripotency is established, the expression of 
extra-genomic transcription factors is not required for its maintenance (Abujarour 
and Ding, 2009). This integration-free method therefore generates cells which are 






1.3.3  Somatic cell source 
 
Initially, pluripotency was induced in fibroblasts with retroviral vectors, but since 
then the field of iPS cell technology has grown rapidly, with many aspects modified 
and optimised. As well as the method of reprogramming, the optimal somatic donor 
cell for reprogramming has been investigated. Fully pluripotent iPS cells have been 
derived from keratinocytes (Aasen et al., 2008), peripheral blood cells (Loh et al., 
2009) and neural progenitor cells (Eminli et al., 2008), to name a few examples. In 
comparison with traditionally used fibroblasts, many of these studies report enhanced 
reprogramming efficiencies. For example, human scalp keratinocytes are 
reprogrammed with 100-fold more efficiency than human fibroblasts (Aasen et al., 
2008). Furthermore, it appears in a number of cases that iPS cells differentiate 
preferentially along the cell lineage of their donor cell type (Bar-Nur et al., 2011). 
For example, along a blood differentiation protocol, blood-derived iPS cells formed 
more hematopoietic colonies than fibroblast-derived iPS cells. Conversely, 
differentiation to osteoblasts (bone progenitor cells derived from mesenchymal stem 
cells) was more successful in fibroblast-derived iPS cells than blood-derived iPS 
cells, demonstrated by formation of osteogenic colonies, and high expression of 
osteoblast-associated genes (Kim et al., 2010). Many of these reports suggest that 
variable reprogramming efficiency of somatic cells and subsequent differentiation 
bias of the derived iPS cells is due to their epigenetic profiles: it is likely that cells 
which are reprogrammed with relative ease have an epigenetic profile amenable to 
reprogramming. For example, Chou et al. (2011) reported that mononuclear cells 
derived from peripheral and cord blood had epigenetic features and gene expression 
profiles closer to pluripotent stem cells than age-matched fibroblasts have to 
pluripotent stem cells. They reported that these cell types reprogrammed with a 
higher efficiency than fibroblasts. The reprogramming process involves resetting of 
the epigenome, meaning the erasure of characteristic chemical modifications of DNA 
and chromatin structures of the donor cell that dictate gene activation and repression. 
If this erasure is incomplete, some of these epigenetic characteristics remain on the 
iPS cells, which are relayed into donor gene expression patterns. Reports suggest that 
epigenetic marks at centromeres and telomeres are particularly resistant to 
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reprogramming (Lister et al., 2011). This can result in iPS cells which, whilst 
pluripotent, can be more efficient in differentiation back to their original donor cell 
type.  
Advances have been made recently in identifying hematopoietic and endothelial cell 
alternatives to fibroblasts as more attractive cell types for reprogramming. Geti et al. 
(2012) isolated endothelial outgrowth cells (EOC) from peripheral blood and 
generated iPS cells with normal karyotypes through viral reprogramming. 
Reprogramming kinetics and efficiency was higher for EOCs than fibroblasts, and 
was performed in a 96 well format, which is promising for translation to high 
throughput platforms. Additionally, 80% of derived iPS cell lines did not acquire any 
copy number variations during reprogramming. Also derived from mobilised human 
peripheral blood, cells expressing the hematopoietic and endothelial marker CD34 
are amenable to reprogramming via retroviral transduction of the Yamanaka factors 
(Loh et al., 2009). The resulting iPS cells were described as indistinguishable from 
embryonic stem cells and were able to differentiate in vitro and in teratomas. In 
comparison to fibroblasts, CD34+ peripheral blood cells had increased 
reprogramming efficiency. A key benefit to using this cell type is the ease with 
which they are obtained: a blood sample is a less invasive cell source than a skin 
biopsy (required with fibroblasts). In addition, Loh et al. report that blood-derived 
cells only required a short time in culture prior to reprogramming. Haase et al. (2009) 
report successful reprogramming of cells obtained from cord blood. They found that 
cord blood-derived endothelial cells were more efficiently reprogrammed than 
primary lung fibroblasts, adult peripheral blood mononuclear cells or monocytes. 
The cord blood endothelial cells had the added benefit of being free from any nuclear 
or mitochondrial mutations that accumulate as organisms progress to and through 
adulthood. HUVECs have also been used as a source of iPS cells. Lagarkova et al. 
(2009) report that HUVECs can be successfully reprogrammed using retroviral 
delivery of Yamanaka’s transcription factors, to generate bone fide iPS cells with ES 
cell-like properties. They demonstrated that these cells could be differentiated back 
to endothelial cells in vitro. Furthermore, HUVEC-derived iPS cells were found to 
have an epigenetic profile, which had been ‘reset’ to resemble that of ES cells. 
Promoter elements of endothelial specific genes had been silenced during 
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reprogramming, whilst promoters of pluripotency-associated genes were activated, at 
similar levels to ES cells. Relatively efficient and rapid HUVEC retroviral 
reprogramming has also been demonstrated by Panopoulous et al., 2011, who report 
that iPS cell colonies appeared six days following HUVEC reprogramming, 
compared with the standard ~three weeks.  
These studies described in this section give credibility to the hypothesis that 
endothelial cells can be expected to reprogram with higher efficiency than fibroblasts, 
and thus may be an optimal somatic cell substrate for the generation of iPS cells.  
 
1.3.4  Comparison between ES and iPS cells 
 
When human iPS cells were initially derived in 2007, they were found to be 
strikingly similar to ES cells in their ability to self-renew and differentiate when 
provided with the right stimuli. However, as the field progressed, reports of 
differences between the two cell types emerged. Genomic variations occur between 
many stem cell lines, and collectively, some iPS cell lines have been shown to 
deviate from ES cells in terms of expression of hundreds of genes (Chin et al., 2009) 
and DNA methylation patterns (Doi et al., 2009). It has been reported that the 
epigenome of the two cell types may vary considerably, in particular as some iPS cell 
lines have similar gene expression patterns to the donor cells from which they were 
derived (Ghosh et al., 2010).  
There are however other studies that find ES and iPS cells indistinguishable, and 
argue that reported differences can be attributed to variations in reprogramming 
method and culture conditions between laboratories. In a review by Yamanaka (Cell 
Stem Cell, 2012), it is noted that the studies which report significant differences 
between the two cell types often compared low numbers of clones; whereas those 
which argue that it is difficult to distinguish between them typically have compared 
higher numbers of ES and iPS clones. This suggests that whilst some cell lines are 
notably different in their gene expression patterns, variation in gene expression arises 
to some extent between all stem cell lines and types. It also raises the point that iPS 
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and ES cell lines can be of variable quality, either in their induction, or in their 
continued culture, and stresses that continued assessment of pluripotency is required 
throughout the passaging of the cells to ascertain that they retain their characteristics 
in vitro.  
Differentiation efficiencies of ES and iPS cells can be compared when the two cell 
types are subjected to the same protocol in the same laboratory, to eliminate variable 
factors. There have been reports that the two cell types differentiate in the same way: 
Zhang et al. (2009) reported comparable efficiencies of differentiation of ES and iPS 
cells to pancreatic insulin-producing cells. Chambers et al. (2009) also reported 
similarities in neural differentiation by ES and iPS cells. Conflicting publications, 
however, conclude that there are differences between ES and iPS cell differentiation. 
Takayama et al. (2013) reported variability in iPS cell differentiation to hepatocytes; 
whilst some lines were comparable to ES differentiation, some were not. Grigoriadis 
et al. (2010) suggested that intrinsic differences exist between all pluripotent stem 
cell types, after studies showed variations in hematopoietic differentiation efficiency 
between all stem cell lines tested, which were not specific to ES or iPS cell types. 
iPS cell lines can have variable differentiation propensities; this can be an 
inconsistent factor in the comparison of different ES cell lines as well (Osafune et al., 
2008). These differences should be taken into account when selecting pluripotent 
stem cell lines for cellular applications. More robust differentiation protocols may, 
however, overcome this variation. Through describing variation in differentiation 
abilities of their ES and iPS cell lines, Kim et al. (2010) described a small molecule 
approach to inhibiting BMP and Activin/Nodal signalling for differentiation to neural 
progenitor cells, which is efficient in all lines regardless of any initial differentiation 
propensity. 
In terms of endothelial differentiation, it is often difficult to compare ES and iPS 
differentiation if they are not carried out in the same laboratory following the same 
protocol. Taura et al. (2009) reported that ES and iPS cell differentiation kinetics 
were comparable; between 1.5-2.2% of their ES cell lines and 1.3-4.4% of their iPS 
cell lines expressed endothelial markers vascular endothelial growth factor receptor 
2  (VEGFR2) and Vascular Endothelial (VE) Cadherin after 10 days of endothelial 
differentiation. Also, Yamashita (2000) reported that comparable levels of 
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cardiovascular cells (all derived from VEGFR2+ cells) could be induced from ES and 
iPS cells. 
 
1.3.5  Risks and limitations of iPS cells 
 
Whilst iPS cell technology offers many benefits in terms of generation of large 
numbers of cells for the study of disease conditions, there are risks and limitations 
associated with its use.  
Teratoma formation could occur in vivo from inadvertent administration of an 
undifferentiated iPS cell. Moreover, iPS-derived cells are genetically manipulated 
and thus pose safety and regulatory concerns; even episomal plasmids carry a risk of 
genomic integration. The original paper describing their use reported an iPS clone, 
which contained copies of EBNA-1 DNA, likely the result of inadvertent plasmid 
integration (Okita et al., 2011). For therapeutic use, rigorous screening for pure 
populations of pluripotent cell-derived endothelial cells would have to be carried out 
prior to their administration.  
A limitation of iPS cell research is the lack of standardised differentiation protocols, 
hence the difficulties in comparing iPS cells and their derivatives between 
laboratories. This is evident by comparison of published studies in this field, which 
vary in terms of differentiation protocols, time points for characterisation and 
markers used for validation. A more standardised approach is required to minimise 
variation and allow direct comparison of different iPS cell lines.  
 
1.4 Induced pluripotent stem cells for the study of endothelial biology 
 
As discussed in Chapter 1.2.4, clinical assessments of vascular cell function are 
informative, but provide limited insight into endothelial cell biology. Culture of 
endothelial cells - from a primary or commercial source - has improved 
understanding of their biology, but there are issues that need to be overcome. For 
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example, the derivation of primary endothelial cell cultures often require invasive 
procedures, such as biopsy of the superficial forearm vein. Furthermore, often these 
cells are isolated from vascular beds that do not develop atherosclerosis (e.g. 
umbilical vein). Also, primary cell cultures have a limited lifespan and begin to 
senesce after a number of population doublings (unpublished observations), meaning 
that researchers have finite period of time in which to analyse these cells. 
Therapeutic strategies require large numbers of cells, which may not be obtained in 
sufficient quantity from blood or biopsy samples. As an alternative, pluripotent stem 
cell-derived endothelial cells have many advantages over primary cultures. In the 
future, patient-specific stem cells could be generated that are renewable and 
expandable, thus representing an infinite source from which endothelial cells can be 
derived. Also, iPS cells could be differentiated into other patient specific 
cardiovascular cell types, for example cardiomyocytes, smooth muscle cells and 
pericytes, as it is likely that cardiovascular regenerative therapies will require a 
multi-cellular approach. 
iPS cell technology lends itself to the study of diseases which are suspected to have a 
strong genetic component, either monogenic or polygenic. Cells from these patients 
can be cultured, reprogrammed and differentiated to the disease-affected cell type, 
which is likely to display the disease phenotype when compared to healthy controls. 
In comparison, in patients with diseases that have arisen as a consequence of 
environmental or epigenetic factors, derived cells are unlikely to carry the disease 
phenotype (Figure 1.1). The study of cells from patient specific iPS cells can assist in 



















Figure 1.1: Generation of patient-specific iPS cells for disease modelling. Diseases 
with a genetic component lend themselves to iPS cell generation for directed 
differentiation and disease modelling. Figure adapted from Cherry & Daley (2012), 
with permission. 
 
Many recent studies have shown persistence of a disease phenotype in iPS-derived 
cells following cellular reprogramming and differentiation. This was first reported in 
cells derived from a patient with spinal muscular atrophy (Ebert et al., 2009). 
Fibroblast-derived iPS cells were generated from a spinal muscular atrophy patient 
using lentiviral constructs containing Oct3/4, Sox2, Nanog and Lin28 transcription 
factors. These patient-specific cells were then differentiated to motor neurones, 
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which displayed selective deficits in comparison with healthy controls, and therefore 
may reflect disease processes.  In vitro disease modelling has also been carried out 
with iPS cells derived from patients with amylotrophic lateral sclerosis (Dimos et al., 
2008). iPS cells were generated from the fibroblasts of an elderly patient with the 
condition, through retroviral reprogramming with transgenes encoding the 4 
Yamanaka factors, Klf4, Sox2, Oct3/4 and c-myc. Small molecules were used to 
direct differentiation to generate neuron-like outgrowths, and the data suggested that 
iPS-derived motor neurons arose from progenitors similar to those found in the 
developing spinal cord, indicating the resemblance between the in vitro conditions 
and in vivo processes. IPS cells have also been derived retrovirally from the 
fibroblasts of patients with LEOPARD syndrome (Carvajal-Vergara et al., 2010), a 
disease phenotype, which includes hypertrophic cardiomyopathy. In vitro derived 
cardiomyocytes from these patients were found to be bigger and have other nuclear 
features synonymous with diseased cardiomyocytes, in comparison with healthy 
controls. The patient derived iPS-cardiomyocytes were also used to investigate the 
signalling pathways, which contribute to the disease phenotype. Overall, these 
reports show that the generation of iPS cells from patients with genetic disorders can 
be used in the elucidation of the causes and mechanisms by which complex diseases 
develop.  
 To date, endothelial cells have not been derived from patients with a genetic 
predisposition to endothelial dysfunction. A strong genetic component is suspected in 
patients with premature atherosclerosis in the absence of environmental risk factors 
(Damani and Topol, 2007), and it is likely that iPS derived-endothelial cells from 
these patients will have a phenotype representative of their endothelial cells in vivo. 
The studies in this thesis form the foundation for investigations into the functions of 
iPS-derived endothelial cells from patients with premature atherosclerosis, to give 
insight into genetic and molecular mechanisms of endothelial cell dysfunction.  
iPS cell technology lends itself to the development of personalised cellular therapies 
for vascular regeneration - the restoration of functional vascular networks. After 
correction of suspected intrinsic genetic defects, patient derived endothelial cells 
could be administered to aid in reparative mechanisms and reendothelialisation of 
damaged vessels. They could also be involved in promotion of angiogenesis and 
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neovasculogenesis for the recovery of ischaemic tissues. Cells could be administered 
by injection to the site of injury or used in the ex vivo engineering of stents or vessel 
grafts. For example, a report by Ott et al. (2008) claimed that de-cellularised rat 
hearts reseeded with endothelial and cardiac cells were restored with basic heart 
function in response to physiological load and electrical stimulation after 8 days.   
 
1.5 Endothelial differentiation of pluripotent stem cells 
 
Traditional techniques for the study of endothelial biology (outlined in Chapter 1.2.4), 
whilst informative, have limitations. Thus, in vitro studies provide greater insight 
into the molecular biology of endothelial cells, and the scope of this research has 
been greatly expanded by derivation of large numbers of endothelial cells from ES 
and iPS cells. Cells derived from iPS cells have the same molecular and genetic 
characteristics of the individual from whom they originated (Park et al., 2008) and, 
therefore, can be used in the study of the effects of genetic or epigenetic alterations 
on endothelial function (Wu and Hochedlinger, 2011).  
 
1.5.1  Derivation of endothelial cells from human embryonic stem cells 
 
Since embryonic stem cells were derived in culture by Thomson et al. in 1998, 
attempts have been made to optimise directed differentiation protocols, to generate 
pure populations of somatic cell types. Many publications document successful 
endothelial cell differentiation from embryonic stem cells, a process often governed 
by exposure to soluble growth factors, endothelial cell-inducing cytokines, and the 
extracellular matrix to which the differentiating cells adhere.  
A logical approach to the development of mesodermal cells is the formation of stem 
cell aggregates known as embryoid bodies (EBs), which mimic the conditions of 
embryonic development (Baker, 2008). EBs are grown in suspension culture, and 
within them spontaneous differentiation occurs. Over time, the three primary germ 
layers (endoderm, mesoderm and ectoderm) appear. In the case of endothelial cell 
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differentiation, initial embryoid body formation is a method employed by many 
groups by which to obtain mesodermal cells, from which endothelial cells can be 
derived (Vittet et al., 1996; James et al., 2010). Use of embryoid bodies for the 
derivation of endothelial cells from human embryonic stem cells was first used by 
the laboratory of Robert Langer (Levenberg et al., 2002). After 13 days, they 
identified a population of cells expressing endothelial cell markers: CD31, VE-
cadherin and von Willebrand Factor (vWF), organised as vascular-like tubules. 
When isolated from embryoid bodies and transplanted subcutaneously into Non-
Obese Diabetic/ Severe Combined Immunodeficiency/ Gamma (NSG) mice, these 
cells formed perfusing microvessels. Vittet et al. (1996) also utilised the close 
parallels between embryonic vasculogenesis and differentiation of ES cells within 
EBs. Through detection of endothelial cell markers VEGF-R2, CD31, Tie2 and VE-
cadherin they identified primitive vascular-like structures in the embryoid bodies, 
and found that their formation was encouraged by addition of vascular endothelial 
growth factor (VEGF). Ferreira et al. (2007) reported that they could spontaneously 
differentiate embryonic stem cells into vascular progenitor cells after 10 days of 
embryoid body formation. Following this, cells expressing CD34 were differentiated 
into either endothelial or smooth muscle-like cells, when supplemented with 
angiogenic factor VEGF or platelet derived growth factor (PDGF), respectively. 
Another approach to directed endothelial differentiation of embryonic stem cells is 
via 2-dimensional culture conditions, in which cells are grown either on feeder layers 
that provide soluble factors supporting growth, or on a substrate (for example 
collagen or gelatin) that mimics connective tissue adhesions that occur in vivo. Step-
wise differentiation can be induced by the addition of growth factors, (such as basic 
fibroblast growth factor (bFGF) and VEGF) and/or mesoderm-inducing cytokines, 
(such as bone morphogenic protein (BMP) 4 and Activin A). Endothelial cell 
differentiation in vitro in various culture conditions has been demonstrated in 
multiple studies. Sone et al. (2007) differentiated human ES cells on OP9 feeder cells 
(a murine stromal cell line which releases soluble factors such as VEGF-C and Ang1; 
Kono et al., 2006). They found that over the first 8 days a distinct population of 
TRA160-VEGFR2+ cells emerged. This population was isolated, and upon further 
culture in medium supplemented with VEGF, a CD34+VE-cadherin+CD31+eNOS+ 
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population of cells emerged which were similar to mature endothelial cells in terms 
of their morphology and angiogenic capacity. Yamashita et al. (2000) also derived 
vascular cells from embryonic stem cells. VEGFR2+ cells were induced from culture 
of undifferentiated human ES cells as a monolayer on collagen IV in media 
containing 10% serum. On sorting the VEGFR2+ cells and adding VEGF to the 
culture medium, endothelial cells were derived- identified based on morphology, 
expression of endothelial markers VE-cadherin, CD105 and CD34, and ability to 
organise into 3-dimensional tubule-like structures in vitro. It was concluded that 
VEGFR2+ cells from ES cells have the potential to serve as common vascular 
progenitor cells.  Kane et al. (2010) differentiated human embryonic stem cell lines 
as a monolayer in endothelial differentiation media: large-vessel endothelial growth 
media supplemented with hydrocortisone, epidermal growth factor, basic fibroblast 
growth factor and heparin. Over 21 days, expression of pluripotency associated genes 
(Oct3/4, Sox2 and Nanog) was decreased whilst those associated with an endothelial 
phenotype (CD34, CD31 and VE-cadherin) increased. At this stage, the cells formed 
a cobblestone monolayer, were producing nitric oxide, and responded to 
pharmacological stimulation similarly to mature endothelial cells. In vivo, ES-
derived endothelial cells were found to contribute to neovascularisation and recovery 
of blood flow via engraftment into the vasculature, demonstrated by the hind limb 
murine model of ischemia (Sone et al. 2007). 
In addition to biochemical stimuli, the effect of shear stress has been investigated in 
vitro on the endothelial differentiation of mouse ES cells (Yamamoto et al., 2005), as 
shear stress is thought to influence epigenetics in embryonic development (Illi et al., 
2003). ES cells were cultured in Minimal Essential Medium (MEM) containing FBS 
and β-mercaptoethanol. Supplementation of 50ng/ml VEGF induced VEGFR2+ cells, 
which were isolated and exposed to controlled levels of shear stress. In comparison 
to cells in static conditions, VEGFR2+ cells exposed to some degree of shear stress 
had enhanced expression of endothelial markers (CD31 and VE-cadherin) measured 
at both the protein and mRNA level. An in vitro angiogenesis assay on collagen gel 
(formation of tubule connections between cells) also showed angiogenesis in shear 
stress-exposed cells. Increased endothelial characteristics after shear stress exposure 
have been attributed to two phenomena: increased transport of bioactive factors to 
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the cells (speeding up the differentiation process) and/or the exertion of a mechanical 
force on the cell, thought to influence endothelial morphology, alignment and 
function.  
Though these studies demonstrate effective derivation of endothelial cells from 
embryonic stem cells, iPS cells may represent a better source for endothelial cell 
derivation. The ethical issues surrounding embryonic stem cells continue to hamper 
their use in research, limiting the commercial availability of ES cell lines. Practical 
considerations involved in obtaining embryonic tissues for the isolation of embryonic 
stem cells is another limitation to their large scale production. iPS cells offer a non-
controversial alternative, which are more likely to secure funding and support. 
Somatic cell sources of iPS cells are more readily available, and there are abundant 
options of somatic cell lineages, which can be reprogrammed. These are relatively 
easily obtained, in comparison with embryonic tissue, and often relatively low 
numbers of cells (0.1-0.5x106) are required for each reprogramming attempt. Somatic 
cells can be expanded in culture and banked for multiple transfection experiments. 
Clinically, large scale production of stem cells is useful for their use in in vitro 
differentiation protocols to generate cells for the elucidation of disease mechanisms, 
drug screening, toxicology studies and development of cellular therapies. There are 
safety issues concerning the immunogenicity of allogenic embryonic stem cell 
derivatives. Their use in cellular therapies would likely involve co-administration of 
immunosuppressant drugs, adding complexity. In comparison, iPS cells are patient-
specific, therefore suited to autologous cell therapy, avoiding the risks of 
immunorejection. Another major advantage of iPS cells is that they can express a 
certain disease phenotype for both Mendelian and complex genetic disorders, for the 
modelling of disease processes in vitro. In comparison, ES cell derivatives would 
have to be exposed to disease-inducing conditions, which are less likely to accurately 






1.5.2  Derivation of endothelial cells from human induced pluripotent 
stem cells 
 
Endothelial differentiation from iPS cells has been attempted by several groups, but 
not to the same extent as ES cell differentiation. In the initial publication detailing 
the induction of pluripotency of human fibroblasts (Takahashi et al., 2007), iPS cells 
were differentiated to neuronal and cardiac lineages, and two years later the same 
group differentiated iPS cells to endothelial cells (Taura et al., 2009). Though 
generally the approaches used for ES cell differentiation can be applied to the 
differentiation of iPS cells, there is not yet a well-established endothelial 
differentiation protocol for iPS cells. 
Embryoid body (EB) formation has been used for endothelial differentiation of 
human iPS cells. Rufaihah et al., (2011) formed EBs from iPS cells derived 
retrovirally from human foreskin fibroblasts. EBs were suspended for 4 days in 
differentiation media, (α-Minimum Eagle’s Medium, fetal bovine serum (FBS), β-
mercaptoethanol and non-essential amino acids) supplemented with VEGF and 
BMP4. These were then disaggregated and the cells seeded onto gelatin-coated plates 
for 10 days, from which a population of CD31+ cells was isolated. As well as 
possessing phenotypic similarities to endothelial cells, these cells were capable of 
forming vascular networks and increasing blood flow to ischemic hind limbs of NSG 
mice. Wong et al. (2012) used a very similar endothelial differentiation protocol via 
EB formation for 4 days in the presence of VEGF and BMP4. Again, disaggregated 
EBs were seeded on gelatin-coated plates, though differentiation continued in the 
absence of BMP4. A population of CD31+ VE-cadherin+ cells was isolated which 
could be expanded and maintained in endothelial growth medium.  
Choi et al. (2009) describe hematopoietic and endothelial differentiation of human 
iPS cells. They plated iPS cells on an OP9 feeder layer, in differentiation medium 
(consisting of α-MEM, FBS and monothioglycerol) and after 8 days and were able to 
select CD34+CD31+ cells. These were further cultured in medium supplemented with 
endothelial cell growth factor, and appeared to develop endothelial characteristics: 
expression of endothelial markers VEGFR2, CD146 and VE-cadherin, and formation 
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of connections on Matrigel, an indication of angiogenic potential. Taura et al. (2009) 
also differentiated human iPS cells into endothelial cells by co-culture with an OP9 
feeder layer. After 8 days, they isolated and further cultured a Tra-1-60-VEGFR2+ 
population, which expressed endothelial cell markers: CD31, CD34, VE-cadherin 
and eNOS. The properties of iPS cell endothelial differentiation via this protocol 
were very similar to ES cell endothelial differentiation under the same conditions 
(Sone et al., 2007). 
1.6 Scope of studies in this thesis 
 
Within this thesis, protocols were developed for the generation of iPS cells from 
cellular reprogramming of fibroblasts and endothelial cells. The endothelial 
differentiation protocols used herein were developed from assessment of the 
literature, preliminary studies carried out in our own laboratory and following 
correspondence with Professor Andrew Baker at the University of Glasgow. 
Extensive phenotypic and functional characterisation of pluripotent stem cell derived 
endothelial cells was carried out in vitro and in vivo. All studies were performed on 








This thesis addresses the hypothesis that endothelial cells can be derived from human 
embryonic and induced pluripotent stem cells, which are functional and able to 
contribute to neovasculogenesis in vivo. Furthermore, it is hypothesised that iPS cells 
generated from endothelial cells will differentiate back to endothelium with greater 
efficiency than iPS cells generated from other somatic cell sources.  
 
1.8 Aims  
 
 To induce pluripotency in human fibroblasts and endothelial cells via 
episomal plasmid transfection.  
 To derive functional endothelial cells from human embryonic and induced 
pluripotent stem cells. 
 To characterise the morphology and phenotype of endothelial cells derived 
from embryonic and induced pluripotent stem cells.  
 To characterise the functionality of endothelial cells derived from embryonic 











2.1 General solutions 
 
4% Paraformaldehyde (PFA): 4g PFA (Sigma, UK) was added to 100ml PBS 
(Gibco, UK) and heated to 60°C. 1M NaOH (Sigma, UK) was added dropwise until 
the solution cleared; pH was adjusted to 7.4 with 1M HCl (Sigma, UK). 
5X Tris-Borate EDTA (TBE): 54g Tris base (Sigma, UK) and 27.5g Boric acid 
(Sigma, UK) were added to approximately 900ml dH2O. 20ml 0.5M EDTA 
(Invitrogen, UK) was added and the final volume adjusted to 1 litre. The solution 
was diluted to 1X (working concentration) with dH2O. 
Induced pluripotent stem (iPS) cell culture medium: 400ml KO-DMEM, 100ml 
KOSR, 5ml NEAA, 1ml β -mercaptoethanol, 1ml L-glutamine (all supplied by Gibco, 
UK). 
Modified iPS culture medium: 400ml KO-DMEM, 100ml FCS (Gibco, UK), 5ml 
NEAA, 1ml β -mercaptoethanol, 1ml L-glutamine. 
Endothelial medium: 450ml Endothelial Basal Medium (Lonza, UK), with 
supplements: 0.2ml hydrocortisone, 2ml hFGF-B, 0.5ml VEGF, 0.5ml R3-IGF-1, 
0.5ml ascorbic acid, 0.5ml heparin, hEGF, 0.5ml GA-1000 (all supplied by Lonza, 
UK, provided as EGM-2 bullet kit supplements), 50ml Hyclone-FBS (Gibco, UK). 
Wash medium, PBST: PBS, 0.5% (v/v) Tween (Sigma, UK). 










2.2 Cell culture 
 
2.2.1  Ethics 
 
These studies were performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki. The written consent of 
each participant was obtained before entry into these studies.   
 
2.2.2  Endothelial cell lines 
 
All endothelial cell lines were maintained either on collagen I coated plates (BD 
Biosciences, UK) or on tissue culture treated plastic in endothelial medium (Chapter 
2.1). Upon reaching 70-80% confluence, endothelial cell lines were passaged 
enzymatically. Firstly, wells were washed with phosphate buffered saline (Gibco, 
UK; approximately 1ml per well of a 6 well plate), then incubated for 5-7 minutes in 
TrypLE Select (Gibco, UK; approx. 1ml per well of a 6 well plate) at 37°C, after 
which cells could be observed rounding up and detaching from the plate. Two times 
the volume of endothelial medium was added (i.e. 2ml per well of a 6 well plate), to 
stop the TrypLE Select activity, and at this point the cells could be collected and 
counted with a haemocytometer. Cells were centrifuged for 5 minutes at 10,000 
RPM. The supernatant was discarded and the pellet resuspended in the required 
volume of endothelial medium, either for experimental use or for further culture.  
Seeding density of subculture was kept consistent throughout endothelial cell culture. 









 Surface Area 
(mm2) 
Seeding density (x105) 
Plates (data per well) 
6 well 960 0.48 
12 well 400 0.2 
24 well 200 0.1 
Flasks 
T-25 2500 1.25 
T-75 7500 3.75 
 
Table 2.1: Typical seeding densities of endothelial cells cultured in various sized 
culture vessels 
 
Endothelial cell lines could typically be used up to passage 9 or 10, at which point 
signs of senescence appeared: for example ‘stringy’ morphology and increased 
population doubling times (Wagner et al., 2001). 
 
2.2.2.1 Human Umbilical Vein Endothelial Cells  
 
As a representative population of mature endothelial cells, commercially-supplied 
human umbilical vein endothelial cells (HUVEC) were used (Lonza, UK). HUVEC 
were cultured on tissue culture treated plastic flasks or plates in endothelial medium 




Five healthy volunteers were used in the study, from which late outgrowth 
endothelial cells from blood, endothelial cells from the vessel wall and fibroblasts 






Age Sex Type 
Endothelial cells 
Fibroblasts 
Blood Vessel wall  
D1 30 M British South 
Asian 
   
D2 30 F Caucasian *   
D3 29 F Caucasian    
D4 31 M Caucasian    
D5 65 M Caucasian    
 
Table 2.2: Details of five healthy donors, whose somatic cells were used for 
reprogramming. Endothelial cells were derived either from blood (*cord blood) or 
the vessel wall. Fibroblasts were derived from skin biopsy. 
 
 
2.2.2.3 Late outgrowth endothelial cells 
 
Late outgrowth endothelial cell (EOC) culture was an established technique in the 
laboratory, performed as described by Tura et al. (2007). EOC were obtained and 
cultured by Olga Tura and Mairi Brittan. Briefly, 100ml peripheral or cord blood was 
collected into EDTA (Gibco, UK), from which mononuclear cells were isolated by 
density gradient centrifugation, using Ficoll-Paque PLUS (GE Healthcare, UK), 
according to the manufacturer’s protocol. The cells were seeded in endothelial 
medium, plated onto collagen I coated plates (Becton Dickinson, UK) and incubated 
at 37°C / 5% CO2 / 95% relative humidity for 3-4 weeks. Medium was changed 
every 2 days for 7 days and then twice a week until first passage. Colonies, 


















Figure 2.1: EOC in culture have a rounded ‘cobblestone’ morphology, typical of 
endothelial cells.  Bar = 1mm. 
 
2.2.2.4 Vessel wall-derived endothelial cells 
 
Vessel wall-derived endothelial cells were obtained and cultured by Mairi Brittan. 
Endothelial cells were derived via intimal wire biopsies of the superficial forearm 
vein, as previously described (Colombo et al., 2002). A J-shaped wire (0.018-inch 
diameter) was inserted into the superficial forearm vein through an 18-gauge 
angiocatheter. Following a number of passes, the distal end of the wire was removed 
and transferred to a 50ml falcon tube containing EGM2. Cells were washed with 
phosphate buffered saline (PBS), recovered by centrifugation (5 minutes at 10,000 
RPM), and seeded on collagen I-coated 6 well plates.  
 
2.2.2.5 Dermal fibroblasts 
 
Dermal fibroblasts were obtained and cultured by Mairi Brittan. Using aseptic 
technique and local anaesthesia (lidocaine 2%), a 2-3mm punch skin biopsy was 
obtained from the lower back. The skin was stretched taut and the punch biopsy 
instrument applied firmly downwards to obtain a full thickness skin biopsy. The 
samples were cut into small pieces and plated down onto plastic underneath a 13mm 
coverslip in DMEM (BD, UK) supplemented with 10% (v/v) Hyclone-FBS and 0.1% 
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(v/v) penicillin-streptomycin. The cultures were incubated at 37°C / 5% CO2 / 95% 
relative humidity, media was changed every 2-3 days. After 2-3 weeks fibroblast 
explant cultures became visible and could be passaged with 0.25% trypsin-EDTA.  
 
2.2.3  Pluripotent stem cell lines 
 
2.2.3.1 Embryonic stem cell lines: H1 and H9 
 
Human embryonic stem cell lines H1 and H9 were supplied by Wicell, USA. Both 
lines were derived by the Thomson laboratory at the University of Wisconsin 
(Thomson et al., 1998). They had normal karyotypes and were NIH registry 
approved. H1 cells were derived from a male with blood type O+;  H9 cells were 
derived from a female with blood type A+. They were used between passages 25-80. 
 
2.2.3.2 Induced pluripotent stem cell lines: 33D6, 33D9 and 34D6 
 
Stock iPS cell lines, 33D6, 33D9 and 34D6 were kindly provided by G Sullivan, 
University of Edinburgh (Sullivan et al., 2010). They were derived retrovirally from 
healthy donors, as detailed by Sullivan et al. (2010). Briefly, fibroblasts were 
isolated and reprogrammed via infection with 4 retroviral plasmids (PMXs). Each 
contained a single reprogramming factor, either Oct3/4, Sox2, Klf4 or c-myc, 
referred to as the ‘Yamanaka factors’, or ‘Y4’. Three days post infection the cells 
were plated into 10cm plates on a feeder layer of irradiated mouse embryonic feeder 
cells (MEFs) and cultured under ES cell conditions (Chapter 2.2.2.5). Successfully 
transfected fibroblasts started to proliferate and colonies were generated after 2 to 3 
weeks. These colonies were isolated with a wide-tipped pipette tip, and cultured 
separately in ES cell conditions. Successfully established colonies proliferated and 
were analysed for signs of pluripotency, based on phenotype (Chapter 2.3) and 
genotype (Chapter 2.4). They could be used for differentiation between passages 25-
80. Passage 25 was assumed to be enough time in culture for these lines to be stable, 
established and ready to be experimented with, whilst by passage 80 is was possible 
53 
 
that the cells were sub-optimal for use given the negative effects of extended culture, 
for example development of karyotypic abnormalities (Buzzard et al., 2004). 
 
2.2.3.3 Fibroblast-derived induced pluripotent stem cell line, fiPS 
 
Fibroblasts were derived from a 30 year old male, by skin biopsy and explant culture 
as detailed in Chapter 2.2.1.5. Upon confluence, the cells were reprogrammed by 
transfection with episomal plasmids containing the Yamanaka factors (Takahashi et 
al., 2007), Oct3/4, Sox2, Klf4 and L-myc, in combination with Lin28 and Shp53, 
using the Amaxa system (Lonza; detailed in Chapter 2.8.2). Successfully transfected 
cells arose as colonies and were cultured in iPS cell conditions (Chapter 2.2.2.5). 
Established lines were characterised as iPS cells based on phenotype and genotype 
(Chapter 2.3 and 2.4, respectively). 
 
2.2.3.4 Endothelial-derived induced pluripotent stem cell line, eiPS 
 
Cord blood late endothelial outgrowth cells were derived as detailed in Chapter 
2.2.1.3. Cord blood EOC were established in culture and, upon confluence, were 
reprogrammed by transfection with episomal plasmids containing the Y4 
transcription factors with Lin28 and Shp53, using the Neon system (Invitrogen), see 
Chapter 2.8.3. Successfully transfected cells arose as colonies and were cultured in 
iPS cell conditions (Chapter 2.2.2.5). Established lines were characterised as iPS 
cells based on phenotype and genotype (Chapter 2.3 and 2.4, respectively).  
 
Detailed characteristics of all donors from which iPS cell lines were derived are 











Gender Age Type Reprogramming 
method 
33D6 Fibroblast 
M 56 Caucasian 
Retroviral 
33D9 Fibroblast Retroviral 
















Table 2.3: Characteristics of the somatic cell lines from which the iPS cell lines have 
been derived. 
 
2.2.3.5 Maintenance of pluripotent stem cell lines 
 
All ES and iPS cell lines were maintained long term on an irradiated mouse 
embryonic fibroblast (MEF) (VHBio, UK) feeder layer in 6 well Matrigel-coated 
plates with iPS culture medium (Chapter 2.1), at 37°C / 5% CO2 / 95% relative 
humidity. Media was replenished every 24 hours. When 70-80% confluent, cells 
were passaged using enzymatic and mechanical methods. Firstly, the wells were 
washed with PBS, then incubated with collagenase IV (1ml per well of a 6 well plate; 
Gibco, UK) for approximately 5 minutes at 37°C. Then the wells were observed 
under the microscope – the colonies could be seen ‘rounding up’ at the edges. They 
were once again washed with PBS, and fresh media was added, at the appropriate 
volume for the split ratio. A cell scraper (Corning, UK) was used to detach the cells 
from the plate: firm but gentle pressure was applied across the plate until most of the 
colonies had detached, but were not broken up too small. The colonies were collected 
and replated on fresh Matrigel-coated plates, atop a MEF feeder layer. The new 
plates were shaken gently in the incubator to allow colonies to settle over the whole 
well area. Wells were observed every day for signs of growth. Areas of spontaneous 
differentiation could be removed by direct aspiration or by brief incubation in 
collagenase IV for 1 minute, followed by PBS wash and media replenishment.  
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Shortly prior to differentiation, if required, cells were transitioned to feeder free 
conditions. They were passaged onto growth factor-reduced (GFR) Matrigel (BD 
Biosciences, UK)-coated plates and maintained either in MEF-conditioned media 
(R&D Systems, UK) supplemented with bFGF (10µg/ml; Peprotech, UK) or in 
mTeSR-E8 (Stem cell technologies, UK). Towards the second half of this PhD, both 
ES and iPS cell lines were maintained long term, feeder free on Matrigel-coated 
plates in mTeSR-E8. iPS cell culture technology is continuously developing, and this 
more cost-effective method of maintenance was advised from another laboratory 
(Megaw R, University of Edinburgh). Cell lines had the same characteristics when 
maintained in either MEF or feeder free conditions: morphology was the same, as 
was expression of pluripotency markers and differentiation potential (unpublished 
observations).  
Characterisation of the cell lines for pluripotency was performed by flow cytometry, 
immunocytochemistry, embryoid body assay, polymerase chain reaction and 
genomic DNA analysis via SNP array (descriptions of these techniques to follow). 
Cells were also routinely tested for mycoplasma infection. Supernatant of a confluent 
layer of cells was collected, at least 24 hours after feeding, and analysed via the 




2.3 Phenotypic analysis 
 
2.3.1  Flow cytometry 
 
2.3.1.1 Immunofluorescent staining of cell samples 
 
Cells were trypsinised as previously described, counted and resuspended in their 
original culture medium (100µl per 1x105 cells). They were pipetted into the required 
number of FACS tubes (determined by the number of antibody panels + blank 
control) and were incubated with the appropriate pre-conjugated mouse anti-human 
monoclonal antibody/ies (Table 2.4) for 30 minutes in the dark at room temperature. 
Blank controls were left unstained. Cells that required permeabilisation for 
intracellular staining were first incubated for 15 minutes on ice with 
Cytofix/cytoperm (BD Biosciences, UK; 400µl per 100µl cell solution). They were 
washed twice with 1X PermWash solution (BD Biosciences, UK), pelleted by 
centrifugation (5 minutes 10,000 RPM) and resuspended in 1X PermWash, to which 
the primary antibody/ies were added. All subsequent wash steps were performed 
with 1X PermWash to maintain the cells in a permeabilised state. After antibody 
incubation, cells were washed with PBS (1ml per FACS tube), centrifuged for 5 min 
at 10,000 RPM and resuspended in 10% Cell Fix solution (300µl per FACS tube; BD 
Biosciences, UK). Cells could be analysed immediately or stored for up to a week at 






Flurochrome Clone Host 
species; 
isotype 





























CD34 APC/Cy7 581 Mouse 
IgG1, κ 
Biolegend Red 780/60 













































Table 2.4: Mouse anti-human antibodies used in flow cytometry for characterisation 
of surface antigens of a particular cell line. Antibodies typically used to stain 
endothelial cells; antibodies typically used to stain stem cells. * required 
permeabilisation prior to staining. 
 
Cells were analysed with the BD LSRFortessa Flow Cytometer using BD FACS 
Diva software. A gating strategy based on unstained controls (to select live single 
cells of interest) is displayed in Figure 2.2. Initially, the cell population of interest 
was gated based on cell size and granularity, which excluded dead cells and debris. 
From this population, single cells were then selected, based on their height to area 
ratio. Finally, negative gates were drawn around the populations, which would 
58 
 
distinguish between stained and unstained cells when applied to the sample. A 
minimum of ten thousand events per sample was collected; data were analysed with 
FlowJo (Treestar Inc., USA).  
Experimental design of multicolour flow cytometry included the use of single-stain 
compensation beads (BDTM CompBeads, BD Biosciences, UK) to remove ‘spill 
over’ of fluorescence emission between fluorophores. Separate positive and negative 
peaks were observed for each bead set, and compensation automated by the 
FACSDiva software, which was applied to all analysis experiments.  
Figure 2.2: Gating strategy applied to the phenotypic analysis of cells by flow 
cytometry. FSC-A vs SSC-A: live population of cells based on size and granularity. 
SSC-A vs SSC-H: singlet population, excluding doublets or aggregates of cells. SSC-





2.3.1.2 Fluorescence-activated cell sorting (FACS) 
 
Cells were harvested as detailed in Chapter 2.2.1, carefully filtered through a 5ml 
cell strainer-capped tube (BD Biosciences, UK), counted with a haemocytometer and 
resuspended at 5x106 cells per ml. 1x105 cells were removed and kept as the 
unstained control sample, while the rest were incubated with the appropriate 
antibody (10µl per 5x106 cells) for 30 minutes at room temperature. The stained and 
unstained samples were washed in PBS, centrifuged for 5 minutes at 10,000 RPM 
and resuspended in culture medium adjusted to 2% serum. 10% serum culture 
medium was prepared for collection of cells after sorting. Immediately prior to 
sorting, the cells were stained with 7-AAD, a viability stain, which can enter dead 
cells through disrupted membranes and bind to DNA. Cells were sorted through a 
BD FACSAria II machine. Gating strategy of the cell populations based on unstained 
controls was similar to that used for analytical flow cytometry, with an extra stain 


















Figure 2.3: Gating strategy (based on unstained control) applied for FACS isolation 
of CD31+ cells. FSC-A vs SSC-A: live population of cells based on size and 
granularity. SSC-A vs SSC-H: singlet population, excluding doublets or aggregates 
of cells. SSC-A vs 7AAD: 7AAD negative cells (live). SSC-A vs FITC: CD31 
positive cells. 
 
Upon collection, cells were centrifuged for 3 minutes at 8,000 RPM and resuspended 
in culture medium at a volume in accordance with cell count and plate size. Media 




2.3.2  Immunocytochemistry 
 
Cells were fixed by washing twice with PBS and then incubating with 4% PFA for 
10 minutes at 4°C. They were again PBS washed twice and left in PBS at 4°C; the 
plate was sealed with Parafilm® (Bemis Flexible Packaging, USA) for long term 
storage. If permeabilisation was required (for intracellular staining), the cells were 
permeabilised with 0.1% Triton X (Sigma, UK) for 5 minutes on a rocking platform. 
To prevent non-specific antibody binding they were then blocked with 10% Normal 
Goat Serum/ Phosphate buffered saline/ Triton X (NGS-PBST) for 30 minutes. 
Following three PBST washes, samples were incubated with the appropriate primary 
anti-human antibodies overnight at 4°C, or for 1 hour at room temperature (Table 
2.5). One well per ‘raised in’ species was used as a negative control - instead of the 
primary antibody, samples were incubated with either isotype control for mouse 
primary antibody (Invitrogen, UK) or isotype control for rabbit primary antibody 
(Invitrogen, UK). 
 
Antibody Manufacturer  Isotype Raised in Dilution 
eNOS Abcam IgG Rabbit 1:200 
vWF BD Biosciences Ms IgG1, Κ Mouse 1:250 
CD31 Dako IgG1, Κ Mouse 1:100 
TRA160 Millipore IgM Mouse 1:200 
NANOG Abcam IgG Rabbit 1:200 
OCT3/4 Santa Cruz IgG2b Mouse 1:400 
Table 2.5: Primary mouse and rabbit anti-human antibodies used in 
immunocytochemistry. Antibodies typically used to stain endothelial cells; 
antibodies typically used to stain stem cells. 
 
After primary antibody incubation, cells were washed with PBST and stained with 
the appropriate secondary fluorophore-conjugated antibody, either AF488 Goat Anti-
Mouse IgG (Invitrogen, UK) to detect antibodies raised in mouse, or AF568 Goat 
Anti-Rabbit IgG (Invitrogen, UK), to detect antibodies raised in rabbit. Samples were 
then incubated at room temperature for one hour, after which they were washed with 
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PBST, followed by dH2O, to remove any saline, which may crystallise. A droplet of 
Prolong gold anti-fade DAPI (Life Technologies, UK) was applied to the cells as a 
nuclear stain, then they were cover-slipped and stored at 4°C in the dark until 
imaging on Zeiss Observer microscope with Axiovision software 4.8 (Carl Zeiss 
microscopy). 
 
2.3.3  Embryoid body assay  
 
A widely used method for pluripotency assessment in vitro is the formation of 
embryoid bodies (EBs) from stem cells. EBs are three-dimensional aggregates of 
stem cells, in which spontaneous differentiation gives rise to cells derived from all 
three primary germ layers (Sheridan et al., 2012).  
Wells of confluent ES and iPS cells were aggregated into embryoid bodies, using cell 
scrapers, and resuspended on ultra-low adherent plates. The cells were maintained 
for seven days in modified iPS culture media (Chapter 2.1). Then they were seeded 
down on 0.1% gelatin-coated plates in the same media and maintained for 10 days. 
After this period, the cells were fixed and immunostained with markers of all three 
germ layers: mesodermal (smooth muscle actin), ectodermal (beta-tubulin) and 




2.4 Genotypic analysis 
 
2.4.1  Reverse transcriptase polymerase chain reaction 
 
2.4.1.1 RNA extraction 
 
Cultured cells were washed twice with PBS and lysed by treatment with Trizol (Life 
technologies, UK; 1ml/well of a 6 well plate). Immediately after Trizol application, 
the trizol/cell mixture was collected in a 1.5ml Eppendorf tube; at this point samples 
could be stored long term at -80°C if required. For phase separation, 200µl 
chloroform was added per 1ml of trizol sample and the tubes vortexed for 15 seconds. 
Samples were incubated on ice for 10 minutes and then centrifuged for 15 minutes at 
12000 RPM at 4°C. The upper aqueous phase containing the RNA extract was 
transferred to a new tube and isopropanol was added at a 1:1 volume ratio to 
precipitate the RNA from the aqueous phase. This mixture was incubated on ice for 
30 minutes and then centrifuged at 12000 RPM for 15 minutes at 4°C to pellet the 
RNA. The supernatant was discarded and the RNA pellet washed with 70% ethanol. 
The sample centrifuged again at 7500 RPM for 5 minutes at 4°C. The ethanol was 
then carefully pipetted off and the pellet air-dried for 10 minutes. 20µl RNase-free 
H2O was then added, and the pellet resuspended. After 5-10 minutes RNA 
concentration was measured with a NanoVue spectrophotometer (GE Lifesciences, 
UK). Extracted RNA was treated to remove potential contaminants. For this, the SV 
Total RNA Isolation System was used (Promega, UK). The following reaction mix 
was set up on ice: 1µg extracted RNA, 1µl Promega buffer, 2µl Promega DNase, 
made up to 10 µl with Nuclease free H2O. The reaction was incubated at 37°C for 
one hour, then 1µl DNase stop reagent was added and the sample incubated at 65°C 
for 10 minutes. The quality of the RNA was assessed by measuring the ratio of 
absorbance at 260 versus 280nm using a NanoVue spectrophotometer (GE 
Lifesciences, UK). RNA values greater than 1.8 were acceptably pure to use for 
cDNA synthesis, as advised by GE Lifesciences; lower values indicate the presence 





2.4.1.2 cDNA synthesis 
 
RNA was reverse transcribed into cDNA with the High Capacity cDNA transcription 
kit (Applied Biosystems, Roche, UK). The following reaction was set up in an 0.5ml 
PCR tube on ice: 0.5µg RNA, 2µl 10X RT buffer, 2µl 10X RT Random Primers, 
0.8µl 25X dNTP Mix (100mM), 1µl Multiscribe Reverse Transcriptase, made up to 
20µl with Nuclease free water. In parallel, tubes were set up for each sample without 
reverse transcriptase (multiscript) as a negative control. The tubes were transferred to 
the Hybaid express PCR thermal cycler for the following incubation: 25°C for 10 
minutes, 37°C for 120 minutes, 85°C for 5 minutes, held at 4°C. The reaction 
product, cDNA, was stored at -20°C or used immediately for PCR amplification. 
Again, cDNA quality was assessed using a NanoVue spectrophotometer. cDNA 260 
versus 280nm ratios which were greater than 1.8 were acceptable to use for PCR. 
cDNA samples were diluted 1:1 with nuclease free water before PCR amplification. 
 
2.4.1.3 Polymerase Chain Reaction 
 
To each PCR tube, the following were added: 10µl AmpliTaq Gold PCR master mix 
(Applied Biosystems, Roche, UK), 2µl forward primers, 2µl reverse primers (Table 
2.6), and 1µl template cDNA. The reaction mix was made up to 20µl per tube with 
nuclease free H2O. The forward and reverse primer sequences for each gene are 
displayed in Table 2.6.  The samples were loaded into the Hybaid PCR express 
thermal cycler. Standard PCR cycle parameters were as follows: initiation (required 
for hot start polymerases to be heat activated) at 95ºC for 5 minutes, denaturation at 
95ºC for 15 seconds, annealing at 60ºC for 15 seconds, extension at 72ºC for 65 
seconds, final elongation at 72ºC for 7 minutes and final hold at 4ºC. Denaturation, 
annealing and extension steps were repeated for 30 cycles. Taq DNA polymerase 
acts by extending the annealed oligonucleotides to synthesise DNA from the 3‘end of 
the oligonucleotide. This process of denaturation, annealing and synthesis is repeated 
numerous times, with each newly synthesised DNA acting as a template for the next 
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reaction. Agarose gel electrophoresis (Chapter 2.4.1.4) was used to ensure that the 
PCR product was the correct size. 
Plasmid-spanning primer sequences: exogenous Product 
size 
OCT 3/4 Forward CATTCAAACTGAGGTAAGGG 134bp 
Reverse TAGCGTAAAAGGAGCAACATAG 
KLF4 Forward CCACCTCGCCTTACACATGAAGA 282bp 
Reverse TAGCGTAAAAGGAGCAACATAG 
SOX2 Forward TTCACATGTCCCAGCACTACCAGA 160bp 
Reverse TTTGTTTGACAGGAGCGACAAT 
L-MYC Forward GGCTGAGAAGAGGATGGCTAC 258bp 
Reverse TTTGTTTGACAGGAGCGACAA T 
Genome-spanning primer sequences: endogenous 
OCT 3/4 Forward CCCGCCGTATGAGTTCTGTG 130bp 
Reverse CATCGGAGTTGCTCTCCACC 
KLF4 Forward AGCATCGTGGCCCCGGAAAAGGACC 152bp 
Reverse TGATTGTAGTGCTTTCTGGCTGGGCTCC 
SOX2 Forward AGTCCGAGGCCAGCTCCA 119bp 
Reverse TAGTGCTGGGACATGTGAAGTC 
L-MYC Forward TACCCTCTCAACGACAGCAG 136bp 
Reverse GTCTCCTCATGGAGCACCAGG 
Table 2.6: Primer sequences, and their PCR product sizes, for the detection of 
episomal plasmid (exogenous) or genomic (endogenous) Oct3/4, Klf4, Sox2 and L-
myc. Bp= base pair. 
 
2.4.1.4 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used for separation of different sized DNA 
fragments within a sample. A 1.5% agarose gel solution was prepared in 1X 
Tris/Borate/EDTA (TBE) buffer (Chapter 2.1). Heating was required to dissolve the 
agarose; once cooled, 3X GelRed (Biotium, UK) was added and the mixture poured 
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into a gel tray containing a gel comb to create the wells. This was allowed to set, then 
10X loading dye (Thermo Scientific, UK) was added to the DNA samples (3.2µl per 
20µl sample). The samples were loaded into the gel wells, along with a 1kb 
GeneRuler marker (Fermentas, UK). DNA gels were typically run at 120 V in 1X 
TBE buffer. Bands were visualised using a UV light source (Sygene), and imaged 
with GeneSys software. 
 
2.4.2  Detection of genetic variations via single nucleotide polymorphism 
array 
 
In order to verify that there were no aberrations in genomic DNA following 
reprogramming, iPS karyotypes were analysed for duplications, deletions and areas 
of homozygosity, via SNP array. 
DNA extraction was performed using MasterPure Complete DNA and RNA 
Purification Kit (Epicentre, UK). First of all, the cell samples were lysed. 
Approximately 0.5-1.0x106 cells were collected per well and pelleted by 
centrifugation. The supernatant was discarded and the pellet resuspended in Tissue 
and Cell Lysis solution containing Proteinase K at a dilution of 1:300. This was 
mixed thoroughly and incubated at 65°C for 15 minutes; the sample was vortexed 
every 5 minutes. 1µl of 5mg/ml RNase A was added per sample and the samples 
incubated for 30 minutes at 37°C. After this, the samples were placed on ice and 
150µl MPC Protein Precipitation Reagent added. They were vortexed for 10 seconds, 
then the debris pelleted by centrifugation at 4°C for 10 minutes at 10 000G. The 
supernatant was transferred to a clean tube and the pellet (containing protein and 
other contaminants) discarded. 500µl isopropanol was added to each sample of 
recovered supernatant and the tubes inverted 30-40 times. The DNA was pelleted by 
centrifugation at 4°C for 10 minutes. The DNA pellet was rinsed twice with 70% 
ethanol and resuspended in 35µl TE buffer. DNA concentration and purity was 
measured using a NanoVue spectrophotometer. The samples were processed by 
AROS (Denmark) who analysed the samples with the HumanCytoSNP-12 DNA 




2.5 In vitro functional analysis 
 
2.5.1  Vascular tubule formation  
 
A key feature of endothelial cells is their capacity for angiogenesis, the sprouting of 
new blood vessels from pre-existing ones, which occurs in both physiological and 
pathological processes (Lamalice et al., 2007). Angiogenic potential of endothelial 
cells can be tested in vitro. When cultured on Matrigel (a laminin-based substrate; 
BD biosciences, UK), endothelial cells form connections that resemble tubules. The 
movement of endothelial cells and the connections they form with each other is an 
indication of their ability to form new vessels through angiogenesis in vivo. As this 
assay is fairly simple and quick to perform, it has become a prominent in the in vitro 
study of angiogenesis (Grant et al., 1989). 
Phenol free, GFR Matrigel was thawed at 4°C until it reached a gel state. 150µl 
Matrigel was plated out per well of a 48 well plate. The surrounding wells were filled 
with PBS. The plate was incubated at 37°C for 1 hour. Meanwhile, cells were 
harvested, filtered through a 20µm cell strainer and counted. 20 000 cells were 
suspended in 250µl medium and applied to the Matrigel plates. After 24 hours, the 
plates were imaged with the Zeiss Observer microscope, connected to an AxioCam-
mRM camera (Carl Zeiss microscopy, Germany) and processed via AxioVision 4.8 
software (Carl Zeiss microscopy, Germany). The whole well was photographed 
using the Axiovision Mosaic tool. Images were quantified by ImageJ to count the 
number of tubules formed, and the number of junctions between tubules. 
 
2.5.2  Wound healing 
 
A scratch assay was used for in vitro modelling of the processes of cell migration and 
proliferation that occur during wound healing. In this assay, the endothelial 
monolayer is scratched; the cells at the edges of the scratch are observed over time as 
they move towards each other, until the wounded area is recovered and cell-cell 
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connections are re-established. This assay mimics the processes of migration and 
proliferation that occur in vivo in response to endothelial denudation of blood vessels 
(Haudenschild and Schwartz, 1979). 
Cells were grown to confluence in 6 well plates. A P1000 pipette tip was used to 
mark a vertical line down the middle of the well. The wounded area was washed and 
maintained in Endothelial Medium at 37°C in a humidified 5% CO2 incubator. The 
width of the wounded area was imaged at time points: 0hr, 6hr and 24hr, using the 
Zeiss Observer microscope. The Axiovision Mosaic tool was used to image the 
whole well. Data were quantified as percentage area of cell coverage over time, 
calculated by ImageJ software (National Institutes of Health, USA).  
 
2.5.3  Nitric oxide release 
 
A key function of endothelium is the release of vasodilator Nitric Oxide (NO). In 
order to assess NO release in vitro, the ‘Total NO/Nitrate/Nitrite Assay’ kit was used 
(R&D Systems, UK). Confluent layers of cells were stimulated with ACh (10µM) 
(Miochol-E; Bausch + Lomb, UK). Supernatant was collected after 24 hours, 
centrifuged to remove debris and stored at -20°C until the assay was run.  
Due to the short half-life of NO, the R&D kit measures the concentrations of its 
metabolites: nitrite and nitrate, in the cell supernatant. The assay utilises the Griess 
reaction- the measurement of organic nitrite compounds within a sample. Thus an 
initial step of enzymatic conversion of nitrate to nitrite is required, by use of nitrate 
reductase. Firstly the concentration of endogenous nitrite was measured, then 
endogenous nitrate was converted to nitrite, so that total nitrite could be measured. 
Endogenous and converted nitrite were detected colourimetrically as azo dye 
products (which absorb light at 540-570nm) of the Griess reaction, a test widely used 
for the detection of organic nitrite compounds (Eid et al., 2007; Kuklinska et al., 
2009). Standard dilutions of both nitrite and nitrate (provided with the kit) were run 
in parallel with the samples, ranging from 0 to 200µmol/L. Negative controls were 
also included: blank wells and media-only controls. Standard curves were plotted 
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along a log of concentration verses log corrected optical density. The equation of the 
line of best fit was used to calculate the concentrations of the samples. 
2.6 In vivo functional analysis 
 
2.6.1  Sponge implantation 
 
To assess the function of derived endothelial cells in vivo, the murine subcutaneous 
sponge implantation model was used. This model is widely used to assess the 
influence of compounds (Hague et al., 2002; Small et al., 2005) or cells (Barclay et 
al., 2012) on spontaneous vascularisation of subcutaneous sponges. The protocols 
described here are derived from Barclay et al. (2012). All animal experiments were 
carried out in accordance with the British Home Office Animals (Scientific 
Procedures) Act 1986. 
Cells to be implanted were harvested and counted. 1 x 105 cells per sponge were 
suspended in 100µl 1:1 EGM2/ phenol free GFR Matrigel (BD Biosciences, UK). 
Sponges were compressed into this suspension in 0.5ml eppendorf tubes, and 
incubated at 37°C for 30 minutes to allow the Matrigel to reach a gel-like state. 
Matrigel-only sponges were prepared as matched controls. Male NSG mice aged 10-
12 weeks (Charles River, UK) were anaesthetised intraperitoneally with Domitor 
(containing Medetomidine; Orion Pharma, UK) and Vetalar (containing Ketamine; 
Pfizer, UK); both were administered at 0.1ml per 10g body weight. Upon sedation, 
an analgesic, Vetergesic (containing buprenorphine; Alstoe Animal Health, UK), was 
administered subcutaneously at 0.1mg per kg body weight. The site of surgery was 
shaved and wiped with anti-bacterial surgical swab. The skin was ‘nicked’ with fine 
scissors, and subcutaneous pouches were created with curved forceps and scissors. 
Matrigel-only sponges were implanted into the left flank and cell-embedded sponges 
in the right. The sides of the wound were apposed with forceps and closed using skin 
staples (9mm Autoclips, Harvard Apparatus, USA). After surgery, a reversal agent, 
Antisedan (containing Atipamezole; Orion Pharma, UK) was administered 
subcutaneously at 0.05ml per 10g body weight and the mice observed on a heat mat 
until recovery. The wound was checked every day for 3 days post-surgery and after 7 
days the staples were removed. After 21 days, mice were sacrificed by cervical 
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dislocation and the sponges removed. Sponges were fixed in 4% PFA overnight, then 
transferred to 70% IMS and stored at 4°C. 
  
2.6.2  Sponge processing 
 
Fixed sponges were processed by the histology service, QMRI, University of 
Edinburgh. Briefly, sponges were embedded in paraffin wax, and 4µm transverse 
sections were cut and adhered onto poly-l-lysine coated slides. Slides were oven 
dried overnight at 37°C, then dewaxed by xylene and rehydrated through a series of 
5 minute emersions in ethanol, at 99%, 90% and 70%.  
Sections to be assessed for vessel density (Chapter 2.6.3) were stained with 
haematoxylin and eosin (H&E) for five minutes, rinsed in distilled water, dipped in 
acid alcohol and rinsed in distilled water for a further 15 minutes. Slides were then 
immersed in eosin for one minute and then washed with distilled water. Stained 
slides were dehydrated prior to cover slipping, by emersion for one minute in 95% 
ethanol, followed by one minute in 100% ethanol, then five minutes in xylene.  
2.6.3  Vessel density counts 
 
H&E stained sponge sections were scored by means of a Chalkley count, to 
determine blood vessel density (Fox et al., 1995; Hague et al., 2002). A 25-point 
Chalkley eyepiece graticule was used to examine the sponge sections at x40 
magnification. Three non-overlapping counts were performed in the areas with the 
highest vascularity, subjectively identified under low magnification (x10); slides 
were examined blinded to whether the sponge contained cells or was a Matrigel 
control. The eyepiece was rotated to the point where the maximum number of vessels 
was overlaid by dots. The mean of these triplicate counts was taken on two slide 
sections per sponge to give the overall Chalkley score.  
 
2.6.4  Immunocytochemistry 
Paraffin sectioned sponges were also analysed by immunocytochemistry, to 
determine whether the cells lining the vessels were of mouse or human origin. 
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Vessels were identified by staining with either SMA or CD31 antibodies (raised in 
rabbit) reactive to both mouse and human cells. These were paired with human 
specific antibodies (CD31 and CD146, respectively), raised in mouse (Table 2.7), for 
the detection of human cells within the sponges.  
Paraffin embedded sponge sections were first dewaxed in 100% xylene (10 min) and 
rehydrated by immersion (5 min in each) in a graded sequence of alcohols: 100% - 
90% - 80% - 70% ethanol, and dH2O. Heat-induced epitope retrieval was then 
performed: the slides were placed in simmering 1X EDTA solution for 20 minutes in 
a water bath. They were cooled in running tap water, then transferred to a Sequenza 
staining rack. 3 drops of Image-It-Fx signal enhancer were applied to each slide, then 
slides were blocked with PBST-10% NGS for 30 minutes. The slides were then 
washed three times with PBST (wash medium) and the primary antibodies added at 
the appropriate dilution (Table 2.7). 
Table 2.7: Details of the primary and secondary antibodies used for 
immunocytostaining of paraffin embedded sponge sections. Each set comprised an 
antibody cross reactive to mouse and human (stained green), and an antibody specific 
to human cells (stained red). Antibodies were diluted with PBST-2% NGS. 
200µl of each antibody set was added per slide, and they were incubated either 













Isotype matched IgG control to mouse or rabbit primary 
antibodies; negative control 
AF488, green 








Abcam 1:100 AF488, green 





Epitomics 1:100 AF488, green 
CD146 Mouse Human Abcam 1:100 AF568, red 
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five times with wash medium, and stained with secondary antibodies (fluorescent 
conjugates). AF568 Goat Anti-Mouse IgG (Invitrogen, UK) and AF488 Goat Anti-
rabbit IgG (Invitrogen, UK) were prepared in PBST-2% NGS at dilutions of 1:200; 
200µl added to each slide. They were incubated at 37°C for 3 hours, then washed 
five times with wash medium. The slides were removed one at a time from the 
Sequenza rack and washed in tap water, blotted, and Prolong Gold Antifade Reagent 
with DAPI applied. Slides were cover-slipped and stored at 4°C in the dark until 
analysis using light microscopy. Stained sponges were visualised using the Zeiss 
microscope (Axiovision software) or the Olympus BX61 microscope (Velocity 
software) for higher resolution. The Matrigel-only sponges were used as positive 






2.7 Endothelial differentiation of ES and iPS cell lines 
 
Optimal endothelial differentiation of ES and iPS cell lines was developed through 
comparison of four different protocols. These protocols were based on preliminary 
investigations, published protocols and collaboration with Professor Andrew Baker’s 
laboratory (University of Glasgow). 
Many protocols begin with transferring stem cell populations to standard 
Differentiation Medium (αMEM, FCS, β-mercaptoethanol; Sone et al., 2007; 
Narazaki et al., 2008; Choi et al., 2009), and this medium was found to produce the 
highest endothelial differentiation efficiency from previous studies in the laboratory 
(E Skinner, MSc in Cardiovascular Biology, 2010). Cells were isolated using FACS 
based on their expression of CD31 or CD34, 7 or 14 days after plating.  
In endothelial differentiation protocol A (Figure 2.4), stem cells were transferred to a 
single-cell monolayer culture system, on collagen I-coated plates in differentiation 
medium. At day seven, cells negative for SSEA3 and SSEA4 pluripotency markers 
were isolated via FACS sorting and further cultured in endothelial medium on 
collagen I. At day fourteen, CD31+ cells were sorted and further cultured on collagen 
I-coated plates in endothelial medium. 
 
Figure 2.4: Endothelial differentiation protocol A. Stem cells were plated onto 
collagen I in differentiation medium. After seven days, SSEA3-SSEA4- cells were 
isolated by Fluorescence-Activated Cell Sorting (FACS) and replated on collagen I 
in endothelial medium. Cells expressing CD31 were isolated by FACS on day 14 and 
culture continued on collagen I in endothelial medium.  
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This protocol was adapted to form endothelial differentiation protocol B (Figure 2.5), 
eliminating the initial pluripotent sort. Stem cells were transferred to a single-cell 
monolayer culture system, on collagen I-coated plates in differentiation medium. At 
day seven, CD31+ cells were isolated via FACS sorting and further cultured in 









Figure 2.5: Endothelial differentiation protocol B. Stem cells were plated onto 
collagen I in differentiation medium. After seven days, cells expressing CD31 were 
isolated by Fluorescence-Activated Cell Sorting (FACS) and replated on collagen I 
in endothelial medium.  
 
Some published protocols use the addition of mesoderm-inducing cytokines (for 
example, BMP4, Activin A, VEGF, FGF) for endothelial differentiation (James et al., 
2010; Goldman et al., 2009; Ferreira et al., 2007). Protocol C (Figure 2.6) was 
developed based on the studies of Ferreira et al. (2007). Stem cells were transferred 
to a single-cell monolayer culture system, on collagen I-coated plates in 
differentiation medium. At day seven, CD34+ cells were sorted and further cultured 





Figure 2.6: Endothelial differentiation protocol C. Stem cells were plated onto 
collagen I in differentiation medium. After seven days, cells expressing CD34 were 
isolated by Fluorescence-Activated Cell Sorting (FACS) and replated on collagen I 
in endothelial medium, with or without VEGF supplementation.  
 
After collaboration with the University of Glasgow, unpublished protocol D (Figure 
2.7) was adopted. Stem cells were aggregated into EBs in suspension with 
mesoderm-inducing cytokines: 10 ng/ml BMP4, 10 ng/ml Wnt3a, 10 ng/ml VEGF, 5 
ng/ml Activin A and 400 nM BIO. At day two, the following cytokines were added 
to the suspension: 20 ng/ml BMP4, 10 ng/ml Wnt3a, 10 ng/ml VEGF, 5 ng/ml 
Activin A, and 10 ng/ml FGFa, along with 400nM BIO (a selective ROCK1 inhibitor; 
ROCK 1 inhibition is thought to contribute to a reduction in vascular inflammation 
through upregulation and activation of eNOS, Noma et al., 2006). At day three, EBs 
were disaggregated and the cells transferred to a single-cell monolayer culture 
system, on 0.1% gelatin in endothelial medium supplemented with 50ng/ml VEGF. 
At day seven, CD31+ cells were sorted and further cultured on 0.1% gelatin coated 
plates in endothelial medium with 50ng/ml VEGF supplementation. This protocol 
was supplied by the University of Glasgow- the decision of which cytokines to use 
and their concentrations had been previously optimised on ES cell lines H1 and H9. 






Figure 2.7: Endothelial differentiation protocol D. Stem cells were aggregated into 
embryoid bodies, and suspended in Stemline media supplemented with mesoderm-
inducing cytokines. At day three, embryoid bodies were disaggregated and plated as 
a monolayer on 0.1% gelatin in endothelium media supplemented with VEGF. At 
day seven, cells expressing CD31 were isolated by Fluorescence-Activated Cell 
Sorting (FACS) and further cultured on 0.1% Gelatin in Endothelial medium 





2.8 Cellular reprogramming of fibroblasts and endothelial cells 
 
2.8.1  Episomal vectors 
 
Episomal vectors are circular plasmids which are replicated in the nucleus of 
eukaryotic cells (Van Craenenbroeck et al., 2000). They were used as a delivery 
system of the cellular reprogramming factors, a method which was first described by 
Okita et al. (2011). Episomal vectors do not integrate into the host genome and 
therefore avoid the risk of mutagenesis, a considerable concern associated with 
traditional retroviral reprogramming methods (Yamanaka, 2009). Three episomal 
plasmids were supplied by Addgene (Accession numbers: pCXLE-hOCT3/4-Shp53: 
27077; pCXLE-hSK: 27078; pCXLE-hUL: 27080; Cambridge, MA, USA; Okita et 
al., 2011).  Between them, they contained the four Yamanaka factors (Y4) required 
for reprogramming: Oct3/4, Sox2, Klf4 and L-Myc, and two factors which increase 
reprogramming efficiency: Lin28 and Shp53. In parallel, cells were transfected with 
a single GFP plasmid, as a positive control and an indication of electroporation 





Figure 2.8: Three episomal expression plasmids, with the pCXLE backbone, were 
used to deliver the reprogramming factors to cells. They contained the Yamanaka 
factors: Octamer-binding transcription factor-3/4 (OCT3/4), SRY-related-high-
mobility-group (HMG)-box protein-2 (SOX2), Krupple-like factor 4 (KLF4), L-
MYC, and two factors to enhance reprogramming efficiency: short hairpin RNA 
against p53 (SHP53) and LIN28. To give an indication of successful transfection, a 
GFP episomal plasmid control was transfected in parallel. 
 
These plasmids were prepared by maxi-preparation, the large-scale method used to 
extract and purify plasmid DNA, which was carried out by Olga Tura and Mairi 
Brittan, using the Genopure Plasmid Maxi Kit (Roche). 
 
2.8.2  Amaxa system: reprogramming of fibroblasts 
 
Fibroblast reprogramming experiments were carried out on the Amaxa system 
(Lonza, UK), used in conjunction with the Amaxa ® NDHF Nucleofector® Kit 
(Lonza, UK). 0.5x106 cells were used for each electroporation, and two 
electroporations were carried out for each cell line: one with the episomal plasmids 
containing the reprogramming factors, and one with the GFP control plasmids. Cells 
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were harvested and counted with a haemocytometer. Each 0.5x106 cells were able to 
take up 5µg DNA: this is enough for efficient reprogramming of the cells whilst 
maintaining viability. 0.5x106 cells were resuspended in 100µl buffer + supplement 
(provided by Amaxa kit) and, 5µg of the three plasmids added. The cell/ plasmid/ 
buffer mixture was carefully pipetted into the electroporation cuvette, and was 
electroporated with the Amaxa machine, at the ‘U-023 NHDF high efficiency’ 
setting (the Nucleofector® program recommended for dermal fibroblast transfection). 
Cells were plated on 0.1% gelatin in 10% DMEM; antibiotics were omitted from the 
media for the first 24 hours. Images of the GFP control were taken after 24 hours, to 
give an indication of successful electroporation and plasmid transfection.  
 
2.8.3  Neon system: reprogramming of endothelial cells 
 
The Neon system provides 24 different nucleofection settings, which vary in terms of 
pulse number, length and amplitude. From previous experiments in the laboratory 
carried out by Olga Tura, setting 18 (2 pulses of 950mV for 30ms) appeared to yield 
the most effective transfection of episomal plasmids into endothelial cells 
(unpublished data). In later experiments, settings 16 to 20 were also used in an 










Table 2.8: Neon system electroporation settings 16-20 used for transfection of 
somatic cells with episomal plasmids containing reprogramming factors.  
Neon Setting Number of pulses mV Duration of 
pulses (ms) 
16 2 1400 20 
17 2 850 30 
18 2 950 30 
19 2 1050 30 
20 2 1150 30 
80 
 
Cells were harvested, counted and centrifuged into 0.1x106 cell pellets. As before, 
for each cell line to be transfected, two electroporations were carried out: one with 
the episomal plasmids containing the reprogramming factors, and one with the GFP 
control plasmid. Each 0.1x106 cell pellet was resuspended in 10µl Neon buffer, in a 
V-bottomed tube and plasmids were added (1µg total DNA per 0.1x106 cell pellet). 
The cell/plasmid solution was carefully drawn up into the 10µl gold tip of the Neon 
pipette, and electroporated by the Neon system, at the appropriate setting. 
Electroporated cells were seeded onto pre-warmed collagen I coated plates in 
endothelial medium; antibiotics were omitted from the media for the first 24 hours. 
GFP transfected cells were imaged after 24 hours. 
In the laboratory, the Amaxa system had previously been used successfully for the 
reprogramming of fibroblasts, using its fibroblast-specific settings for high efficiency. 
As there were no endothelial-specific settings for electroporation of endothelial cells, 
the Neon system was used instead. This had the added benefit of multiple 
electroporation settings which were required in later experiments. 
 
2.8.4  Culture of transfected cells  
 
Electroporation causes transient permeabilisation of cell membranes, allowing entry 
of the plasmids. Following transfection, cells were cultured in their original media 
for seven days (the first 24 hours of which were without antibiotics to prevent them 
entering the still-permeabilised cell membranes), which was replenished every 2-3 
days. After 7 days, the cells were transferred to iPS cell culture conditions in a 9cm 
culture dish: either on a MEF feeder layer in iPS cell culture medium (Chapter 2.1), 
or on Matrigel-coated plates with E8 media. Media was replenished every 2-3 days 
(Figure 2.9). Successfully transfected cells proliferated into clonogenic colonies and 
could be detected by eye three to four weeks after electroporation. Individual 
colonies were manually isolated with a wide-tipped P20 pipette tip, and cultured 





Figure 2.9: Episomal plasmids and protocol for the reprogramming of fibroblasts or 
endothelial cells, to generate fibroblast-iPS (fiPS) or endothelial-iPS (eiPS) cells.      
* First 24 hours without antibiotics 
 
2.8.5  Characterisation of reprogrammed colonies 
 
Once the colonies had been established and could be expanded into 6 well plates, 
they were characterised to verify their pluripotency. Their phenotype was assessed 
based on detection of pluripotency markers SSEA3, SSEA4, TRA 1 60, Nanog and 
Oct3/4 by flow cytometry (Chapter 2.3.1) and immunocytochemistry (Chapter 2.3.2). 
Reverse transcriptase PCR was carried out to identify the presence of endogenous 
expression of Oct3/4, Sox2, Klf4, L-Myc, and to make sure that there was no longer 
expression of these genes exogenously, within any remaining episomal plasmids 
(Chapter 2.4.1). Cells were also used to form embryoid bodies to test whether they 
could spontaneously differentiate to all three germ layers: an indication of their 
pluripotency (Chapter 2.3.3). Genomic DNA was extracted to be assessed for any 
aberrations or alterations following transfection (Chapter 2.4.2). Successfully 
transfected clones expressed all pluripotency markers, had endogenous rather than 
exogenous expression of the Y4 genes, could form all three germ layers and had 
‘normal’ genomic DNA, i.e. were free from significant deletions or duplications. 
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2.9 Data analysis and statistics 
 
All statistical analyses were carried out using Microsoft Excel and Graphpad Prism 
(GraphPad Software, USA). Quantitative data are shown as mean ± standard error of 
the mean (SEM) unless otherwise indicated. Student’s t tests (paired or unpaired), 
one-way and two-way ANOVA were used to determine statistical significance of 
differences between data sets, followed by Bonferroni post hoc corrections. 













Introduction: Induced pluripotent stem cell technology primarily focussed on the 
reprogramming of fibroblasts to an embryonic-stem cell like state. As the field has 
developed, the importance of cell source has been studied to enhance reprogramming 
and differentiation efficiencies. There are reports that iPS cell lines, whilst fulfilling 
the criteria for pluripotency, have enhanced differentiation potential towards their 
cell type of origin (Kim et al., 2010). Endothelial cells can be obtained from blood 
outgrowth and would be a convenient source of cells for reprogramming. 
Furthermore, pluripotent stem cells derived from endothelial cells may have 
enhanced capacity to reform endothelium, and therefore may have applications in 
therapeutic vascular regeneration. 
Methods and Results: Fibroblasts and endothelial cells (from cord or peripheral 
blood, and the vessel wall) were obtained from five healthy donors. They were 
reprogrammed via transfection of episomal plasmids, for delivery of ‘Yamanaka’ 
transcription factors Oct3/4, Sox2, Klf4 and L-myc, as well as Lin28 and Shp53. 
Two out of three fibroblast lines and one endothelial cell line were successfully 
reprogrammed. Reprogramming efficiency - taken as the percentage of cells from the 
starting population from which colonies were derived - was low for fibroblasts 
(0.0002%) and endothelial cells (0.003%). Reprogramming was unsuccessful in all 
endothelial cell lines derived from vasculature or from peripheral blood. This was 
despite GFP positive controls run in parallel, demonstrating successful 
electroporation and plasmid transfection. Fibroblast-induced pluripotent stem (fiPS) 
cells and endothelial-induced pluripotent stem (eiPS) cells were successfully 
expanded in culture for multiple passages. Expression of Oct3/4, Sox2, Klf4 and L-
myc was apparent at passages 31-35 and appeared endogenous, suggesting plasmids 
had been shed and cells were inherently pluripotent. Apart from a minor deletion on 
chromosome 6 of fiPS, both lines were karyotypically normal. Flow cytometry 
analysis showed high expression of pluripotency markers SSEA3 (fiPS, 79%±6%; 
eiPS, 79%±5%) and SSEA4 (fiPS, 91%±4%; eiPS, 96%±1%) in late passage cells, 
whilst immunocytochemistry demonstrated expression of Nanog, Tra 1 60 and 
Oct3/4 in both lines. Spontaneous differentiation within embryoid bodies (stem cell 
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aggregates) demonstrated that both fiPS and eiPS could differentiate to all three germ 
layers, confirming their pluripotent nature.   
Conclusions: Pluripotency can be induced in fibroblasts and endothelial cells through 
episomal plasmid transfection of Oct3/4, Sox2, Klf4, L-myc, Lin28 and Shp53. 
Reprogramming efficiency, though low, was marginally higher for endothelial cells 








Pluripotent stem cells may be used to generate endothelial cells for therapeutic use in 
the treatment of patients with coronary heart disease or peripheral vascular disease. 
Induced pluripotent stem (iPS) cell technology offers many benefits: patient-derived 
stem cells can be stored for long periods of time, are readily expandable, have 
unlimited capacity for renewal, and would avoid immune-rejection if administered 
back to the same patient (Yamanaka, 2012; Cherry and Daley, 2013).  
 
Initially, iPS cell technology focussed on the reprogramming of fibroblasts to an 
embryonic stem cell-like state (Takahashi et al., 2006; 2007). However, as the field 
has progressed over the past decade, other somatic cell types have been 
reprogrammed. For example, iPS cells have been derived from pancreatic islet beta 
cells (Bar-Nur et al., 2011), keratinocytes (Aasen et al., 2008), peripheral blood cells 
(Loh et al., 2009) and neural progenitor cells (Eminli et al., 2008). These studies 
suggest that somatic tissues have variable reprogramming efficiencies, many of 
which may be greater than fibroblasts. For example, induction of pluripotency has 
been reported as 100 fold more efficient in keratinocytes than in fibroblasts (Aasen et 
al., 2008). In addition, differentiation efficiency along lineages related to the donor 
cell may be enhanced (Kim et al., 2010), thought to be a consequence of epigenetic 
memory. 
 
For these reasons, it could be suggested that iPS cells derived from endothelial cells 
represent the ideal population for generation of patient-specific endothelium, and are 
likely to offer benefits over fibroblast-derived iPS cells. Another benefit is that 
endothelial outgrowth cells are more readily accessible as they are obtained from a 
blood sample, a minor well-tolerated procedure, rather than fibroblasts which require 
a skin biopsy. Therefore, endothelial cells obtained from vascular biopsies and 




3.2. Hypothesis  
 
Endothelial cells can be reprogrammed to pluripotency with greater efficiency than 
fibroblasts, and, therefore, represent an optimal starting somatic cell population for 




 To compare the reprogramming efficiency of dermal fibroblasts to that of 
endothelial cells. 
 To characterise fibroblast- and endothelial cell-derived iPS cells, and 




3.4. Method development 
 
3.4.1. Cellular reprogramming 
 
Typically, somatic cells have been reprogrammed by delivery of transgenes within 
retroviral vectors (Takahashi et al., 2007). However, these integrate into the genome, 
and, therefore, have the potential to create mutations which may affect differentiation 
potential, thus limiting the utility of these cells in both research and clinical 
applications (Varas et al., 2009). For these reasons it was decided to use an episomal 
plasmid system of reprogramming, described by Okita et al. (2011) as a viral- and 
integration-free method which avoids risk of genomic abnormalities (Chapter 2.8).  
 
Somatic cell populations to be reprogrammed were either fibroblasts or endothelial 
cells, harvested from healthy volunteers as detailed in Chapter 2.2.1. Five healthy 
donors were used to obtain endothelial cells from the superficial forearm vein, 
peripheral blood or cord blood. Three of these donors were also used to obtain 




Age Sex Type 
Endothelial cells 
Fibroblasts 
Blood Vessel wall  
D1 30 M British South 
Asian 
   
D2 30 F Caucasian *   
D3 29 F Caucasian    
D4 31 M Caucasian    
D5 65 M Caucasian    
 
Table 3.1: Details of five healthy donors, whose somatic cells were used for 
reprogramming. Endothelial cells were derived either from blood (*cord blood) or 
the vessel wall. Fibroblasts were derived from skin biopsy. 
 
Cells were reprogrammed as detailed in Chapter 2.8. Of the multiple endothelial 
lines (four from human peripheral blood and four from vascular biopsies) that were 
transfected with the reprogramming factors, no colonies formed (Table 3.2). This 
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indicates that reprogramming efficiency is low. In contrast, a cord blood endothelial 
cell line (from donor 2) was successfully reprogrammed, as were 2 out of 3 fibroblast 
lines (from donors 1 and 5). Attempts to improve reprogramming efficiency in 
peripheral blood and vessel wall endothelial cells were made by altering 
electroporation parameters. Endothelial cells derived from donors 1, 2, 3 and 4 were 
electroporated with Neon system setting 18; however, the majority of these lines did 
not produce colonies. Therefore, settings 16-20 were used for D5 but this did not 














Table 3.2: Attempted reprogramming of endothelial cells from blood and the vessel 
wall, and fibroblasts. = colonies arose following Y4 plasmid transfection. X= no 
colonies arose following Y4 plasmid transfection. All endothelial lines were 
reprogrammed with the Neon system setting 18. Endothelial cell lines marked * were 
also reprogrammed with Neon system settings 16, 17, 19 and 20. P= endothelial cells 
derived from peripheral blood; C= endothelial cells derived from cord blood. 
 
 
Donor reference Endothelial cells Fibroblasts 
Blood Vessel wall 
D1 XP X 
D2  C   
D3  XP X X 
D4  XP X  
D5  XP X*  
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To verify plasmid uptake, a GFP control plasmid was transfected into cells in parallel 
to reprogramming plasmid transfection. The presence of GFP positive cells indicated 


































Figure 3.1: Representative examples of expression of GFP 24 hours after 
electroporation of cells with pCXLE-eGFP, in endothelial cells derived from blood, 
vessel wall, and fibroblasts derived from healthy donors. Bar: 1mm.  
 
Successfully reprogrammed fibroblast populations exhibited morphological changes 
approximately 2 weeks after transfection, prior to the emergence of colonies. The 
cell layer, which once comprised solely long spindle-like fibroblasts (Figure 3.2A), 
developed areas of small rounded cells (Figure 3.2B). These were the first stages of 
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development of pluripotent stem cell colonies. Similar morphological changes 
occurred in successfully transfected cord blood derived endothelial outgrowth cells.  
 
 
Figure 3.2: Morphological changes occur in culture following reprogramming. A) 
Monolayer of fibroblasts 5 days after transfection with reprogramming factors, B) 
Morphological changes occur in the monolayer after approximately 12 days- some 
cells became small and rounded (arrows). Bar = 1mm  
 
With further time in iPS culture conditions, many of these morphologically distinct 
areas developed into ‘emerging colonies’ (Figure 3.3). The small, rounded cells had a 
high nucleus-to-cytoplasm ratio (determined by eye, not quantitatively verified), 
typical of embryonic stem cells (Thomson et al., 1998). As they grew, they became 
















Figure 3.3: Colonies emerge in iPS culture conditions, prior to isolation. The 
morphology of successfully transfected fibroblasts and EOC changed considerably, 
to resemble embryonic stem cells. A&B = examples of colonies from D1 fibroblasts, 
C&D = examples of colonies from D2 cord blood derived endothelial outgrowth 
cells. Bar = 1mm.  
 
At the early stages (before passage 10) of expanding colonies in culture, passaging 
and sub-culture was a delicate procedure as the colonies were very small and highly 
sensitive to cell culture conditions. Consequently, despite labour intensive 
maintenance (daily observation, aspiration of differentiated areas within the well and 
media replenishment), some colonies differentiated and were lost over time. This 
accounts for the difference seen between number of colonies isolated versus number 




Reprogramming efficiency was determined by calculating the percentage of cells 
from the starting population which were successfully reprogrammed and formed 
established iPS cell lines: number of established colonies generated / number of cells 
in starting population transfected with reprogramming factors * 100.  
Reprogramming efficiency was low for all donors and cell types. It was highest in 



















D1 Fibroblast Amaxa 500 000 76 1 0.0002 
D5 Fibroblast Amaxa 500 000 35 3 0.0006 
D2 CB-EOC Neon 100 000 11 3 0.003 
 
Table 3.3: Two fibroblast lines (from donors 1 and 5) and one cord blood-derived 
endothelial cell line (from donor 2) were successfully reprogrammed, via the Amaxa 
and Neon systems, respectively. In all cases, the majority of isolated colonies were 
lost and did not expand. Reprogramming efficiency, calculated as the percentage of 
cells, which were reprogrammed from the starting population, was low for all lines, 
but highest in cord blood-derived endothelial cells. CB-EOC: Cord blood-derived 
endothelial outgrowth cells.  
 
Of the colonies, which expanded and became established lines, the D1-fibroblast line, 
referred to as ‘fiPS’ and D2 cord blood EOC line, clone 1 of 3, referred to as ‘eiPS’, 
were fully characterised and used for further studies. D1 was was selected over D5 
for practical reasons: this line was the first to be reprogrammed and therefore was the 
first to expand to the required population size. 
 
As the fiPS and eiPS cell lines expanded they became more resilient in culture – the 
colonies reached approximately 0.5-1.5mm in size and had clearly defined edges 
with no signs of differentiation (Figure 3.4). The cells were small, round and tightly 
compacted into colonies – typical of embryonic stem cell-like morphology (Thomson 
et al., 1998). This appearance was consistent over extended passaging (at least up to 






Figure 3.4: After multiple passaging, the morphology of established cell lines fiPS 
and eiPS resembles embryonic stem cells. Cells are small with a high nucleus-to-
cytoplasm ratio and are compacted into distinct colonies. P= passage number. A&B= 
examples of colonies from D1 fibroblasts, C&D= examples of colonies from D2 cord 
blood derived endothelial outgrowth cells. Bar=1mm.  
 
 
The properties of these two lines are shown in the following figures, detailing 
experiments used to assess pluripotency. 
 
Episomal plasmids replicate once per cell cycle, and are lost at a rate of ~5% per cell 
cycle due to defects in vector synthesis and partitioning (Yu et al., 2009). 
Reprogramming factors are required for induction of pluripotency rather than 
maintenance (Okita et al., 2007), so in bone fide iPS cells, over time expression of 
the Yamanaka factors changes from exogenous (from remaining plasmids) to 
endogenous (inherent to the properties of the cell). Reverse Transcriptase-
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Polymerase Chain Reaction (RT-PCR) was carried out with plasmid or genome 
specific primers to distinguish whether expression of the reprogramming factors was 
exogenous or endogenous (Chapter 2.4.1). At passage 35 (fiPS) and passage 31 
(eiPS), expression of Oct3/4, Sox2 and L-Myc was endogenous. Klf4 too was 
detected endogenously, though this was faint in the eiPS, and there appeared to be 
residual exogenous expression in the fiPS (Figure 3.5). These results indicate that 
pluripotency is largely inherent to the fiPS and eiPS cell lines, and is not a 















Figure 3.5: Endogenous or exogenous expression of the Y4 factors octamer-binding 
transcription factor-3/4 (Oct3/4), SRY-related-high-mobility-group (HMG)-box 
protein-2 (Sox2), Krupple-like factor 4 (Klf4) and L-Myc by fiPS and eiPS, assessed 
with plasmid (exogenous) and genome (endogenous) specific primers via Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR). fiPS cells were analysed at 
passage 35, eiPS cells were analysed at passage 31. Product sizes were as follows: 
Endogenous Oct3/4: 130bp (basepairs), Sox2: 119bp, Klf4: 152bp, L-Myc: 136bp; 
Exogenous Oct3/4: 134bp, Sox2: 160bp, Klf4: 282bp, L-Myc: 258bp. 
 
Though episomal vectors are non–integrating, it was important to confirm that the 
derived cells were free from genomic defects, as a normal karyotype is desirable for 
clinical translation of iPS cell lines (Ben-David et al., 2011). Karyotypes, and genetic 
abnormalities of the derived cells were analysed via highly sensitive single 
nucleotide polymorphism (SNP) arrays (HumanCytoSNP-12 DNA Analysis 
BeadChip Kit; Illumina, UK; analysis carried out using GenomeStudio software; see 
Chapter 2.4.2). Briefly, the test sample DNA was amplified, fragmented, and 
hybridised to complementary 50-mer probes on the SNP array. From enzymatic 
single-base extension with fluorescently labelled nucleotides, hybridisation signal 
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intensities for each probe were used by specialised software to generate the Log R 
Ratio of test/normal signals.  These corresponded to copy number variations. Beta 
allele frequency for each SNP was calculated by B/(A+B), where allele varients A=0 
and B=1. There was a microdeletion in chromosome 6 of the fiPS line, which spans 
PARK2 gene isoforms (Figure 3.6). eiPS were karyotypically normal. Full analysis is 
displayed in Appendix Figure 1 and Figure 2.1 
Figure 3.6 A) Genome-wide SNP array analysis of fiPS, displayed as beta allele 
frequency, identified a microdeletion at the end of chromosome 6, identified in red 
box, expanded in B. B) Closer analysis of this region showed that the microdeletion 
region was defined as chromosome 6: 162,242,404 to 162,790,478, spanning 
isoforms of PARK2/parkin. 
                                                          
1 Non-reprogrammed donor cells were also supplied for analysis and determined to be normal [data 
not shown], meaning that they could be represented by the standardised probes. This eliminates the 
possibility that the microdeletion was already present in the donor, and suggests that it has come 
about as a result of the reprogramming process.   
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In summary, the iPS cell lines produced had the following characteristics: 
 




D1; fiPS Healthy 
volunteer 
M 30 Fibroblast Amaxa, setting: 
‘NHDF high 
efficiency’ 










EOC from cord 
blood  




Table 3.4: Summary of established iPS cell lines, fibroblast-derived induced pluripotent stem cells (fiPS) and endothelial-derived induced 
pluripotent stem cells (eiPS), detailing characteristics of starting somatic cell population, method of reprogramming, expression of 




3.4.2. Characterisation of pluripotent stem cell lines 
 
Detailed characterisation was carried out to assess pluripotency of established fiPS 
and eiPS cell lines. Flow cytometry was used to detect levels of SSEA3 and SSEA4 
expression (Chapter 2.3.1), and immunocytochemistry to detect Nanog, Tra 1 60 and 
Oct3/4 (Chapter 2.3.2). An in vitro ‘embryoid body’ assay was carried out to allow 
spontaneous differentiation of the iPS lines, after which differentiated derivatives of 
the three primary germ layers were detected through immunocytochemical staining 
of α-fetoprotein (AFP), β-tubulin and smooth muscle actin (SMA), which are 
markers of endoderm, ectoderm and mesoderm, respectively (Chapter 2.3.3).  
 
fiPS and eiPS cell lines expressed pluripotency markers SSEA3 and SSEA4, 
assessed by flow cytometry (Figure 3.7). This analysis was split into early passage 
(P13-18) and later passage (>P22), to determine whether surface antigen expression 
was stable over time. eiPS had consistently high SSEA3 and SSEA4 levels, whereas 
fiPS gained this high level of expression over time, as early passage levels were 
significantly lower, P=0.042. Expression level of both pluripotency markers in fiPS 

























































Figure 3.7: SSEA3 and SSEA4 expression on fibroblast-derived induced pluripotent 
stem cells (fiPS) and endothelial-derived induced pluripotent stem cells (eiPS) at 
early and late passage, in comparison with embryonic stem (ES) cell lines. Data are 
expressed as mean ± SEM, and were analysed by unpaired Student’s t-test, *= 




In combination with expression of the pluripotency markers SSEA3 and SSEA4, 
eiPS were analysed for loss of their endothelial phenotype. Levels of CD31, CD105 
and eNOS, which were high in cord blood EOC, were negligible following 
reprogramming. VEGFR2, which was highly expressed in cord blood EOC, was still 
apparent in a proportion of reprogrammed cells (Figure 3.8). The EOCs used in this 
experiment were passage 6. Previous experiments carried out by Tura et al. 2013 in 
the laboratory demonstrated that expression of these markers was stable in EOCs 
through passaging up until at least passage 9.  
 
 
Figure 3.8: Expression of all endothelial markers was decreased following 
reprogramming. Representative histograms show expression of surface markers 
associated with endothelial cells (CD31, VEGFR2, CD105 and eNOS), on EOC and 
eiPS, assessed by flow cytometry. VEGFR2= vascular endothelial growth factor 
receptor 2, eNOS= endothelial nitric oxide synthase, EOC= endothelial outgrowth 









To further examine expression of pluripotency markers, immunocytochemistry was 
performed to detect Nanog, Oct3/4 and Tra 1 60. All were strongly expressed by the 
derived cell lines (Figures 3.9 and 3.10). All staining appeared specific to the 
colonies apart from Nanog, which was also detected on surrounding cells. This is 
likely because MEFs have been known to express pluripotency markers, including 
Nanog (Yusuf et al., 2013) 
 
Figure 3.9: fiPS colonies were positively stained by antibodies against pluripotency 
markers Nanog (red), Oct3/4 (green) and Tra 1 60 (green). Nuclei were stained by 








Figure 3.10: eiPS colonies were positively stained by antibodies against 
pluripotency markers Nanog (red), Oct3/4 (green) and Tra 1 60 (green). Nuclei were 





After spontaneous differentiation in embryoid bodies (the equivalent to the teratoma 
assay in vivo; Takahashi et al., 2006), AFP, β-tubulin and SMA were detected 
(Figure 3.11). This indicates that both fiPS and eiPS have the ability to differentiate 
into derivatives of all three primary germ layers: mesoderm, ectoderm and endoderm. 































Figure 3.11: Following spontaneous differentiation of fiPS and eiPS in embryoid 
bodies (stem cell aggregates in suspension), derivatives of all three germ layers-
endoderm, ectoderm and mesoderm- were detected by immunocytochemistry, 
demonstrating pluripotency.  Alpha fetoprotein (AFP), β-tubulin and smooth muscle 
actin (SMA) are stained green, representing endoderm, ectoderm and mesoderm, 
respectively. Nuclei are stained blue by DAPI. Bar= 100µm. Lack of staining on 
undifferentiated colonies by these three primary antibodies was run as a negative 






The work described in this chapter tested the hypothesis that endothelial cells 
reprogram to pluripotency with greater efficiency than fibroblasts. This was 
investigated by reprogramming both cell types via transfection of episomal plasmids 
containing all the factors required to induce pluripotency. The overall finding was 
that endothelial cells derived from cord blood reprogram with marginally higher 
efficiency than fibroblasts (though efficiency of both was low). Reprogramming of 
endothelial cells derived from peripheral blood was unsuccessful, despite multiple 
attempts with different electroporation settings. iPS cell lines derived from 
fibroblasts and cord blood-derived endothelial cells both appear similar to embryonic 
stem cells, in terms of their expression of pluripotency markers, and ability to 
spontaneously differentiate to cell types from all three primary germ layers.  
 
3.5.1. Fibroblasts and endothelial cells can be reprogrammed to 
pluripotency using a viral- and integration-free episomal plasmid 
system. 
 
Through episomal plasmid transfection, fibroblasts and endothelial cells can be 
induced into pluripotency by a process which does not require genomic integration or 
the continued presence of exogenous reprogramming factors. Whilst mature 
umbilical vein endothelial cells and endothelial outgrowth cells from peripheral 
blood have been reprogrammed before using retroviruses (Panopoulos et al., 2011; 
Chang et al., 2013), to date, this is the first time that endothelial outgrowth cells from 
cord blood have been reprogrammed. The studies in this thesis form the basis for the 
generation of endothelium from patient-specific iPS cells, for disease modelling and 







3.5.2. The process of reprogramming is inefficient and only a minority of 
transfected cells progress to pluripotent stem cells. 
 
Though technically straightforward, reprogramming is widely reported to be 
inefficient; a finding independent of reprogramming method or somatic cell type 
(Yamanaka, 2012). To some extent this is unsurprising, and indicates the complexity 
of the mechanisms involved in the resetting of an adult somatic nucleus back to a 
pluripotent state. Reprogramming efficiency of fibroblasts by Y4 episomal plasmid 
transfection is reported to be 0.003% by Yu et al. (2009), and 0.005% by Okita et al. 
(2011). Of the fibroblast lines transfected here, two out of three were successful, with 
lower efficiencies (D1: 0.0002%, D5: 0.0006%) than reported in the literature. 
Possible reasons for the low efficiencies seen here could be variation in induction 
technique and subsequent laboratory or culture conditions. Interestingly, 
reprogramming efficiency of endothelial outgrowth cells from cord blood (0.003%) 
was higher than for fibroblasts, supporting the finding that somatic cells other than 
fibroblasts have the potential to become iPS cells (González et al., 2011). 
 
Episomal plasmids were used for delivery of reprogramming factors for a variety of 
reasons. Human iPS cell derivation previously required retroviral vectors, which 
apart from logistical obstacles (the risks involved with viral work, and the need for 
proper facilities and equipment for their use) are not ideal as they integrate into the 
genome, which can create mutations and limit their use for clinical application (Ji et 
al., 2012). Thus the use of an episomal plasmid was desirable as a non-integrating, 
single transfection alternative (Okita et al., 2011). With time in culture, the episomal 
plasmids are shed, resulting in iPS cell lines free from vector or transgene sequences, 
thus removing one obstacle from the clinical application of iPS cells (Argyros et al., 
2008). Episomal plasmids were first described by the laboratory of James Thomson 
(Yu et al., 2009), and initially comprised pEP4-based plasmids containing the Y4 
reprogramming factors. Since then much work has been done to determine the 
optimal combination of transcription factors, and the plasmid backbones to use. The 
approach described here used pCXLE plasmids, described by Okita et al. (2011), as 
they were found to be more efficient than pEP4 based plasmids. As well as the 
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original Y4 factors, of which c-Myc was replaced by the less oncogenic L-Myc, the 
optimal combination of reprogramming factors included Lin28 and short hairpin 
RNA against p53, which were both found to enhance iPS cell generation (Yu et al., 
2007; Hong et al., 2009). The episomal plasmid system is routinely used by many 
laboratories for reprogramming, and is favoured for its simplicity and reproducibility. 
In addition, a systematic comparison of viral, episomal and mRNA reprogramming 
methods found that the episomal plasmid method was the most efficient and robust 
for reprogramming primary human fibroblasts, and described it as the most suitable 
for the production of GMP grade iPS cells (Goh et al., 2013).  
 
In terms of translating this to clinical situations, low efficiency could be overcome by 
scaling up cell populations to guarantee generation of a certain number of iPS 
colonies. A more pressing issue is that certain donor cell types did not reprogram. 
GFP positive cells were present 24 hours after electroporation with pCXLE-eGFP, 
indicating that the settings used for electroporation were suitable for entry of Y4 
plasmids (a similar size to the GFP plasmid). Genetic differences between donor may 
influence the ability of their cells to reprogram, a finding highlighted by Kajiwara et 
al. (2012). This study indicated that the major determinant of reprogramming 
efficiency is the donor’s genetic background, and that this is more important than cell 
type or reprogramming method. Further experiments are required to determine 
possible genetic features of a cell, which may predispose it to reprogramming. 
Further experiments could also investigate other mechanisms of reprogramming to 
determine the conditions which could most effectively reprogram these ‘resistant’ 
populations.  
 
3.5.3. Reprogramming efficiency of different somatic cell types 
 
Based on the literature, it was predicted that endothelial cells would reprogram with 
greater efficiency than fibroblasts, as this has been reported before (Geti et al., 2012; 
Chang et al., 2013). This hypothesis was confirmed in EOC derived from cord blood, 




Of all the cellular substrates, cord blood derived endothelial outgrowth cells were 
most efficiently reprogrammed, followed by fibroblasts. The greater efficiency of 
reprogramming of cells derived from cord blood has been described before, in 
comparison with fibroblasts or other mature cell types. For example, mononuclear 
cells (MNC) derived from cord blood have a reprogramming efficiency 100 fold 
greater than fibroblasts, with colonies which appeared 1-3 weeks earlier (Hu et al., 
2011). MNC from cord blood are also reported to have gene expression and 
epigenetic profiles which are closer to embryonic stem cells than they are to 
fibroblasts, which may explain their readiness over mature cells to revert to a 
pluripotent state (Chou et al., 2011). EOC from cord blood are derived from MNC 
(Tura et al., 2013; Ingram et al., 2004), so these reports may help to explain why 
they too are more efficiently reprogrammed. Though the reprogramming of defined 
endothelial progenitor cell populations from cord blood has not been reported before, 
CD34+ (Okita et al., 2013) and CD133+ (Giorgetti et al., 2009) cells derived from 
cord blood have been successfully reprogrammed to pluripotency. Interestingly, 
Giorgetti et al. report that CD133+ cells only require two (Oct3/4 and Sox2) of the 
four traditional reprogramming factors to generate iPS cells, and suggest that the 
progenitor status of cord blood-derived cells predisposes them to more efficient 
reprogramming. 
 
There may be differences between cord blood EOC and peripheral blood EOC which 
could explain the former’s more successful reprogramming. Ingram et al., (2004), 
described a hierarchy of endothelial progenitor cells, reporting that EOC colonies 
derived from cord blood arose earlier, were larger, and could undergo more 
population doublings than those derived from peripheral blood. They also had greater 
levels of telomerase activity. This description could explain the increased affinity of 
cord blood EOC to revert to a pluripotent state (as they are closer to their multipotent 
mesodermal/endothelial precursor), rather than peripheral blood EOC. It is also 
possible that the faster cell kinetics associated with cord blood EOC over peripheral 
blood EOC may account for their increased reprogramming efficiency. Recent 
reports suggest that actively dividing cells more successfully reprogram, compared to 
non-adherent, slow cycling cells (Haase et al., 2009). The replication of EBNA1-
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based episomal plasmids (including pCXLE plasmids) is synchronised with host cell 
division, therefore host cell proliferation is important for the maintenance of the 
episomal plasmids and the expression of the reprogramming factors they contain 
(Okita et al., 2013; Hanna et al., 2009).  
 
There are however contradictions to the concept that differences in cord and 
peripheral blood EOC account for variation in their reprogramming efficiencies. It 
has been found that EOC from blood (both cord and peripheral) are indistinguishable 
in culture to mature HUVEC (Tura et al., 2013), in terms of their phenotypic profile, 
proliferative capacity and functional abilities. They may not represent a true 
‘progenitor’ population in vitro and thus it is unclear if the increased reprogramming 
efficiency of cord blood EOC reported here is due to their progenitor or endothelial 
properties. 
  
Despite repeated attempts of the reprogramming of cells from multiple donors, and 
variation of electroporation settings for transfection, reprogramming of peripheral 
blood-derived EOC and vessel wall-derived endothelial cells was unsuccessful. This 
was unexpected, as was the higher reprogramming efficiency of fibroblasts in 
comparison, a finding most apparent when these three cell types were reprogrammed 
from the same individuals, (D1 and D5). This contradicts reports in the literature, 
many of which detail higher reprogramming efficiencies of umbilical vein 
endothelial cells (Panopoulos et al., 2011) and peripheral blood endothelial cells 
(Geti et al., 2012) compared with fibroblasts. Geti et al, (2012) describe higher 
reprogramming kinetics and efficiencies of CD34+ EOC derived from peripheral 
blood in comparison with fibroblasts, and report fewer karyotypic differences 
between iPS and donor cells with reprogrammed endothelial cells rather than 
fibroblasts. Chang et al. (2013) also reprogrammed late outgrowth endothelial 
progenitor cells from peripheral blood, by retroviral delivery of the Y4 factors. In the 
characterisation process, they analysed the transcriptome and found gene expression 
profiles similar to those of embryonic stem cell controls.  Though less research has 
been carried out on the reprogramming of mature endothelial cells, retroviral 
reprogramming of HUVEC (Panopoulous et al., 2011), had increased efficiency in 
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comparison with fibroblasts, and that iPS like colonies arose earlier. Panopoulous et 
al., reported that HUVEC-derived iPS were indistinguishable from embryonic stem 
cells. However, all of these referenced studies used viral delivery systems, and to the 
best of my knowledge, reprogramming of endothelial cells with episomal plasmids 
has not been published before. This difference in reprogramming technique may 
account for the lack of success reported in this thesis. Optimisation of the episomal 
reprogramming technique, or experimentation with alternative reprogramming 
methods, is required for induction of pluripotency in the peripheral blood and vessel 
wall endothelial cells. 
 
 
3.5.4. Established fiPS and eiPS cell lines are pluripotent and have 
similar characteristics to ES cells 
 
High expression levels of pluripotency markers SSEA3 and SSEA4 (in cells 
expanded beyond passage 22), as well as Nanog, Tra 1 60 and Oct3/4 indicate that 
these cells are pluripotent and similar to embryonic stem cells. Nanog was however 
also detected in cells surrounding the iPS colonies, as it is not specific to 
undifferentiated cells (Ambady et al., 2010). Differentiation to derivatives of all 
three primary germ layers is additional proof that these cells are pluripotent and able 
to differentiate to complex tissues.  
 
There were however minor differences between fiPS and eiPS lines. eiPS expression 
of endogenous Klf4 was very faint - it may be possible that these cells require more 
time in culture for full endogenous expression to be more apparent. There also 
appears to be residual exogenous Klf4 expression in fiPS. This again suggests that 
more time in culture may be required for complete shedding of the episomal 
plasmids, and the switch from exogenous to endogenous expression of all of these 
factors. SSEA3 expression was lower in early passage fiPS compared with early 
passage eiPS, which may indicate that they take longer to fully reprogram, or that 





Abnormalities of reprogrammed cells or differentiation bias can manifest due to 
abnormal karyotypes (Robinton and Daley, 2012). SNP arrays were used as a more 
informative method of genomic analysis than traditional Giemsa staining of the 
karyotype, as the readout detects the presence of deletions, duplications or areas of 
homozygosity (detailed in Devine et al., 2011). The microdeletion in the fiPS cell 
line came within the gene PARK2, which encodes the protein parkin. Loss of 
function mutations of this gene lead to dopaminergic cell death in autosomal 
recessive juvenile Parkinson’s disease (Hattori et al., 2004). This is, therefore, 
unlikely to have an effect on stem cell function, or on performance in mesodermal 
differentiation protocols. The reprogramming process may have caused this 
abnormality, and whilst it does not appear to have affected the cell type or function, 
it emphasises the need to analyse the karyotype of all derived pluripotent stem cells 
prior to their use in differentiation protocols. Though subtle, these minor differences 
may indicate that cord blood EOC more quickly adopt pluripotency following 
reprogramming than fibroblasts, which would be consistent with enhanced 
reprogramming efficiencies of cord blood-derived cells (Okita et al. (2013); Giorgetti 
et al. (2009)). There is an indication of residual VEGFR2 expression following EOC 
reprogramming. VEGFR2 is a marker found on endothelial cells as well as on 
hematopoietic stem cells. Its expression on the eiPS suggests that the resulting cells, 
whilst pluripotent, may still have mesodermal features remaining. It is possible that 




3.5.5. Limitations and future studies 
 
The reprogramming efficiency was low for all lines, with multiple unsuccessful 
attempts at peripheral blood EOC and vessel wall-derived endothelial cell 
reprogramming. Though it was exciting and interesting that cord blood EOC were 
successfully reprogrammed, it was disappointing that peripheral blood EOC were not. 
Peripheral blood would have been the optimal source for the derivation of iPS cells 
from patients, requiring only a blood sample, whereas cord blood EOC are unlikely 
to be applicable for generation of patient iPS cell lines. The optimisation of 
reprogramming of peripheral blood endothelial cells would, therefore, be worthwhile 
future work. In the meantime, reprogramming experiments could be scaled up to 
counteract low efficiency. In addition, plasmid design may be optimised. It is likely 
that the reprogramming factors transfect a higher proportion of cells than those 
successfully reprogrammed, and that in the majority of transfected cells incomplete 
reprogramming takes place. In these cells, the reprogramming process may not be 
completed due to variable plasmid uptake by the cell, and, therefore, variable 
dosages of reprogramming factors. This could call for optimised episomal plasmid 
design – for example development of a single plasmid containing all the required 
plasmids to ensure delivery of a complete set of reprogramming factors to every 
transfected cell. An issue for consideration is large plasmid sizes (above 15kb), 
which typically have low transfection efficiencies, and can compromise cell viability, 
so may be a limiting factor in plasmid design. Single transfection reprogramming 
methods have been used before- Chou et al., (2011) described reprogramming using 
a single OriP/EBNA plasmid, which contained 5 reprogramming factors (Y4 and 
Lin28) and was able to replicate extra-chromosomally as a circular episome in many 
types of primate cell. Through this method, they reported 0.001% iPS-like colonies 
arising from fibroblast transfection; still low efficiency but higher than that reported 
in this thesis. Kaji et al., 2009 also report somatic cell reprogramming using a single 
plasmid, containing the Y4 factors linked with 2A peptides. Again, this approach was 
designed to ensure that all electroporated cells received an equal dose of all 
transcription factors. This method could be considered for increasing reprogramming 
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efficiency of future reprogramming attempts. The “three-plasmid” method described 
in this thesis was adopted based on laboratory experience and available resources. 
 
Reproducing these results with more healthy volunteers is required, with further 
attempts to reprogram all cell types from a single volunteer, so that reprogramming 
efficiency of somatic cell source could be investigated without genetic background as 
a variable factor. Genetic background of the donor is thought to have an impact on 
reprogramming efficiency: iPS cell induction is reported to vary between donors, 
independent of age or gender, (Okita et al., 2013), and it has been reported that this is 
a major determinant of efficiency rather than reprogramming method or starting cell 
type (Kajiwara et al., 2012). Repeating these experiments with more healthy 
volunteers would lead to greater understanding of the characteristics of starting cell 
populations which influence successful reprogramming, and may improve the 




3.6. Conclusions  
 
Fibroblasts and cord blood-derived endothelial cells can be induced into pluripotency 
through transfection with episomal plasmids containing reprogramming factors. 
These lines express multiple pluripotency markers and can differentiate into all three 
primary germ layers. This process of reprogramming is in general fairly inefficient, 
but consistent with current literature.  
 
Though more cellular reprogramming work is required, the work presented in this 
chapter suggests that endothelial outgrowth cells from healthy cord blood reprogram 
with greater efficiency than those from healthy peripheral blood or fibroblasts. It is 
unclear if this is due to their progenitor or endothelial phenotype.  
 
Whether iPS cells derived from endothelial cells have a greater potential for 




















Introduction: The study of endothelial cells in vitro may elucidate the mechanisms of 
endothelial dysfunction in patients with atherosclerosis. Functional tests and culture 
of primary endothelial cell lines can offer insight, but understanding of endothelial 
biology could be extended by studying the differentiation of endothelial cells from 
patient-specific pluripotent stem cells. The aim of this chapter was to compare the 
efficiency of endothelial differentiation protocols from human embryonic stem cells 
and iPS cells.  
Results: The first three endothelial differentiation protocols tested (adapted from 
preliminary studies in the laboratory and published protocols) were unsuccessful, 
with very low yields of endothelial cells that were unable to expand in culture. 
Endothelial differentiation through a protocol involving embryoid body formation 
and exposure to mesoderm-inducing cytokines, followed by culture in endothelial 
cell conditions (supplemented with VEGF) was successful. Differentiation efficiency 
was determined by the percentage of cells expressing endothelial cell marker CD31 
at day 7. Although this was a low yield (ES: 2.5%±0.5; iPS: 1.0% ± 0.3%), isolated 
CD31+ populations were maintained and expanded in culture. CD31+ cells isolated 
from differentiating ES and iPS cells had a cobblestone morphology, typical of 
endothelial cells, and expressed high levels of endothelial cell markers over long 
term culture, in particular CD31 (ES-EC: 84±8%; iPS-EC: 97±2%), CD146 (ES-EC: 
67±8%; iPS-EC: 83±13%) and CD105 (ES-EC: 73±14%; iPS-EC: 98±2%). 
Comparatively, expression of hematopoietic and pluripotency markers was low (all 
<5%). vWF and eNOS were also detected in these populations by 
immunocytochemistry. In vitro functional assays demonstrated similar properties of 
ES-EC and iPS-EC to endothelial cell controls, in terms of vascular tubule formation 
and wound healing. In a subcutaneous sponge implant model of neovascularisation, 
ES-EC and iPS-EC significantly increased vessel density when compared to controls 
(by 1.83 vessel counts, P≤0.01 and 3.50 vessel counts, P≤0.001 for both), whilst 
control endothelial cells did not.   
Conclusions: Differentiation of ES and iPS cell lines produced CD31+ cells that 
could be isolated and expanded with endothelial-like morphology, phenotype and 
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function in vitro. These derived endothelial cells were pro-angiogenic, increasing 
vessel density in a subcutaneous sponge model of neovasculogenesis. This approach 
has major potential to generate endothelial cells for future therapeutic application in 






Atherosclerosis, the primary cause of coronary heart disease, is the commonest cause 
of premature death in the UK (British Heart Foundation). There are patients who 
present with premature atherosclerosis (symptoms occurring under the age of 50) in 
the absence of typical environmental factors (Jousilahti et al., 1996); in this patient 
population genome-wide association studies have identified that defects in 
endothelial function may be responsible for the disease (Damani and Topol et al., 
2004). The study of endothelial cells derived from this patient population is, 
therefore, important to assess their molecular characteristics and functionality and to 
possibly identify causative mutations and to develop novel therapeutic approaches. 
Aspects of endothelial dysfunction can be investigated with functional tests - for 
example forearm venous occlusion plethysmography (Newby et al., 1999) - but the 
molecular characteristics of dysfunctional endothelium are still unclear and are 
complicated by endothelial heterogeneity in the cardiovascular tree (Hendrickx et al., 
2004). For example, biomechanical forces can influence endothelial phenotype, and 
determine if they are susceptible to atherosclerosis (atheroprone) or not 
(atheroprotective) (Berk, 2008). The extraction of endothelial cells from patients 
suffering clinical symptoms is difficult, therefore the study of patient endothelial 
cells has been coupled with induced pluripotent stem (iPS) cell technology. It is 
envisioned that iPS cells derived from patients can be differentiated to produce large 
quantities of endothelial cells with the same molecular characteristics of the patients 
from which they were derived. Genetic defects that may predispose these patients to 
endothelial dysfunction may persist through reprogramming and differentiation 
processes. This has previously been observed in motor neurons in iPS cells derived 
from patients with Parkinson’s disease (Sanchez-Danes et al., 2012), allowing 
disease modelling in vitro, with the potential for genetic correction and clinical 
translation.  
Although there are various published protocols to generate endothelial cells from 
stem cells (for example: Levenberg et al., 2002; Taura et al., 2009; Narazaki et al., 
2008), there is not a universal protocol. Published endothelial differentiation 
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protocols differ in terms of culture conditions, time point(s) at which cells are 
analysed, definition of an endothelial cell, the species in which these protocols have 
been developed, whether or not they have been carried out with ES or iPS cells, and 
the functionality of the differentiated cells. 
Though the cells derived from these protocols may appear endothelial-like, based on 
morphology and phenotype, many studies do not isolate a definitive endothelial cell 
population, meaning there is likely a degree of heterogeneity in the resultant 
population. This could pose a problem if cells are to be used therapeutically, as there 
is a risk that multi/pluripotent cell types may be present. There is therefore a need to 
optimise and validate an endothelial differentiation protocol in order to determine a 
robust, reproducible system to generate pure populations of functional endothelial 




Directed differentiation of human embryonic and induced pluripotent stem cells 
generates populations of cells with similar characteristics to endothelial cell lines. 
 
4.3. Aims 
 To compare endothelial cell differentiation from healthy human ES and iPS 
cell lines, using published and unpublished protocols. 
 To use phenotypic and functional assays (in vitro and in vivo) to characterise 
endothelial-like cells derived from stem cells, and compare them with mature 






4.4. Experimental design 
 
4.4.1. Endothelial differentiation of ES and iPS cells 
 
As detailed in Chapter 2.7, ES and iPS cells were subjected to four endothelial 
differentiation protocols. These protocols varied in terms of cell culture system (2D 
or 3D), cell culture conditions and the time point at which endothelial-like cells were 
isolated by FACS. The number of replicates of each differentiation protocol is given 





Reference Chapter 2 
figure reference 




Choi et al., 2009 
and Sone et al., 
2007 
Figure 2.4 ES 1 H9; 2 H1 
iPS 2 34D6 
B Adaptation of 
protocol  A 
Figure 2.5 ES 1 H9; 2 H1 
C 
 
Ferreira et al., 
2007 
Figure 2.6 ES 2 H9; 2 H1 








Figure 2.7 ES 5 H9; 7 H1 
iPS 3 34D6; 4 
33D9 
Table 4.1 Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells were 
differentiated via four different protocols.  
 
4.4.2. Characterisation of CD31+ derived cells 
 
In vitro analysis of the CD31+ cell populations was carried out for phenotypic and 
functional characterisation between passages 2-5 post-sort, as detailed (Chapter 2.3 
& 2.5). Phenotype was characterised by flow cytometry and immunocytochemistry; 
function by their ability to form connections when cultured on Matrigel, reparative 
mechanisms following a scratch healing assay, and nitric oxide production following 
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stimulation with acetylcholine. The derived cells were compared to control 
endothelial cell lines, HUVEC and EOC (derivation of which is detailed in Chapter 
2.2.1.3). In vivo analysis of the CD31+ cell populations was carried out using the 
subcutaneous sponge implant murine model of vascularisation (see Chapter 2.6). 10-
12 week old NSG mice, which are inbred for immunodeficiency, were used. This 
meant that implantation of material containing human cells did not elicit an immune 
response. Mice were grouped according to sponge treatments (Table 4.2). EOC 
conditioned media was used as a negative control, to detect any effects media has on 
vascularisation. Cell treated sponges were grouped as: EOC control, embryonic stem 
cell-derived endothelial cells (ES-EC) and induced pluripotent cell-derived 
endothelial cells (iPS-EC).  
 
Treated sponge contents Number of mice 
per group 





Table 4.2 Sponge implants and group sizes for the murine subcutaneous sponge 
angiogenesis assay. EOC= late endothelial outgrowth cells; ES-EC: embryonic stem 
cell-derived endothelial cells; iPS-EC: induced pluripotent cell-derived endothelial 
cells.  
  
Species specific antibodies were used to identify cells (Chapter 2.6.4). Two sets of 






4.5. Results: summary 
The proportions of CD31+ or CD34+ endothelial cells derived via protocols A, B and C were low (0.1-0.9%, 0-0.6%, 0-0.9%, respectively; 
Table 4.3). As such, there were not sufficient numbers of CD31+ or CD34+ cells for characterisation. CD31+ cells derived via protocol D 
were maintained and expanded in culture for comparison with endothelial controls.  
Protocol  Reference Key features of the 
protocol 
ES/iPS 
cell line  





A Choi et al., 2009 
Sone et al., 2007 
Pluripotency sort day 
7; CD31 sort day 14 
ES 0.1-0.9% No Low yield, did not survive 




protocol  A 
CD31 sort day 7 ES 0-0.5% No CD31+ expression lost 
C Ferreira et al., 
2007 





0-0.6% No CD34+ expression lost; VEGF 
supplementation did not 







EB formation; CD31 
sort day 7 
ES 0.3-6.2% CD31+ day 7 Yes Despite low yields, CD31+ 
expression was maintained 
and the cells proliferated well 
in culture 
iPS 0.3-2.0% CD31+ day 7 Yes 
 
Table 4.3: Overview of the key features and efficiencies of embryonic stem (ES) and induced pluripotent stem (iPS) cell endothelial 





The following results detail the characteristics of CD31+ cells isolated from 
differentiation of ES and iPS cells via endothelial differentiation protocol D. This 
protocol was selected as the most successful due to the relative ease of cell culture 
following isolation of cells expressing CD31.  
 
4.5.1. In vitro analysis of endothelial-like cells derived from ES and iPS 
cells via differentiation protocol D 
 
Seven days of endothelial differentiation of ES and iPS cells generated a mixed 
population of cells, expressing various endothelial (CD31, CD34, VEGFR2, CD146 
and CD105), hematopoietic (CD133 and CD45) and pluripotent (SSEA3 and SSEA4) 
markers (Figure 4.1). Morphology was varied: there were some areas of cells which 
appeared endothelial-like, and some which remained small and rounded, 










































Figure 4.1: After seven days of endothelial differentiation, embryonic stem (ES) and 
induced pluripotent stem (iPS) cells formed a mixed population. A) Phenotype 
(expression of endothelial, hematopoietic and pluripotency markers) was assessed by 
flow cytometry; data are expressed as mean ± SEM and were analysed via unpaired 
t-test; *P≤0.05, **P≤0.01; N=7-12. B) & C) Morphology of differentiating ES and 




The percentage of CD31+ cells at day 7 was low for both differentiating ES and iPS 
cell lines. This was used to quantify the differentiation efficiency of each cell line. 
Differentiation efficiency was significantly higher in ES cells compared to iPS cells 
(Figure 4.2). CD31+ cells are referred to as ‘ES-EC’ (Embryonic Stem cell-derived 














Figure 4.2: % of cells expressing CD31 after seven days of embryonic stem (ES) 
and induced pluripotent stem (iPS) cell endothelial differentiation. Data are 
expressed as mean ± SEM and were analysed via unpaired t-test; P≤0.05=*; ES, 
n=12; iPS, N=7. 
 
Though the percentage of CD31+ cells within these differentiating populations was 
low, upon staining with a fluorescent-conjugated CD31 antibody, they appear as a 
distinct population and could be isolated via FACS. A representative example of an 




Figure 4.3: Representative example of isolation of CD31+ cells by fluorescence-
activated cell sorting (FACS) at day 7 of endothelial differentiation of ES cells. 
Gates were set by unstained control. P1= live population; P2: singlets; P3: 7AAD 




Upon reaching confluence in culture, sorted CD31+ cells displayed a ‘cobblestone’ 













Figure 4.4: Differentiated cells and endothelial control lines display similar 
morphology. ES-EC: embryonic stem cell derived endothelial cells; iPS-EC: induced 
pluripotent stem cell derived endothelial cells; HUVEC: Human umbilical vein 
endothelial cells; EOC: Late outgrowth endothelial cells. Bar = 1mm. ES-EC: 
passage 4, post sort; iPS-EC: passage 4, post sort; HUVEC: passage 6; EOC: passage 
4.  
 
Endothelial cells derived from ES cells and iPS cells were phenotypically analysed 
via flow cytometry at early (P1-3) and late (P4-6) passage post-sort, to determine the 
stability of these populations in culture. Expression levels of endothelial markers 
CD31, CD34, VEGFR2, CD146 and CD105 are shown in comparison with 
expression levels prior to differentiation (Figure 4.5). With the exception of 
VEGFR2, both ES and iPS cells displayed very low expression of all endothelial cell 
surface markers prior to differentiation. Both ES-EC and iPS-EC populations 
maintained high levels of CD31 expression in culture following sorting. Although 
there were no significant differences between early and late passage populations, 
there appeared to be a trend for increased expression of CD34, VEGFR2, CD146 and 
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CD105 on late passage ES-EC, and CD34 and VEGFR2 on late passage iPS-EC, 
























Figure 4.5: Expression of endothelial cell surface antigens on embryonic stem cell-
derived endothelial cells (ES-EC), induced pluripotent stem cell-derived endothelial 
cells (iPS-EC) over time and cells prior to differentiation, assessed by flow 
cytometry. Early passage: P2-P3, late passage: P4-P5. Data are expressed as mean ± 
SEM and were analysed via one way ANOVA, P≤0.01=**; P≤0.001=***. N=3-4. 
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Early and late passage data were combined and compared to endothelial cell control 
lines, HUVEC and EOC (Figure 4.6). Expression of endothelial cell markers CD31, 
CD146 and CD105 was high and comparable to HUVEC and EOC control lines. 
CD34 and VEGFR2 expression was lower but also comparable to HUVEC and EOC 
control lines. There were no significant differences in expression of any endothelial 
markers between ES-EC and iPS-EC. 
 
 
Figure 4.6: Expression of endothelial cell (EC) surface antigens on sorted CD31+ 
cells from embryonic stem cells (ES-EC) and induced pluripotent stem cells (iPS-
EC), in comparison with human umbilical vein endothelial cells (HUVEC) and late 
outgrowth endothelial cell (EOC) control lines. Data are expressed as mean ± SEM 







Endothelial cells derived from ES and iPS cells were also analysed based on the 
expression of hematopoietic (CD133 and CD45) and pluripotent (SSEA3 and SSEA4) 
markers. In comparison with undifferentiated starting cell populations, expression of 
CD133, SSEA3 and SSEA4 is very low following differentiation (Figure 4.7). 
Taking into account these expression levels over time (early verses late passage), 

















































Figure 4.7: Expression of cell surface antigens on embryonic stem cell-derived 
endothelial cells (ES-EC) and induced pluripotent stem cell-derived endothelial cells 
(iPS-EC), assessed by flow cytometry. Early passage: P2-P3, late passage: P4-P5. 
Data are expressed as mean ± SEM and were analysed via one way ANOVA; 





Early and late passage data were combined and is shown in comparison to 
endothelial cell control lines, HUVEC and EOC (Figure 4.8).  Expression of 
hematopoietic and pluripotent markers was very low following differentiation and 
comparable to both control endothelial cell lines.  
 
 
Figure 4.8: Expression of hematopoietic and pluripotent cell surface antigens on 
sorted CD31+ cells from differentiating embryonic stem (ES) and induced pluripotent 
stem (iPS) cells, in comparison with human umbilical vein endothelial cells 
(HUVEC) and late outgrowth endothelial cell (EOC) control lines. Data are 





Phenotypic analysis via immunocytochemistry (Figures 4.9 and 4.10) showed that 
ES-EC and iPS-EC both express endothelial markers: von Willebrand Factor (vWF) 
and endothelial Nitric Oxide Synthase (eNOS). 
  
Figure 4.9: Representative images of embryonic stem cell-derived endothelial cells 
(ES-EC) and induced pluripotent stem cell-derived endothelial cells (iPS-EC), 
immunostained with antibodies against vWF (green). Nuclei are stained with DAPI 







Figure 4.10 Representative images of embryonic stem cell-derived endothelial cells 
(ES-EC) and induced pluripotent stem cell-derived endothelial cells (iPS-EC), 
immunostained with antibodies against eNOS (red). Nuclei are stained with DAPI 






ES-EC, iPS-EC and endothelial cell controls perform in a similar way in the in vitro 
Matrigel assay, in which endothelial cells form connections as an indication of their 
angiogenic capacity (Figure 4.11). By comparison, undifferentiated ES and iPS cells 




















Figure 4.11: Endothelial cells derived from embryonic stem cells (ES-EC) and from 
induced pluripotent stem cells (iPS-EC) form connections on Matrigel, which may be 
an indication of angiogenic potential. A) Quantification of cell connections suggests 
similar angiogenic potential of ES-EC, iPS-EC, HUVEC and EOC. Data are 
expressed as mean ± SEM and were analysed via one-way ANOVA, P>0.05; N=3-5. 
Representative images of tubule-like structures formed by B) ES-EC and C) iPS-EC. 
By comparison, both D) ES and E) iPS, did not form tubes when cultured on matrigel. 
Bar = 1mm. 
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ES-EC, iPS-EC and EOC performed similarly in the wound healing assay (Figure 




Figure 4.12: ES-EC and iPS-EC have similar migratory and proliferative abilities 
during recovery from a scratch in the wound healing assay A) Representative images 
of wound healing of ES-EC and iPS-EC over time. Bar= 500µm B) Quantification of 
wound healing of ES-EC, iPS-EC and HUVEC. Data were analysed via one-way 




To mimic NO release in vitro, cells were stimulated with 10µM acetylcholine (ACh) 
for 24 hours. As NO has a short half-life (Hakim et al., 1996), in this assay the levels 
of nitrite and nitrate (its more stable metabolites) were taken as indirect 
measurements (Chapter 2.5.3). With the exception of ES-EC, unstimulated cells had 
similar nitrite and nitrate release to those stimulated with ACh (Figure 4.13). ES-EC 
produced significantly higher levels of nitrite and nitrate when stimulated with ACh.  
Figure 4.13: Concentrations of nitrite and nitrate detected from endothelial cells 
derived from embryonic stem cells (ES-EC), those derived from induced pluripotent 
stem cells (iPS-EC), human umbilical vein endothelial cells (HUVEC) and late 
endothelial outgrowth cells (EOC) under basal conditions or following stimulation 
with acetylcholine (ACh; 10µM) over 24 hours. Data are expressed as mean ± SEM 
and were analysed via Student’s paired t test, P≤0.05=*; N=3. 
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4.5.2. In vivo analysis of endothelial–like cells derived from ES and iPS 
cells via differentiation protocol D 
 
In vitro assays suggested that the differentiated cells have angiogenic capacity 
(Figure 4.11). To further test angiogenic function of these cells in vivo, the murine 
model of subcutaneous sponge implantation was used (Chapter 2.6). The sponge 
sections displayed in Figure 4.14 show hematoxylin staining nuclei blue/purple, 
while eosin stains cytoplasmic structures pink. Blood vessels were identified by the 
presence of red blood cells, stained red by eosin (arrows indicate perfused vessels). 
There were a variety of vessel sizes within the sponges: some areas contained very 









Figure 4.14: Representative images of hematoxylin and eosin stained sections of 
sponge implants. Blood vessels (arrows) were identified by the presence of red blood 
cells. Bar = 200µm. Cells in this section other than those of blood vessels are likely 
to be murine connective tissue cells (such as fibroblasts) which have migrated into 




Vessel density within the sponges was quantified by Chalkley count (Figure 4.15). 
ES-EC and iPS-EC increased vessel density compared to paired Matrigel controls 
within the same mouse, (ES-EC: 5.3±0.5 vs 7.1±0.7, P=0.02; iPS-EC: 4.1±0.3 vs 
7.6±0.4, P<0.001). Neither EOC nor EOC conditioned media increased vessel counts 











Figure 4.15: Vessel density in implanted sponges was increased by the presence of 
endothelial cells derived from embryonic stem cells (ES-EC) and those derived from 
induced pluripotent stem cells (iPS-EC). Sponges contained either endothelial 
outgrowth cell conditioned medium (EOC-CM; cell medium was collected after 24 
hours in culture), EOC, ES-EC or iPS-EC. Vessel density was scored by Chalkley 
count. Data are expressed as mean ± SEM and were analysed via two-way ANOVA; 









Control experiments were carried out to confirm there was no non-specific binding 
of secondary fluorescent antibodies (Figure 4.16). As expected, only 
autofluorescence from erythrocytes and sponges was detected from staining of 
sponge sections with AF488 Goat anti-rabbit IgG (green) and AF568 Goat anti-
mouse IgG (red). Most of the vessels examined contained red blood cells, showing 
that they are functional and perfusing. 
 
 
Figure 4.16: Negative control of sponge section immunocytochemistry. Erythrocytes 
and triangular sponge sections autofluoresce in AF488 (green) and AF568 (red) 







Figure 4.17 shows representative examples of the control Matrigel-treated sponges, 
not containing any human cells, stained with paired antibody sets 2 and 3 (Table 2.7). 
This demonstrates that SMA and CD31 antibodies (from antibody sets 2 and 3, 
respectively), which are cross reactive to mouse and human cells can be used to 
identify vasculature. Absence of red fluorescence (apart from erythrocyte and sponge 
autofluorescence) confirms that the human specific antibodies (CD31 from set 2 and 
CD146 from set 3) do not stain mouse vasculature.  
 
Figure 4.17: As a positive control, murine vessels were detected by staining with 
SMA and CD31 antibodies (left panels). In comparison, murine vessels were not 
stained by human specific antibodies CD31 or CD146 (middle panels). Nuclei were 
stained with DAPI (blue). Erythrocytes autofluoresced in both AF488 and AF568 








As vascularised tissue, human fibroid tissue was used as a positive control to test 
human specific antibodies CD31 and CD146 (Figure 4.18). Positive single stains of 
each of these antibodies showed that they could both be used to detect vasculature 
containing cells of human origin.  
 
Figure 4.18: Human fibroid tissue was stained by human specific antibodies against 











Within the following figures, immunostained sponge sections containing EOC 
(Figure 4.19), ES-EC (Figure 4.20) and iPS-EC (Figure 4.21) are displayed. Vessels 
could be detected by the green fluorescence generated from binding of either smooth 
muscle actin or CD31 antibodies, cross reactive to human and murine cells. Red 
fluorescence, generated from binding of human specific antibodies CD31 or CD146 
indicated the presence of human cells. Red fluorescence within a vessel wall 
therefore indicated that implanted human cells had incorporated into the vasculature. 
Two examples of incorporation are shown in EOC-treated sponges (Figure 4.19). No 
incorporation of human cells into vasculature was detected in ES-EC (Figure 4.20) or 





Figure 4.19 Neovasculature detected in sponge sections containing EOC. A) Some 
vascular structures stained positive for smooth muscle actin antibody (green) and 
human specific CD31 antibody (red), indicating incorporation of human EOC into 
the walls of murine vasculature (‘I’ arrows). Human EOC could also be detected 
outwith vascular structures (‘F’ arrows) B) Vascular structures could also be found 
which stained positive for CD31 (green) and human specific CD146 antibody (red). 
DAPI stained nuclei blue. Erythrocytes autofluoresced in both AF488 and AF568 





Figure 4.20 Neovasculature detected in sponge sections containing ES-derived 
endothelial cells. A) Vascular structures stained positive for smooth muscle actin 
antibody (green), but not human specific CD31 antibody (red). B) Vascular 
structures stained positive for CD31 (green), but not human specific CD146 antibody 
(red). DAPI stained nuclei blue. Erythrocytes autofluoresced in both AF488 and 







Figure 4.21: Neovasculature detected in sponge sections containing iPS-derived 
endothelial cells. A) Vascular structures stained positive for smooth muscle actin 
antibody (green), but not human specific CD31 antibody (red). B) Vascular 
structures stained positive for CD31 (green), but not human specific CD146 antibody 
(red). DAPI stained nuclei blue. Erythrocytes autofluoresced in both AF488 and 




In all sponges, human cells outwith vessels were detected by human specific CD31 
staining (Figures 4.22). 
 
Figure 4.22: Human cells, stained red with CD31 antibody, were identified outwith 
vascular structures, in sponges containing EOC, ES-ECs and iPS-ECs. DAPI stained 
nuclei blue. The large triangular structures are sponge matrix. Bar = 100µm. 
 
Implantation of EOC-CM or EOC did not significantly increase new vessel 
formation in subcutaneous sponges, as measured by the difference in vessel density 
between treated and untreated paired sponges (Table 4.4).  This was despite evidence 
of incorporation of EOC into newly formed vessels. Conversely, vessel density of 
sponges was considerably increased by implantation of endothelial cells derived 





Table 4.4: Performance of endothelial outgrowth cell conditioned medium (EOC-CM), EOC, endothelial cells derived from induced 
pluripotent stem cells (iPS-EC) and endothelial cells derived from embryonic stem cells (ES-EC) in a subcutaneous sponge murine model 
of vascularisation. Neither EOC-CM nor EOC increase vessel density, though there is evidence of EOC incorporation into murine 
neovasculature. iPS-EC and ES-EC significantly increase vessel density within implanted sponges, though do not incorporate into murine 





Vessel density (number of blood vessels per 0.5mm2 
section) 















human cells out 
with vessels? 
EOC-CM 3.79 ± 0.73 4.71 ± 0.6 0.92 0.301 - - - - 
EOC 4.81 ± 0.4 5.14 ± 0.45 0.33 0.557 180 Yes 2 Yes 
ES-EC 5.29 ± 0.51 7.13 ± 0.65 1.84 0.025 * 180 No - Yes 





This chapter tested the hypothesis that endothelial cells can be generated from human 
embryonic and induced pluripotent stem cells through a directed differentiation 
protocol. Though efficiency was low, endothelial cells were successfully generated 
from pluripotent stem cells through a differentiation protocol involving embryoid 
body formation, exposure to mesoderm-inducing cytokines, and further culture in 
endothelial cell conditions supplemented with VEGF.  Differentiated ES and iPS 
cells displayed similar properties to endothelial cell control lines, in terms of their 
phenotype and functionality in vitro. In an in vivo model of vascularisation, they 
appear pro-angiogenic in comparison with endothelial cell controls.  
 
4.6.1. Endothelial differentiation of ES and iPS cells involving embryoid 
body formation in the presence of mesoderm-inducing cytokines is 
successful  
 
Of the four differentiation protocols tested, sorted cell populations were consistently 
low: CD31+ isolated from protocols A, B and D; CD34+ isolated from Protocol C. 
Protocols A and B were adapted from Choi et al., (2009) and Sone et al., (2007), and 
used differentiation media, common in a lot of endothelial differentiation protocols 
(Gerecht-Nir et al., 2003; Yamamoto et al., 2005). Choi et al. (2009) report up to 
4.5% CD31+ cells from iPS cells and 7.2% CD31+ cells from ES cells after eight 
days differentiation in this media. Differentiation media is fairly basic and not 
specific to the culture of endothelial – or even mesodermal – cells; the rationale for 
its use was to allow general differentiation away from pluripotency, followed by 
selection of mesodermal/ endothelial cells via FACS. Protocols A and B were 
unsuccessful, as the low yields of sorted cells did not survive in culture. Some 
published protocols, which have used differentiation media have co-cultured stem 
cells with OP9 cells, a murine stromal cell line, described as a ‘feeder’ layer (Taura 
et al., 2009; Sone et al., 2007). These cells release soluble factors, such as VEGF-C 
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and Ang1, which are thought to influence endothelial differentiation (Kono et al., 
2006), and have also been used in hematopoietic differentiation protocols (Nakano, 
2003). This suggests that whilst differentiation medium provides a ‘base’ culture 
condition, further cytokines/growth factors are likely required for effective 
endothelial differentiation. Consistent with this concept, studies have attempted to 
develop more sophisticated differentiation protocols with the use of defined factors 
thought to induce mesodermal and endothelial differentiation (James et al., 2010; 
Goldman et al., 2009). Protocol C was based on studies by Ferreira et al. (2007) who 
demonstrated that culturing embryonic stem cells for seven days in differentiation 
media generated a population of CD34+ cells, of which 94% express CD31 upon 
further culture with VEGF. However, unexpectedly, in our laboratory this result 
could not be reproduced and addition of VEGF supplement did not alter CD31 
expression in the CD34+ sorted cell population derived from either ES or iPS cells. 
The low yields of cells from protocols A, B and C indicated that optimisation of the 
protocol was required. Being unable to reproduce published findings may be 
explained by differences in the starting stem cell populations and their culture 
conditions prior to differentiation, often a variable factor between laboratories. 
Newman et al., (2010) showed that culture conditions and laboratory environments 
can have an effect on gene expression patterns in stem cell lines, which may affect 
their differentiation potential. This leads on to the suggestion that these protocols are 
not robust enough for their results to be translated across different ES and iPS cell 
lines. The most success came from unpublished endothelial differentiation protocol 
D, from which distinct CD31+ cell populations were generated from ES and iPS cells 
following exposure to a host of mesoderm-inducing cytokines. Signalling of BMP, 
Wnt and Activin are involved in directing embryonic stem cell developmental 
pathways to hematopoietic (Nostro et al., 2008) and cardiovascular (Kattman et al., 
2011) lineages. This indicates the complexity of endothelial differentiation, 
underestimated in protocols A and B. Success with multiple cytokines may indicate 
that VEGF alone (protocol C) was insufficient for endothelial differentiation. CD31+ 
populations generated from protocol D could be isolated, maintained and expanded 
in culture, and CD31 expression was retained over time. Though higher yields of 
cells from protocol D would be desirable (and optimisation may be required to 
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increase differentiation efficiency), for the purpose of characterisation, sizes of 
starting cell populations were increased to compensate for low cell yields. 
Expression of CD31 was low in this mixed population of differentiating ES and iPS 
cells, relative to other endothelial cell markers. Of the endothelial markers analysed, 
CD31 could be considered the most specific for endothelial cells: it is expressed on 
endothelial cells and haematopoietic cells, whereas other cell markers are expressed 
on a wider variety of cell populations. For example, CD105 is found on smooth 
muscle cells and monocytes (Rohde et al., 2006); CD146 is expressed by 
mesenchymal stem cells and pericytes (Espagnolle N, et al., 2014; Blocki et al., 2013) 
as well as endothelial cells. This was the rationale behind using CD31 as a marker of 
differentiating endothelial cells. The expression levels of endothelial haematopoietic 
and pluripotency markers indicate a heterogenous cell population, of which it is 
likely only a small subset of cells are CD31 positive and truly endothelial in nature at 
this stage.  
 
With the exception of VEGFR2, both ES and iPS cells displayed very low expression 
of all endothelial cell surface markers prior to differentiation. This was unexpected, 
as these cells had been shown to be pluripotent (able to differentiate to derivatives of 
all three germ layers), whereas VEGFR2 expression is associated with stem cells in 
the early stages of commitment to a mesodermal cell lineage (Kubo and Alitalo, 
2003). Indeed, it is well known that VEGFR2+ cells represent a common precursor 
for haematopoietic stem cells and endothelail cells (Choi et al 1998). Expression seen 
here may represent a subpopulation of cells, which are tending towards an 
endothelial phenotype in culture. 
 
Based on CD31 expression, ES cells appear to have a higher differentiation 
efficiency than iPS cells. This may be because protocol D had been optimised for ES 
cell differentiation. That iPS are less efficient may indicate that there are underlying 
differences between ES and iPS cells. Though both cell types are pluripotent, in the 
literature there is controversy about how similar these two cell types are, both in 
terms of their characteristics when undifferentiated, and their differentiation potential. 
For example, a study by Bock et al. (2011) involving 20 ES and 12 iPS cell lines 
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found that, despite many common features, gene expression and epigenetic patterns 
varied between different iPS cell lines, between different ES cell lines and between 
iPS and ES cell lines. Chng et al. (2010) have carried out comprehensive studies 
using multiple iPS cell lines (which vary in terms of reprogramming method and 
somatic cell source) showing that lines can be categorised based on their 
differentiation bias towards a certain germ layer. It would be interesting to compare 
the endothelial differentiation potential of other iPS cell lines, generated by other 
laboratories, to identify to what extent this variability may affect endothelial 
differentiation. It would also be interesting to differentiate these iPS lines to other 
lineages, of ectoderm or endodermal origin. This would indicate any propensity they 
may have for directed differentiation to a particular lineage. Another consideration is 
that studies have shown directed differentiation of iPS cells can be influenced by 
residual epigenetic memory of the somatic cells from which iPS cells were derived. 
Methylation patterns of the original somatic cell could potentially remain and 
influence gene expression or differentiation efficiency (Kim et al., 2010; Sullivan et 
al., 2010). This concept is discussed further in Chapter 5. 
 
4.6.2. CD31+ cells isolated from differentiating ES and iPS cells have an 
endothelial-like phenotype. 
 
A mixed population of cells was generated after seven days of endothelial 
differentiation through protocol D. The protocol used specified isolation of CD31+ 
cells, as this is a key endothelial marker, often used in the characterisation of 
endothelial cells (Choi et al., 2009; Kane et al., 2010). However, there are also sub-
populations of cells after seven days of differentiation, which express endothelial 
markers CD34, VEGFR2, CD146 and CD105. Though none of these markers are 
specific to endothelial cells, it is possible that these populations also have the 
potential to develop into endothelial cells, and may acquire CD31 expression at a 
later stage. It would be interesting to test this potential in further experiments. As 
previously discussed, though CD31 is not a definitive marker of endothelial cells, it 
is one of the most specific ones (only being expressed on haematopoietic cells as 
well as endothelial).  Sorted CD31+ cells were phenotypically characterised by flow 
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cytometry and immunocytochemistry. High levels of CD31 expression in ES-EC and 
iPS-EC were comparable to control endothelial cell lines and indicated that this 
marker is retained following sorting. Although there were no significant changes in 
expression of these endothelial markers on ES-EC or iPS-EC over time, expression 
of CD34, VEGFR2 and CD105 appeared heightened in later passage cells. This may 
indicate that these cells retain plasticity in culture and that differentiation towards a 
fully mature endothelial cell is a step-wise process, as has been suggested by 
Fujimoto et al. (2001). Negligible expression of hematopoietic markers (CD133 and 
CD45) indicated that ES-EC and iPS-EC have diverged from mesodermal cells and 
committed to an endothelial, rather than a hematopoietic, lineage. 
 
Interestingly, SSEA3 and SSEA4 expression appeared lower in later passage 
populations, a finding which reached significance in terms of SSEA3 expression of 
ES-EC. This supports the suggestion that differentiation is occurring in stages and 
that these cells display plasticity in culture until they reach a stage of maturity 
towards later passages, with minimal pluripotency marker expression and maximal 
endothelial marker expression. Later passage populations have expression levels of 
SSEA3 and SSEA4 between 2-4%, similar to levels in control endothelial HUVEC 
and EOC populations. These cells may be a distinct population. Studies have shown 
that SSEA3+ cells within a somatic cell culture of fibroblasts (which co-express 
CD105) have properties similar to bone marrow- and fat derived mesenchymal stem 
cells, which proliferate in response to cell injury and may play a role in regeneration. 
(Crespo et al, 2012). It is possible that endothelial cells may too retain plasticity in 
vitro and that the SSEA3+ populations seen here may have progenitor-like potential. 
Wakao et al, 2011 also describe a SSEA3+CD105+ population of cells, named 
multilineage-differentiating stress enduring (MUSE) cells, which have enhanced 
reprogramming efficiency compared to non-MUSE cells. It would be interesting to 
isolate the SSEA3+ populations seen here to ascertain if these cells too display 
enhanced reprogramming properties.  
 
Whilst as a panel, the markers analysed by flow cytometry give an indication of an 
endothelial phenotype, none are completely specific to the endothelial cell. For 
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example, CD146 (melanoma cell adhesion molecule) can also be detected on 
lymphocytes and pericytes, whilst CD105 (endoglin) can be detected on monocytes 
and vascular smooth muscle cells. To complete the phenotypic profile of cells, 
immunocytochemistry was performed to detect factors associated with endothelial 
cells: von Willebrand Factor (vWF) and endothelial Nitric Oxide Synthase (eNOS). 
vWF is a multimeric glycoprotein involved in hemostasis and has a characteristic 
granular staining pattern in endothelial cells. It is stored in, and released from, 
Weibel-Palade bodies in endothelial cells (Wagner et al., 1982), consistent with the 
granular cytoplasmic pattern of staining seen in ES-EC and iPS-EC. eNOS, the 
endothelial-specific form of nitric oxide synthase, plays a key role in the regulation 
of vascular function and maintenance of hemostasis (Lamas et al., 1992), and could 
also be detected in the membranes and cytoplasmic regions of stem cell-derived 
endothelial cells. This is consistent with localisation of eNOS within the endothelial 
cell, where it is targeted to cholesterol-rich domains of the plasma membrane and to 
the Golgi complex (Fulton et al., 2004).  
 
Combined, these results showed that CD31+ cells sorted from differentiating ES and 
iPS cells had a similar phenotype to control endothelial cell lines, suggesting that this 
is an effective protocol for the production of endothelial cells. 
 
4.6.3. ES and iPS derived endothelial-like cells are functional and may 
have potential for therapeutic use 
 
4.6.3.1.  In vitro analysis 
 
A series of in vitro functional assays demonstrated that the ES- and iPS-derived 
endothelial cells were functional, with similar capabilities as control endothelial cell 
lines. ES-EC and iPS-EC formed connections in vitro when applied to Matrigel, in a 
similar way to control endothelial lines. This suggests they may be able to form 
tubules or contribute to capillary growth in vivo. Matrigel is prepared from 
Engelbreth-Holm-Schwann (EHS) tumour cells- its primary component is laminin, a 
biologically active protein of the basement membrane (Aumailley et al., 1998). Upon 
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contact with endothelial cells, laminins promote adhesion, migration and 
differentiation (Grant et al., 1989), and they also play a key role in the organisation 
and establishment of the basement membrane matrix (Davis and Senger, 2005). With 
Matrigel as a scaffold, endothelial cells characteristically form connections, 
sometime described as tube-like structures (Logie et al., 2010); this assay has been in 
use since 1988 (Kubota et al., 1988), and is used to demonstrate the cell-cell 
communication that occurs in angiogenesis. Whilst angiogenesis is a complex 
process, this in vitro assay is a rapid, quantitative way to determine the potential of 
endothelial cells for the migration and differentiation stages of the angiogenic 
cascade, and is a useful assay to precede in vivo angiogenesis experiments. Though 
this assay is commonly used in the analysis of endothelial cells, other cell types have 
been found to form connections on Matrigel. For example, primary human 
fibroblasts and U87-MG (a glioblastoma cell line) form tubules (Donovan et al., 
2001). It is, nonetheless, still an indication of angiogenic potential of endothelial 
cells, and there is a distinction in the morphology of the tubules formed between 
endothelial cells and connections formed between other cell types (Arnaoutova et al., 
2009). More frequent imaging of the tubules, or tracking their formation with time 
lapse microscopy would give more insight into the rate (and possibly mechanism) of 
formation of these tubule-like structures (Logie et al., 2010). Further experiments 
could also include testing functional responses to angiogenic factors (for example, 
VEGF, demonstrated by Donovan et al., 2001). Elucidation of how these cells might 
react to pro-angiogenic factors or compounds could be included in the design of 
cellular therapeutic approaches for repair of atherosclerotic vessels or 
revascularisation of ischaemic tissue.  
 
The ability of cells to migrate and proliferate to undergo wound healing in vitro was 
quantified by a scratch assay with ES-EC, iPS-EC and endothelial control line 
HUVEC. This assay looks at the totality of cell behaviour following wounding; 
through both migration and proliferation of recovering cells (adapted from Liang et 
al., 2007). This assay mimics the process of wound healing in vivo: disruption of the 
endothelial layer induces migration and proliferation of nearby endothelial cells to 
repair the area (Alberts et al., 2002). The wounding assay is usually used as 
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measurement of a cytokinesis response. However, in this case, no growth factors or 
cytokines were added to the media, therefore these experiments represent the 
migrational response and movement of cells post-wounding. These experiments 
could be developed further to assess responses to VEGF, for example, to demonstrate 
cytokinesis of endothelial cells. In all cell lines used in these experiments, the cell 
layer had completely recovered after 24 hours; and there was no significant 
difference in wounding after 6 hours, suggesting that rates of cell migration are the 
same for all cell lines, another indication of the endothelial nature of the ES- and 
iPS- derived cells. 
The production of nitric oxide (NO), a potent vasodilator catalysed by eNOS, is a 
key function of the endothelium (Ignarro et al., 1987). As eNOS was present on ES-
EC and iPS-EC (detected by immunocytochemistry), the NO assay would have 
confirmed it’s functionality in response to stimulation by acetylcholine. However, as 
neither nitrite nor nitrate could be detected from endothelial cell control lines, this 
assay may not be best suited to the detection of NO release in vitro. It is therefore 
unlikely that the increases in nitrite and nitrate concentrations in the supernatant of 
ES-EC are real. Though experimentally, ACh has been shown to stimulate NO 
release (Amezcua et al., 1988; Joannides et al., 1995), this is usually an immediate 
reaction. For example, in isolated arteries, acetylcholine causes muscarinic receptor-
mediated release of NO within seconds (Cohen and Vanhoutte, 1995). Further 
studies need to be carried out to optimise the concentration of acetylcholine used for 
stimulation, and the length of time before supernatant collection. Also, as an 
alternative to ACh, LPS could be used in future experiments as a positive control for 
stimulation of NO release (Cendan et al., 1994). Whilst the colorimetric Griess assay 
is widely used for the detection of organic nitrite compounds (Granger et al., 1996; 
Schulz et al., 1999), there are limitations associated with it. Failure to detect nitrite 
produced from reduction of nitrate may indicate that this reaction is incomplete 
(Sharma et al., 2008). Incomplete nitrate reduction could be due to the presence of, 
for example, azide, ascorbic acid or sulphydryl-containing compounds within the 
sample, which could interfere with nitrate reductase, lowering the conversion of 
nitrate to nitrite and therefore giving rise to lower estimates of NO. (Yao et al., 2004). 
Ascorbic acid is present in the culture media (EGM-2). In repeating this experiment, 
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a different culture media could be used, for example Minimal Essential Medium, 
which does not contain ascorbic acid.  The Griess reaction itself is inhibited by the 
presence of pyridine nucleotides (NADH and NADPH) (Grisham et al. 1995); the 
former is involved in the nitrate reductase process. Unreacted levels of NADH prior 
to colour detection may account for a lack of signal from the Griess reaction. An 
alternative method of nitric oxide detection is via a Chemiluminescence NO analyser, 
in which nitric oxide, upon reaction with ozone, produces luminescence directly 
proportional to the levels of NO in the conditioned media (Bussolati et al., 2001). As 
this measures NO directly, rather than its metabolites, it may be more suited to 
analysis of production from endothelial cells, and is something to consider in the 
design of future experiments. 
 
In summary, in vitro assays confirmed that there are many similarities between stem-
cell derived CD31+ cells and endothelial cells. In combination with phenotypic 
analysis, and in comparison with endothelial cell controls, it is clear that endothelial-
like cell populations have been derived from differentiation of stem cells.  
 
 
4.6.3.2.  In vivo analysis 
 
In vitro assays have a limited capacity to inform about the functional properties of 
endothelial cells, due to the 2 dimensional and artificial nature of cell culture. Flat 
monolayers of cells in culture do not take into account interactions with other cell 
types, or exposure to circulating cytokines or shear stress that occurs within the 
tissues microenvironment. Greater insight into the functions of these cells can be 
provided by in vivo studies. 
 
Though there were no differences between stem cell derived cells and endothelial 
controls in the in vitro angiogenesis assay, ES-EC and iPS-EC displayed increased 
angiogenic potential in vivo in comparison to EOC or EOC-conditioned media. This 
was in the form of increased vessel density, and suggests that they are a pro-
angiogenic cell type in comparison with endothelial cell controls. The disparity 
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between in vitro and in vivo assays likely reflects the sheer complexity of 
angiogenesis, many factors of which are not considered in the in vitro assay.  
 
Many in vivo studies concerning endothelial cells have been published, to assess their 
functional potential, ranging from attempts to induce neovasculogenesis (Hague et 
al., 2002), to assistance in the processes of reendothelialisation following injury 
(Xiao et al., 2006). In the design of these experiments it is important to consider the 
optimal cell type to promote angiogenesis. Whilst there is confusion around the 
precise definition of an ‘endothelial progenitor cell’ (Yoder et al., 2007), cellular 
outgrowth from mononuclear cells in blood which express an endothelial cell 
phenotype are thought to have a heightened capacity for migration and proliferation 
to aid in repair and regeneration of the endothelium (Dimmeler et al., 2004). These 
blood outgrowth cells have been widely used in in vivo models of vasculogenesis and 
angiogenesis (Barclay et al., 2012). Endothelial outgrowth cells from cord or 
peripheral blood are thought to be the best example of an endothelial progenitor cell, 
and have demonstrated potential to form blood vessels in vivo. For example, Au et al. 
(2007), implanted EOC in a cranial window model of angiogenesis to test their 
stability and function over time in vivo, and found that both cord blood and 
peripheral blood-derived EOC formed vessels. Ott et al. (2005) found that CD34+-
derived EOC form vascular structures in a model of ischaemic myocardium, and are 
able to improve left ventricular function in a model of myocardial infarction. Though 
the EOC used as a control cell line in this thesis did not have any effect on vessel 
density, this may be because they had gone through 5 passages. Barclay et al., 2012 
commented that EOC of P0/P1 did incorporate into vasculature, whereas later 
passage cells did not. This period of time in culture may be enough to alter cell 
characteristics, reducing their angiogenic potential, as has been reported by Melero-
Martin et al 2008. Melero-Martin et al. (2008) reported that maturation of EOC lines 
in vitro decreased their ability to vascularise Matrigel plugs in vivo.  
 
Immuno-analysis by species-specific panels of antibodies was robust, as shown by 
clear positive and negative controls. All the vessels analysed from the sponges 
treated with ES-EC and iPS-EC appear to be of mouse origin, demonstrated by the 
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absence of human specific antibody staining in the vessel walls. Apart from one 
example of incorporation, this was also the case for implanted EOC. From antibody 
set 2, green SMA staining was bright in most cases, and appeared to stain the 
endothelial lumen, which was useful for the detection of vessels. Other studies have 
shown SMA staining of endothelial cells (Azuma et al, 2009; Lu et al., 2004), though 
it is also known to stain mesenchymal cells (Melero-Martin et al., 2008). Set 3 
staining of CD31 is distinctive, indicating that it is an appropriate marker of 
endothelial cells in vessel walls. Some of the fields imaged contained ‘free’ CD31+ 
human cells, not contained within vascular structures, confirming that the implanted 
human cells were able to survive the process of implantation for 21 days, even if they 
were unable to incorporate into vascular structures. A substantial proportion of the 
sponge was sectioned for analysis, therefore I am confident that human cell 
incorporation is not being missed due to methodological reasons.  
 
In addition to lack of incorporation, a common feature of all sponges is that the 
vessels are mostly, if not all, found towards the periphery of the sponge, suggesting 
that the vessels which form are predominantly mouse vessels growing in to the 
sponge from outside (angiogenesis), rather than the embedded cells sprouting vessels 
from within the sponge (neovasculogenesis). As ES-EC and iPS-EC increase vessel 
density without incorporating into vascular structures, it is likely that they are 
secreting paracrine factors that stimulate migration and differentiation of nearby 
mouse endothelial cells, enhancing angiogenesis. In vivo studies into paracrine 
effects on vessel growth have been investigated before and suggest that a number of 
factors (including IL-8, MCP1, HGF, bFGF, VEGFa) secreted by implanted cells can 
be pro-angiogenic (Krenning et al. 2013).  Further experiments are required to 
ascertain the mechanism by which these cells are exerting their pro-angiogenic 
effects. For example in vitro analysis of migration kinetics of murine endothelial 
cells in response to ES-EC or iPS-EC conditioned media. Metabolomic analysis of 






4.6.4. Limitations and future studies 
 
In some cases, variable differentiation efficiencies exist between iPS cell lines that 
have originated from different laboratories, possibly due to variations in cell type of 
origin or reprogramming technique (Bock et al., 2010). A clearer assessment of the 
suitability of the endothelial differentiation protocol would be gained from testing it 
on a wider panel of iPS cell lines. Experiments were limited to three iPS cell lines 
that were available within the institute, due to the time-consuming maintenance 
demands of stem cell culture. Further studies could include iPS cells derived from 
other reprogramming methods or from other cell types of origin, to scrutinise the 
efficiency of the endothelial differentiation protocol and assess its suitability for 
application to multiple ES and iPS cell lines.  
 
There may be advantages in implanting a non-purified population of differentiating 
cells for in vivo angiogenic assessment, as systemic factors may facilitate the 
differentiation and maturation of endothelial cells; as such it would be interesting to 
further study cells recovered from sponges, to assess effects of exposure to systemic 
in vivo conditions. Conversly, implantation of immature cells, or populations still 
containing pluripotent cells may lead to their differentiation down non-endothelial 
pathways, or tumour formation.  
 
The in vivo murine model of subcutaneous sponge implantation of endothelial cells is 
more suited to assessment of angiogenic potential than in vitro assays, though it too 
has its limitations. The cells used in the murine subcutaneous sponge implant model 
were tested under non-stressed physiological conditions (the mice were healthy and 
immuno-compromised), and therefore pathological factors associated with 
atherosclerosis which influence angiogenesis do not feature in these experiments. For 
example, in atherosclerosis, inflammation contributes to the stimulation of 
angiogenesis (Carmeliet and Jain, 2000). Inflammatory cells surrounding the lesion- 
monocytes, macrophages and other leukocytes- produce soluble factors including 
VEGF, Ang1, and bFGF (Seljelid et al., 1999) which stimulate angiogenesis. Also, 
angiogenesis can be stimulated by hypoxia, which can arise from the disruption of 
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blood flow due to atherosclerotic plaques (Felmeden et al., 2002). In this case, 
hypoxic inducible transcription factors are activated, which function downstream to 
induce expression of various angiogenic factors, for example VEGF, eNOS, PDGF 
and Ang2 (Semenza, 1998). As the overarching aim of this study is the generation of 
endothelial cells that have the potential to repair ischaemic tissues following 
myocardial injury, a progression of these studies could be in vivo assessment of 
differentiated cells in a pathological model of angiogenesis. This could determine 
how they respond to pro-angiogenic factors, (which include VEGF, Ang1, bFGF, 
TGF-β1, PDGF, TNF-α, among many others; Carmeliet and Jain, 2000), released 
from stromal cells and inflammatory cells. Additionally, assessment of differentiated 
endothelial cells in hypoxic conditions could be carried out in the murine ischaemic 
hindlimb model. Rufiahah et al. (2011) report that implanted iPS-ECs secrete 
angiogenic cytokines (Ang-1, VEGF-A, VEGF-C and PDGF).  Testing these cells in 
vitro showed that these secretions are upregulated in hypoxic conditions, compared 
with normoxic conditions. Further studies may also help to elucidate any differences 
between the processes of angiogenesis in physiological and pathological conditions. 
It would also be interesting to further understand the effect of EOC on 
neovascularisation of an implanted sponge by using a fully murine model with 
murine EOC (obviating the need for NSG mice). Murine EOC have been found to act 
as endothelial progenitors, and have demonstrated persistant seeding in liver, lung, 




The work described in this chapter demonstrated that endothelial cells can be 
generated from both human embryonic and induced pluripotent stem cells. ES-EC 
and iPS-EC had a typical endothelial phenotype, similar to that of EOC and HUVEC, 
and, despite their low differentiation efficiency, could be expanded and maintained in 
culture. In vitro functional assays confirm that endothelial cells derived in this way 
were functional within the tested parameters. In vivo studies suggested that implanted 
ES-EC and iPS-EC, in a murine sponge implant model, were pro-angiogenic, and 
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likely increasing vessel density through paracrine mechanisms. Therefore, this is a 
suitable method for generating populations of endothelial cells for in vitro and in vivo 
functional studies. In the future, iPS cell technology could be applied to generate 
patient specific cell lines to elucidate the mechanisms of endothelial dysfunction in 




Differentiation of fibroblast- and endothelium-derived iPS 






Introduction: Endothelial differentiation of human pluripotent stem cells is 
challenging, with low yields of functional endothelial cells. Reports suggest that iPS 
cells derived from sources other than fibroblasts may have enhanced differentiation 
potential towards their cell type of origin. This chapter hypothesised that that 
pluripotent stem cells derived from endothelial cells (eiPS) would have enhanced 
capacity for endothelial differentiation compared to those derived from dermal 
fibroblasts (fiPS).  
Results: Differentiation of eiPS generated more CD31+ endothelial cells after 7 days 
compared to differentiation of fiPS (21±3% versus 3±2% respectively; P<0.05). 
Endothelial cells from eiPS cells (eiPS-EC) have many similar properties to 
endothelial cell controls, with high expression of CD31 (75%±7%), CD146 
(86%±6%), CD105 (91%±3%), vWF and eNOS. Endothelial cells from fiPS (fiPS-
EC) were similar, with the exception of CD105 expression, which at 30%±12% was 
significantly reduced compared to control endothelial cells. In addition, fiPS-CD31+ 
retained some expression of pluripotency markers SSEA3 (16%±7%) and SSEA4 
(23%±5%) and appeared to have diminished migratory and proliferative properties in 
the wound healing assay. In comparison to endothelial cell controls, the angiogenic 
capacity of fiPS-EC and eiPS-EC was similar in vitro, though enhanced in vivo when 
compared to endothelial cell controls. In a murine subcutaneous sponge implant 
model of neovasculogenesis, fiPS-EC and eiPS-EC cells increased vessel density (by 
3.50 and 3.47 vessel counts respectively, P≤0.001 for both), whereas endothelial cell 
controls did not (P>0.05).  
Conclusions: Endothelial differentiation efficiency is enhanced using induced 
pluripotent stem cells derived from somatic cells of endothelial lineage, in 
comparison to iPS cells from dermal fibroblasts. The mechanisms that underpin this 
are unclear, but it seems likely that these cells retain epigenetic factors that increase 
efficiency. Endothelial cells derived from eiPS are phenotypically closer to control 
endothelial cells than fiPS-EC, suggesting they may be the ideal source for 





The genetic risk factors predisposing individuals to atherosclerosis (the major cause 
of coronary heart disease) are poorly understood. Impaired capacity of the 
endothelium to repair and regenerate following injury is one of the earliest events in 
the pathogenesis of atherosclerosis. Genome wide association studies indicate that 
premature atherosclerosis occurs in some instances due to inherited deficiencies in 
endothelial integrity (as reviewed by Damani and Topol, 2007). To elucidate the 
mechanisms of endothelial dysfunction, induced pluripotent stem (iPS) cell 
technology may be used to study the function of endothelial cells from patients with 
atherosclerosis. Theoretically, large quantities of cells can be generated this way, and 
the study of their functional properties in vitro and in vivo can give insight into the 
mechanisms underlying endothelial dysfunction. It is also envisioned that patient-
specific endothelial cells could also be used for drug development and possibly for 
the identification of causative mutations for future genetic therapies.  
 
iPS cells were initially generated from fibroblasts (Takahashi et al., 2007), but as the 
field has developed, other somatic cell types have been reprogrammed. In some cases 
iPS cells possess residual epigenetic memory of their former cell type, in the form of 
characteristic methylation or histone marks. For example, Ohi et al. (2011) report 
that iPS cell lines with the same genetic background but derived from somatic cells 
representative of all three embryonic germ layers have transcriptional memory 
associated with their original somatic cell. Furthermore, this can lead to preferential 
differentiation back towards their cell lineage of origin (Kim et al., 2011), a finding 
that can be exploited to produce somatic cell types that have been otherwise difficult 
to obtain from ES or fibroblast-iPS cell lines. As demonstrated in chapter four, the 
differentiation of endothelial cells from healthy pluripotent stem cell lines is 
challenging, with limited efficiency (from embryonic stem (ES) and iPS cells, 2.5%± 
0.5%, 1.0% ± 0.3% endothelial cells are generated, respectively). Therefore, in an 
attempt to increase endothelial differentiation efficiency, iPS cells were generated 
from an endothelial cell type (Chapter 3), and were expected to have enhanced 
capacity for endothelial differentiation in comparison with fibroblast-derived iPS 
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cells. This could lead to generation of large numbers of endothelial cells for 
phenotypic and functional analysis, and will form the basis for generation of patient-




Pluripotent stem cells induced from endothelial cells have enhanced capacity to form 




 To compare the efficiency of endothelial cell differentiation from fibroblast- 
and endothelial-derived induced pluripotent stem cells.  
 To compare the phenotype and function of endothelial cells derived from 





5.4.  Experimental design 
 
5.4.1. Cell lines 
 
iPS cell lines were derived in house from fibroblasts or endothelial outgrowth cells 
from cord blood, fiPS and eiPS, via transfection with episomal plasmids containing 
Oct3/4, Sox2, Klf4, L-myc, Lin28 and Shp53, as detailed in Chapter 3.4.1. Two 
endothelial control lines were used. HUVEC were supplied by Lonza, UK, and EOC 
were derived from healthy volunteers, as detailed in 2.2.1.3. 
 
5.4.2. Derivation of endothelial cells from fiPS and eiPS 
 
Differentiation into endothelial cells was carried out using protocol D detailed in 
Chapter 2.7. Briefly, stem cells were aggregated into embryoid bodies in suspension 
with mesoderm-inducing cytokines. After three days, embryoid bodies were 
disaggregated and the cells transferred to a single cell monolayer culture system, on 
0.1% gelatin-coated plates, in endothelial medium supplemented with 50ng/ml 
VEGF. After seven days, CD31+ cells were isolated by FACS and further cultured on 
0.1%-coated gelatin plates in endothelial medium with 50ng/ml VEGF 
supplementation. 
 
5.4.3. Characterisation of fiPS-EC and eiPS-EC: in vitro 
 
Following expansion in culture, sorted CD31+ cells were analysed in vitro for 
phenotypic and functional characterisation, as detailed in Chapter 2.3 and 2.5. For 
phenotypic characterisation, flow cytometry was carried out to assess expression 
levels of a panel of endothelial, hematopoietic and pluripotency cell surface antigens 
(Chapter 2.3.1). Immunocytochemistry was performed to assess expression of 
endothelial markers von Willebrand Factor (vWF) and endothelial Nitric Oxide 
Synthase (eNOS) (Chapter 2.3.2). For functional characterisation, the cells were 
assessed on their ability to form connections when cultured on Matrigel, as an 
indication of angiogenic capacity (Auerbach et al., 2003) (Chapter 2.5.1). They were 
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also subjected to the wound healing assay, in which their ability to recover from a 
scratch was assessed, indicating migratory and proliferative properties (Chapter 
2.5.2). Finally, the cells were assessed for production of nitrite and nitrate 
metabolites (indirect measurements of nitric oxide release) following 24 hours 
stimulation with acetylcholine (Chapter 2.5.3). All parameters were compared to two 
mature endothelial control lines: HUVEC and EOC.  
 
5.4.4. Characterisation of fiPS-EC and eiPS-EC: in vivo 
 
In vivo analysis of the CD31+ cell populations was carried out using the murine 
model of subcutaneous sponge vascularisation, detailed in Chapter 2.6.1. NSG mice 




mice per group 
Conditioned media from Endothelial Outgrowth Cells 4 
Endothelial outgrowth cells 6 
Endothelial cells differentiated from fibroblast-derived induced 
pluripotent stem cells 
6 
Endothelial cells differentiated from endothelial- derived induced 
pluripotent stem cells 
6 
 
Table 5.1: Sponge implants and group sizes of the murine subcutaneous 
angiogenesis assay. Control groups (Conditioned media from Endothelial Outgrowth 
Cells and Endothelial Outgrowth Cells) were the same as those used in chapter 4 [pg 
118]. 
 
After 21 days, sponges were removed and fixed in 70% IMS overnight, then 
transferred to 4% PFA until sectioning. They were analysed in two ways. Firstly they 
were sectioned and stained with H&E, for detection of erythrocyte-perfused vessels. 
From these sections, vessel density was quantified by Chalkley counts, using a 25 
point graticule (Hague et al., 2002). Three areas were scored and a mean count taken 
to give the final score. All analysis was carried out blinded to cell type. The second 
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phase of in vivo analysis was to determine the location of implanted cells, to assess 
whether or not they incorporated into vessels. Paraffin embedded sections were 
prepared and immunostained as detailed in Chapter 2.6.3, with the specifes specific 
antibody sets outlined in Table 2.7.  
 
Vessels were detected around the periphery of the sponge, and scored for red and/or 
green fluorescence to give an indication of incorporation of the implanted human 
cells. Non vascularised sections were also imaged for detection of human CD31+ red 
fluorescence (antibody set 3), to show the presence of implanted cells outwith 





5.5.1. Endothelium-derived induced pluripotent stem cells differentiate 
to endothelial cells with greater efficiency than embryonic stem cells 
or fibroblast-derived induced pluripotent stem cells. 
 
iPS cell lines derived from either fibroblasts (fiPS) or endothelial cells (eiPS) were 
subjected to endothelial differentiation. A greater proportion of CD31+ cells were 
generated from eiPS than fiPS, shown by representative examples of flow cytometry 
dot plots from day 7 FACS sorts (Figure 5.1). 
 
Figure 5.1: Distinct populations of CD31+ cells are present following endothelial 
differentiation of fibroblast-derived iPS cells (fiPS) and endothelial derived iPS cells 
(eiPS); this population is larger following eiPS differentiation. These populations 
were isolated by FACS sorting. Gates were set by unstained controls. 
 
Differentiation efficiency (the percentage of cells expressing the endothelial cell 
marker CD31 at day 7) of fiPS and eiPS was quantified from multiple 
differentiations, and compared against ES and stock iPS cell lines. Differentiation 
efficiency for fiPS was low (3.0 ± 2.2%, N=3) and similar to the ES and stock iPS 
cells previously differentiated (Figure 5.2). Endothelial differentiation efficiency of 




















Figure 5.2: The endothelial differentiation efficiency of the endothelial-induced 
pluripotent stem (eiPS) cell line was higher than that of embryonic stem (ES) cell, 
induced pluripotent stem (iPS) cell, or fibroblast-induced pluripotent stem (fiPS) cell 
lines. Data are expressed as mean ± SEM and were analysed by one-way ANOVA; 





5.5.2. Characterisation of fiPS-EC and eiPS-EC in vitro 
 
Over time, CD31+ cells derived from fiPS and eiPS (referred to as fiPS-EC and eiPS-
EC, respectively) expanded in culture. Both lines appeared rounded with 
‘cobblestone’ morphology, typical of endothelial cells and similar to HUVEC and 
EOC control lines (Figure 5.3). 
 
Figure 5.3: Endothelial cells derived from fibroblast-induced pluripotent stem cells 
(fiPS-EC) and from endothelium-induced pluripotent stem cells (eiPS-EC) display 
typical endothelial morphology, similar to human umbilical vein endothelial cells 
(HUVEC) and late endothelial outgrowth cells (EOC). Bar = 1mm.  
 
Phenotypic analysis of fiPS-EC and eiPS-EC by flow cytometry showed that they 
have some similar characteristics to control endothelial lines (Figure 5.4.). CD31 
expression was maintained in fiPS-EC and eiPS-EC in culture and, at 85±14% and 
75±7% respectively, was similar to control lines. Expression of CD146 was also high 
at 89±9% for fiPS-EC and 86±6% for eiPS-EC, and comparable to control lines 
(CD146: 85±5%, 88±5% for HUVEC and EOC, respectively). Expression levels of 
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CD34 and VEGFR2 were lower (CD34: 17±1% and 19±8%; VEGFR2: 61±7% and 
44±10% for fiPS-EC and eiPS-EC, respectively). These levels appear to vary slightly 
from control lines (CD34: 43±5%, 43±5%; VEGFR2: 30±5%, 28±5% for HUVEC 
and EOC, respectively), however, do not reach statistical significance. fiPS-EC 
differed from eiPS-EC and the control lines in terms of expression of CD105, which 
at 30±12% was significantly lower than CD105 expression of eiPS-EC (91±3), 























Figure 5.4: Endothelial cells derived from fibroblast-induced pluripotent stem cells 
(fiPS-EC) and from endothelium-induced pluripotent stem cells (eiPS-EC) have 
similar phenotypes to human umbilical vein endothelial cell (HUVEC) and late 
endothelial outgrowth cell (EOC) control lines, in terms of expression of endothelial 
cell surface antigens. Data are expressed as mean ± SEM and were analysed by one-
way ANOVA, **= P≤0.01; N=3-8. 
 
Hematopoietic cells are closely linked to endothelial cells - both are derived from the 
mesoderm and there are theories that they originate from a common precursor, the 
hemangioblast (Choi, 2002). In order to confirm that differentiation was leading to 
development of endothelial, rather than hematopoietic cells, fiPS-EC and eiPS-EC 
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were assessed for expression of the hematopoietic markers CD133 and CD45. As 
expected, fiPS-EC and eiPS-EC both had low expression levels of CD45 (fiPS-EC: 
2.0±0.6%; eiPS-EC: 0.8±0.3%; Figure 5.5), though expression of CD133 was 
significantly higher on fiPS-EC (10.6±1.6%) than eiPS-EC (2.0±0.2%). In 
anticipation of the loss of pluripotency, which accompanies differentiation, 
expression of SSEA3 and SSEA4 markers was also assessed (Figure 5.5). Within the 
fiPS-EC population, 15.8±6.9% cells were SSEA3+, and 23.4±4.5% were SSEA4+, 
















Figure 5.5: A higher proportion of endothelial cells derived from fibroblast-induced 
pluripotent stem cells (fiPS-EC) express CD133, SSEA3 and SSEA4, in contrast to 
endothelial cells derived from endothelium-induced pluripotent stem cells (eiPS-EC) 
and control endothelial cell lines. Data are expressed as mean ± SEM and were 
analysed by one-way ANOVA, *= P≤0.05, **= P≤0.01; N=3-8. 
 
To add to this phenotypic profiling of fiPS-EC and eiPS-EC, immunocytochemical 
analysis showed that endothelial cell markers vWF and eNOS were expressed in the 




Figure 5.6 Endothelial cells derived from fibroblast-induced pluripotent stem cells 
(fiPS-EC) and those derived from endothelium-induced pluripotent stem cells (eiPS-
EC) were immunostained with antibodies raised against von Willebrand Factor (vWF) 
(green) and fluorescent nuclear stain DAPI (blue). Bar = 200µm. The majority of 








Figure 5.7 Endothelial cells derived from fibroblast-induced pluripotent stem cells 
(fiPS-EC) and those derived from endothelium-induced pluripotent stem cells (eiPS-
EC) were immunostained with antibodies raised against endothelial Nitric Oxide 
Synthase (eNOS) (red), and fluorescent nuclear stain DAPI (blue). Bar = 200µm.  
 
fiPS-EC and eiPS-EC have the capacity to form connections on Matrigel, a 
characteristic of endothelial cells thought to indicate their angiogenic potential 
(Figure 5.8). Quantification of this assay showed that both lines have similar 









































Figure 5.8 Endothelial cells derived from fibroblast-induced pluripotent stem cells 
(fiPS-EC) and those derived from endothelium-induced pluripotent stem cells (eiPS-
EC) form connections on Matrigel. A) Quantification of cell connections suggests 
similar angiogenic potential of fiPS-EC, eiPS-EC, HUVEC and EOC. Data are 
expressed as mean ± SEM and were analysed via one-way ANOVA, P>0.05; N=3-5. 
Representative images of tubule-like structures formed by B) fiPS-EC and C) eiPS-
EC. By comparison, both D) undifferentiated fiPS and E) undifferentiated eiPS, did 




A wound healing assay was used to assess the ability of fiPS-EC and eiPS-EC to 
migrate and proliferate over time to recover from a scratch (Figure 5.9). After 24 
hours, eiPS-EC had always fully recovered (cell coverage was 100%, comparable to 
HUVEC control). In contrast, in the recovering fiPS-EC monolayer, a scratched area 
remained after 24 hours, suggesting that the proliferative and migratory properties of 





























Figure 5.9 fiPS-EC and eiPS-EC have similar migratory and proliferative abilities 
during recovery from a scratch in the wound healing assay A) Representative images 
of wound healing of fiPS-EC and eiPS-EC over time. Bar= 500µm B) Quantification 
of wound healing of fiPS-EC, eiPS-EC and HUVEC. Data were analysed via one-
way ANOVA, **=P≤0.01, N=3.  
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Nitric oxide release was measured indirectly to complete the in vitro characterisation 
of fiPS-EC and eiPS-EC. Nitrite and nitrate levels were detected colorimetrically 
following stimulation with 10µM ACh. Unstimulated cells had similar nitrite and 
nitrate release to those stimulated with ACh, and levels released from HUVEC and 































Figure 5.10 Similar concentrations of nitrite and nitrate are detected from 
endothelial cells derived from fibroblast-induced pluripotent stem cells (fiPS-EC) 
and those derived from endothelium-induced pluripotent stem cells (eiPS-EC) human 
umbilical vein endothelial cells (HUVEC) and late endothelial outgrowth cells (EOC) 
under basal conditions or following stimulation with acetylcholine (ACh; 10µM) 
over 24 hours. Data are expressed as mean ± SEM and were analysed via Student’s 




5.5.3. Characterisation of fiPS-EC and eiPS-EC in vivo 
 
The murine subcutaneous sponge assay, an in vivo model of vascularisation, was 
used to further characterise the differentiated cells and ascertain their angiogenic 
response to systemic stimuli over a period of 21 days, as detailed in Chapter 2.6 and 
Chapter 5.4.4. 
 
Sponges were treated with EOC conditioned medium, EOC, fiPS-EC or eiPS-EC and 
implanted into the right flank; a Matrigel-treated sponge was implanted into the left 
flank as a paired control. After 21 days, the sponges were removed and sectioned for 
analysis of vessel density, determined by Chalkley counts (Figure 5.11). fiPS-EC and 
eiPS-EC increased vessel density compared to paired Matrigel controls (fiPS-EC: 
4.1±0.3 vessels vs 7.6±0.4 vessels, P≤0.001; eiPS-EC: 4.8±0.4 vessels vs 8.3±0.4 
vessels, P≤0.001). Vessel density was increased to the same extent after implantation 


















Figure 5.11 Vessel density in implanted sponges was increased by the presence of 
endothelial cells derived from fibroblast-induced pluripotent stem cells (fiPS-EC) 
and those derived from endothelium-induced pluripotent stem cells (eiPS-EC). 
Sponges contained endothelial outgrowth cell conditioned medium (EOC-CM), EOC, 
fiPS-EC or eiPS-EC; vessel density was scored by Chalkley count. Data are 
expressed as mean ± SEM and were analysed via two-way ANOVA, ***=P≤0.001; 
N.S.= not significant; N=4-6 mice per group. EOC were used at passage 5.  
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Sponge sections containing fiPS-EC and eiPS-EC were analysed via 
immunocytochemistry, with paired antibody sets detailed in Table 2.7. Sections of 
control Matrigel sponges and human fibroid tissue were used as positive controls to 
test all antibodies (Chapter 4.5.2, Figures 4.17 and 4.18). Within the following 
figures, vessels could be detected by the green fluorescence generated from binding 
of either smooth muscle actin or CD31 antibodies, cross reactive to human and 
murine cells. Red fluorescence, generated from the binding of human specific 
antibodies CD31 or CD146 indicated the presence of human cells. Red fluorescence 
within a vessel wall therefore indicated that implanted human cells incorporated into 
the vasculature. No incorporation of human cells into vasculature was detected in 
fiPS-EC (Figure 5.12) or eiPS-EC (Figure 5.13) treated sponges, though human 






























Figure 5.12 Neovasculature detected in sponge sections containing fibroblast 
induced pluripotent stem cell-derived endothelial cells. A) Vascular structures 
stained positive for smooth muscle actin antibody (green), but not human specific 
CD31 antibody (red). B) Vascular structures stain positive for CD31 (green), but not 
human specific CD146 antibody (red). DAPI stained nuclei blue. Erythrocytes 







Figure 5.13 Neovasculature detected in sponge sections containing endothelial- 
induced pluripotent stem cell-derived endothelial cells. A) Vascular structures 
stained positive for smooth muscle actin antibody (green), but not human specific 
CD31 antibody (red). B) Vascular structures stain positive for CD31 (green), but not 
human specific CD146 antibody (red). DAPI stained nuclei blue. Erythrocytes 





In all sponges, human cells outwith vascular structures were detected with human 
specific antibody against CD31 (Figure 5.14).  
 
 
Figure 5.14: Human cells, stained red with CD31 antibody, were identified outwith 
vascular structures in sponges containing endothelial cells derived from fibroblast- 
and endothelial- induced pluripotent stem cells. DAPI stained nuclei blue. The large 
triangular structures are sponge matrix. Bar = 100µm. 
 
Vessel density was significantly increased (to the same extent) by implantation of 
fiPS-EC and eiPS-EC, whereas implanted EOC or conditioned media from EOC did 
not increase vessel density (Figure 5.11). This indicates enhanced angiogenic 
potential of iPS-derived cells over a control endothelial line. However, 
immunocytochemical analysis of vascular structures did not identify incorporation of 

























EOC-CM* 3.8 ± 0.7 4.7 ± 0.6 0.9 0.301 - - - - 
EOC* 4.8 ± 0.4 5.1 ± 0.5 0.3 0.557 180 Yes 1 Yes 
fiPS-EC 4.1 ± 0.3 7.6 ± 0.4 3.5 ≤0.001, *** 180 No - Yes 
eiPS-EC 4.8 ± 0.4 8.3 ± 0.4 3.5 ≤0.001, *** 180 No - Yes 
 
Table 5.2: Performance of endothelial outgrowth cell conditioned medium (EOC-CM), EOC, endothelial cells derived from fibroblast-induced 
pluripotent stem cells (fiPS-EC) and endothelial cells derived from endothelium-induced pluripotent stem cells (eiPS-EC) in a subcutaneous 
sponge murine model of vascularisation. fiPS-EC and eiPS-EC significantly increase vessel density within implanted sponges, though do not 
incorporate into murine neovasculature. *Neither EOC-CM nor EOC increase vessel density, though there is evidence of EOC incorporation into 
murine neovasculature (data displayed in Chapter 4; Figures 4.19 and 4.23). Data are expressed as mean ± SEM. Probability was determined by 






This chapter confirmed the hypothesis that pluripotent stem cells derived from an 
endothelial cell have enhanced capability to differentiate into endothelial cells 
compared to fibroblasts.  These observations raise fundamental questions about the 
use of different somatic cells for reprogramming and suggest that there may be 
advantages in reprogramming cardiovascular cells for vascular regeneration. 
Differentiated endothelial cells from fibroblast- and endothelial-derived iPS cells 
appeared pro-angiogenic in comparison to endothelial cell controls, and may have 
potential for vascular regeneration. 
 
5.6.1. Endothelial differentiation efficiency is considerably higher in eiPS 
than fiPS.  
 
That eiPS cells more readily differentiate to endothelial cells, in comparison with ES 
and fiPS cell lines, indicates that whilst they meet all the criteria to be defined as 
pluripotent, there are underlying characteristics which distinguish them from other 
pluripotent cell types. This phenomenon has been described before in iPS cells 
derived from a non-fibroblast cell type which preferentially differentiate back 
towards their cell type of origin. For example, Kim et al. (2010) report that blood-
derived iPS cells form more hematopoietic colonies than fibroblast-derived iPS cells 
when both are subjected to a hematopoietic differentiation protocol. Many studies 
have concluded that this is likely due to residual epigenetic memory. Tissue specific 
differences are brought about by epigenetics (variations in chromatin structure and 
chemical modifications of DNA that influence gene expression). The reprogramming 
process reverts the vast majority of these epigenetic features to those of an ES-like 
state (Lister et al., 2011; Doi et al., 2009). However, this epigenetic ‘resetting’ is not 
always complete. For example, Lister et al. (2011) report that certain chromosomal 
regions near telomeres and centromeres are resistant to epigenetic resetting, and that 
donor cell DNA methylation patterns in these regions may persist through 
reprogramming and differentiation processes. Incomplete reversal of the original 
somatic cell’s epigenome is referred to as ‘residual epigenetic memory’. It would 
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therefore be interesting to analyse global gene expression profile (by microarray) of 
eiPS (and fiPS) cell lines in their differentiated and undifferentiated states. DNA 
methylation arrays (Sandoval et al., 2011) could also be used to identify distinctive 
DNA methylation marks or histone modifications on eiPS, which may help to 
elucidate enhanced endothelial differentiation potential. There is, however, some 
disagreement regarding the impact of residual epigenetic memory. Some reports 
indicate that the gene expression and differentiation efficiency variations detected in 
early passage iPS cells are attenuated by long term passaging, implying that 
epigenetic memory is transient and that reprogramming is a gradual process (Polo et 
al., 2010). This suggests that a detectable state of pluripotency in early passage cells 
may be acquired before complete resetting of the epigenome. The cells used for 
differentiation in this chapter were at a fairly early passage (eiPS: between passage 
15-19, fiPS 15-21), whereas all ES and stock iPS cell lines used were passage 42 and 
above. Study of late passage eiPS and fiPS would be interesting, to determine 
whether the enhanced endothelial differentiation potential of eiPS is lost with 
increasing passage. If this was found to be the case, it could be exploited by using 
early passage iPS cells for efficient endothelial cell generation, and would be a key 
consideration in the design of future therapeutic applications. 
 
There are many similarities between the differentiated stem cells and endothelial cell 
line controls, from which it can be concluded that the differentiation protocol 
generates a mature and functional endothelial cell. Many other endothelial 
differentiation protocols do not include an isolation step (for example, Rufaihah et 
al.2013), and instead characterise the levels of endothelial markers within the entire 
differentiating population. Whilst this may generate larger yields of ‘endothelial-like’ 
cells, there is likely to be a high degree of heterogeneity within the population, which 
could confuse analyses or limit use in therapeutic applications. By isolating early 
populations of cells expressing a fairly specific endothelial marker, a much more 
homogeneous population of cells is generated, within which all cells are at the same 
stage of differentiation. As discussed in chapter 4, CD31 was selected as it is 
considered to be one of the most specific endothelial cell markers. Also known as 
platelet endothelial cell adhesion molecule (PECAM-1), it is a major constituent of 
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the endothelial cell intercellular junction (Dejana, 2004) and is required for leukocyte 
transendothelial migration under most inflammatory conditions (Muller et al., 1993). 
It is also present on the surface of various hematopoietic cells, including circulating 
platelets, monocytes, neutrophils and selected T cell subsets (Newman, 1997). 
Expression of CD45 (a molecule that is expressed on the surface of all nucleated 
hematopoietic cells and their precursors) distinguishes between hematopoietic and 
endothelial cell types. As the isolated cells were confirmed to be CD31+ and CD45-, 
they could be placed in the endothelial subset. One of the benefits of this protocol is 
the generation of a proliferative, pure population of endothelial cells after a fairly 
short period of time.  
 
Day seven was the time point optimised for peak expression of CD31 by the 
University of Glasgow’s laboratory from which the protocol was derived 
(unpublished data). As it has been demonstrated that there are variations in 
differentiation kinetics between iPS cell lines (Bock et al., 2011), these experiments 
could be further developed to examine whether emergence of CD31+ cells differs 
between iPS cell lines. For example, it may be that ES and fiPS take longer to 
differentiate than eiPS; as such the differentiation protocol could be altered to 
accommodate this. Assessment of the levels of other endothelial markers over time 
would also be interesting, to determine at which point they are expressed, to give 
insight into the molecular mechanisms behind the differentiation process. This could 
also add to the understanding of possible epigenetic processes, which may be 
affecting eiPS differentiation.  
 
The data in this chapter suggests that there are advantages of eiPS over fiPS for the 
generation of endothelial cells to model disease or develop novel therapeutic 
approaches for vascular regeneration. Larger cell numbers can be generated through 
more effective differentiation, therefore shortening the time in culture required to 
derived large numbers of cells required for analysis or, in the future, therapeutic 
application. In general, less time in culture is desirable, as there are negative effects 
of extended periods of cell culture. Alterations can occur which can mean cells are 
no longer representative of their phenotype in vivo; these can include changes in 
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karyotype, cell surface antigen expression or growth properties (Auerbach et al., 
2000; Staton et al., 2004). 
 
5.6.2. Endothelial cells derived from fiPS and eiPS have similar 
phenotypes and functions 
 
Multiple phenotypic and functional assays indicate that fiPS-EC and eiPS-EC have 
many similar properties, to each other and to the endothelial cell control lines. As 
well as expression of CD31, both lines highly express CD146, an endothelial 
intracellular adhesion molecule, which facilitates the formation of a confluent layer 
of endothelial cells (Bardin et al., 2001). There were no significant differences 
between expression levels of CD34 and endothelial cell controls, a marker also 
expressed on hematopoietic stem and progenitor cells; thought to be up-regulated on 
endothelial cells in angiogenesis (Siemerink et al., 2012).  Also similar to endothelial 
cell controls are the levels of VEGFR2 on fiPS-EC and eiPS-EC, a Tyrosine Kinase-
linked receptor, which binds the angiogenic molecule VEGF (Ferrara et al., 2003). 
The presence of vWF, with a granular staining pattern characteristic of endothelial 
cells, and eNOS, the endothelium-specific constitutively produced enzyme which 
catalyses nitric oxide production (Fleming and Busse, 2003), indicates that these 
differentiated cells have properties characteristic of mature endothelial cells. 
 
In the in vitro angiogenesis assay, fiPS-EC and eiPS-EC appear to form similar 
numbers of connections, to each other and to the endothelial cell controls. By 
comparison, undifferentiated fiPS and eiPS did not form connections on Matrigel. 
This is a quick assay, is easy to set up and reproducible, however it is not necessarily 
sensitive enough to detect differences in function between different types of 
endothelial cell (Staton et al., 2004). Heterogeneity in endothelial cells arises due to 
tissue specific functions, and the response of endothelial cells to growth factors and 
cytokines varies depending on their tissue of origin (Staton et al., 2004; Garlanda et 
al., 1997). Therefore, some endothelial cell populations may have greater angiogenic 
capacity than others. Whilst this assay is a visual indication of the functionality of 
differentiated cells, similar to endothelial cell controls, these limitations meant that 
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angiogenic potential was also assessed in vivo to allow stronger conclusions to be 
drawn regarding functionality.   
 
The scratch assay was used to assess cell migration and proliferation, which occurs 
during wound healing. This technique was adequate for the purposes of this thesis; 
however higher throughput and reproducibility could have been increased by 
automation, for example use of robotic techniques (Simpson et al., 2008). Though 
here there is no distinction between migration and proliferation, two processes 
integral to physiological wound healing, this allows assessment of the totality of 
cellular behaviour in response to injury. From their performance in the wound 
healing assay the fiPS-EC do not appear to reach confluence 24 hours after the 
scratch wound, a finding which reached statistical significance once quantified. This 
could suggest that they have less proliferative and migratory capacities, and would 
support the suggestion that they less readily reach an endothelial cell type than eiPS.  
 
The production of nitric oxide (catalysed by eNOS) is a key function of the 
endothelium. Despite the presence of eNOS on fiPS-EC and eiPS-EC, detected by 
immunocytochemistry, stimulation with acetylcholine did not significantly increase 
production of nitrite or nitrate for either of these cell lines, or the endothelial controls.  
As discussed (Chapter 4.6.3.1), the lack of response was unexpected, as 
acetylcholine has a direct physiological effect on endothelial cell activity by 
increasing nitric oxide production (Amezcua et al., 1988; Joannides et al., 1995). 
Further studies need to be carried out to optimise the concentration of acetylcholine 
used for stimulation, and the length of time before supernatant collection.  
 
Some differences exist between the fiPS-EC and eiPS-EC populations, suggesting 
that some CD31+ cells derived from fiPS lack the full endothelial cell profile. For 
example, significantly higher levels of CD133, a stem cell marker, and the SSEA3 
and 4 pluripotency markers in the fiPS-EC population (compared with levels in eiPS-
EC, HUVEC and EOC), suggest that there may still be a degree of pluripotency 
within the population, which may indicate that these cells are plastic in culture, and 
can express CD31 and SSEA3/4 simultaneously. As pluripotency marker levels in 
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eiPS-EC cells are significantly lower, this finding may suggest that differentiated 
fiPS cells may take longer to form a complete endothelial cell profile, contributing to 
the suggestion that eiPS are a better source for endothelial cell generation.  
 
CD105, also known as endoglin, is a constituent of the transforming growth factor-
beta receptor and is thought to be limited to actively proliferating endothelial cells 
(Nassiri et al., 2011), as well as smooth muscle cells and macrophages. Lower 
expression levels of CD105 on fiPS-EC may indicate that they are less proliferative 
in culture than eiPS-EC or control cell lines. This possibility could be investigated by 
population doubling studies.  
 
5.6.3. fiPS-EC and eiPS-EC increase vessel density in vivo, though they 
appear to have similar angiogenic capacity to EOC in vitro. 
 
In a similar way to the ES-EC analysed in Chapter 4.5.2, fiPS-EC and eiPS-EC 
increased vessel density in vivo, adding to the suggestion that pluripotent stem cell-
derived endothelial cells are pro-angiogenic in comparison with control endothelial 
cell lines. However, neither fiPS-EC nor eiPS-EC appeared to incorporate into 
neovasculature, as no human specific cells could be detected in the vessels after 21 
days. It seems likely, therefore, that that the implanted cells are releasing angiogenic 
factors, thus influencing neovasculature growth in a paracrine manner. Further 
experiments are required to elucidate these paracrine pro-angiogenic mechanisms. 
For example, it is possible that factors are released which stimulate the migration of 
nearby murine endothelial cells, a phenomenon which could be studied by assessing 
the chemotaxis (Schor et al., 2001) of murine endothelial cells across a Boyden 
chamber membrane in response to fiPS-EC or eiPS-EC conditioned medium. 
Implantation of sponges containing fiPS-EC or eiPS-EC conditioned medium may 
also demonstrate paracrine effects on angiogenesis. Increased vessel density could 
also be a result of enhanced proliferation of these cells in vivo; to investigate this it 
would be interesting to study the effect of systemic murine factors on fiPS-EC and 




The in vivo sponge assay was well suited to the study of angiogenesis, as vessels 
were visible around the periphery of sectioned sponges, with erythrocytes often still 
present within them once the sponge had been sectioned and stained. Angiogenesis is 
a complex process in vivo, the intricacies of which are not fully replicated by single 
cell in vitro assays. For example, although endothelial cells are central to the 
angiogenic process, they are supported by other cell types- smooth muscle cells, 
pericytes and fibroblasts (Carmeliet, 2000)- not taken into account in single cell in 
vitro assays. Previous studies within our laboratory used the murine sponge implant 
model of vascularisation in vivo, with extensive research into the optimal 
combinations of human specific and human/mouse cross-reactive antibodies (Barclay 
et al., 2012, including extensive supplementary information). Confidence in this 
method of human cell detection can be drawn from using the same antibodies as 
Barclay et al., and from distinct positive controls (as shown in Chapter 4, Figures 
4.17 and 4.18). Though relatively sparsely spread throughout the sponge, implanted 
fiPS-EC and eiPS-EC were identified by human specific CD31+ staining, showing 
that they were able to survive the process of implantation. Another benefit of this 
study was the demonstration that implantation of both fiPS-EC and eiPS-EC did not 
result in teratoma formation. Typically, subcutaneous injection of mice with human 
ES cells will result in teratomas formed of cells derived from all three germ layers. 
Usually, tumour formation is assessed after 6-12 weeks, Wesselschmidt et al., 2011. 
However, Gropp et al., 2012 report that tumours can be detected 3-5 weeks after 
injection of 1x105 human ES cells. This was the same number of cells used in the in 
vivo experiments reported here, so it is likely that tumours would have been detected 
had any undifferentiated stem cells been injected. A major obstacle anticipated in the 
clinical translation of this work is the teratoma formation associated with 
implantation of (formerly) pluripotent stem cells (Miura et al., 2009). Theoretically 
this could occur from implantation of only one undifferentiated cell, or from cells not 
yet committed to the endothelial lineage. This would be a key feature of safety trials 
prior to therapeutic translation (Hentze et al., 2009).  
 
There are weaknesses to the in vivo murine sponge assay. Species-specific 
differences between human and mouse must also be taken into account, as implanted 
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cells may respond differently upon exposure to murine systemic factors compared 
with human systemic factors. For example, human endothelial cells bind UEA-1 
(Ulex europaeus lectin-1, a plant lectin used as a non-specific marker of human 
endothelial cells; Holthofer et al., 1982) whereas murine endothelial cells do not 
(Staton et al., 2004). The inherent variability between animals must also be 
considered in interpretation of the results. It was fairly difficult to identify human 
cells in the immuno-analysis, as they were sparsely spread throughout the sponge. 
The murine sponge assay was followed as described in the literature (Barclay et al., 
2012, Tura et al., 2013), except for the later passage of implanted cells. As 
previously discussed, this may be a contributing factor to explain why the experiment 
was unsuccessful in terms of vascular incorporation. The experiments could be 
adapted for the sponges to contain more cells. 105 is a relatively small population to 
put in a 0.5cm x 1cm sponge, and this may have been why it was difficult to identify 
human cells in the immuno-analysis. In addition, due to time constraints, it was not 
possible to analyse the entirety of each sponge by immunocytochemistry, however 
non-consecutive sections were stained to give an overview of approximately a third 
of each sponge, therefore I can say with confidence that this is representative of most 
of the sponge. Experimenting with larger cell numbers may allow detection of human 
cells in vascularised regions of the sponge. As an alternative, tagging the implanted 
cells with lentiviral vectors, or GFP reporter vectors would ease their identification 
once sectioned. The assay could also be developed with the use of tracking 
techniques (Magnetic Resonance Imaging or Positron Emission Tomography, for 
example), to determine if the cells stay in the same place, or if they move and 
interact with each other or with murine cells.  
 
To support immunoanalysis, additional studies could be done using fluorescent in 
situ hybridisation, for identification of sex mismatched mouse and human cells (Han 
et al., 2012). This would complement the immunostaining results and ease the 
identification of implanted human cells. Pilot investigations were performed using 
this method but were not completed due to time constraints. In addition, study of 
endothelial cell function in vivo could be expanded by using other models to give 
further insight in to the potential of these cells for vascular regeneration. For example, 
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re-endothelialisation of vessels could be investigated following artery denudation in 
the balloon-injured rat carotid artery model (Tulis, 2007).  
 
5.6.4. Limitations and future studies 
 
The fiPS and eiPS cell lines were not from the same donor, and therefore genetic 
background is a variable factor to consider in their comparison. It has been reported 
that genetic background of donor cells is a major factor in determining iPS cell 
differentiation propensity, and that this may have more of an influence on 
differentiation potential than somatic cell type or epigenetic memory (Kajiwara et al. 
2012, Ghosh et al,. 2010). Ludovic Vallier’s group report that human iPS cell lines 
appear to strongly vary in their capacity to differentiate, for uncertain reasons. They 
found that iPS cell lines can be grouped into two categories, those which have high 
capacity to differentiate to mesoendoderm and those which have high capacity to 
differentiate to neuroectoderm, and that iPS cell lines derived from one individual all 
belonged in the same category, independent of tissue of origin, passage number or 
reprogramming method (as reviewed by Brack and Hochedlinger, 2013). Further 
studies with iPS cells derived from different somatic cell types from the same donor 
would be extremely important for the elimination of genetic background as a variable 
factor. 
 
The eiPS were derived from cord blood outgrowth rather than peripheral blood 
outgrowth, which limits their potential for clinical application, as cord blood is not a 
feasible approach to generating personalised iPS cell lines for regeneration. iPS cells 
derived from endothelial cell outgrowth of peripheral blood would be a more 
therapeutically applicable donor cell type (as this is a more accessible source than 
cord blood), and therefore reprogramming methods must be worked upon to achieve 
this. That an endothelium-based iPS cell can efficiently differentiate back to 
endothelium may suggest that other endothelial cell types (i.e. those from peripheral 
blood outgrowth) would do the same. It is hoped that reprogramming methods will 
be developed to induce pluripotency in endothelial cells derived from the vessel wall, 




The decreased expression of pluripotent cell surface antigens on eiPS after 
differentiation indicates that they are committing to an endothelial cell lineage. It 
may be interesting to exploit the enhanced differentiation potential of eiPS to see if 
they also differentiate more effectively into other mesodermal linages, for example 
cardiomyocytes. This would increase the disease modelling potential and therapeutic 
application of these cells.  
 
This work was carried out in healthy volunteer lines, to establish the reprogramming 
and differentiation protocols before the production of patient-specific stem and 
endothelial cell lines. Further studies on patient specific cells would enable in vitro 
disease modelling to aid in the elucidation of mechanisms of endothelial dysfunction. 
Prior to therapeutic application, all procedures would have to be made GMP (Good 
Manufacturing Practise) grade, meaning that all media used would be fully defined 




Differentiation of human pluripotent stem cells into endothelial cells is an emerging 
technology, one that has proven challenging with consistently low yields of 
endothelial cells generated from ES and iPS cells. However, populations of 
functional endothelial cells can be differentiated with relatively high efficiency from 
endothelium-derived iPS cells of healthy individuals. Though the mechanisms that 
underpin this are unclear, it seems likely that these cells retain epigenetic factors that 
increase efficiency; therefore an endothelium-based iPS cell may be the ideal source 












iPS cell technology can be used to generate large numbers of endothelial cells for the 
study of their function in vitro and in vivo. This thesis examined the hypothesis that 
healthy human embryonic and induced pluripotent stem cells can be used as a source 
for the derivation of large populations of fully functional endothelial cells. It was 
also hypothesised that the generation of endothelial cells is more efficient from iPS 
cells which had been generated from endothelial cells, in comparison to fibroblasts. 
The aims of this research were to induce pluripotency in various somatic cell types, 
and to optimise and validate an efficient endothelial differentiation 
protocol. Furthermore, the functional properties of the resulting endothelial cells 
were analysed in vitro and in vivo.  
 
6.1. Fibroblasts and endothelial cells can be induced into pluripotency 
through transfection with episomal plasmids containing specific 
reprogramming factors 
 
As an integration-free, viral-free and therefore safer method of nuclear 
reprogramming (compared to retroviral vectors), episomal plasmids were used as a 
delivery system for the reprogramming of somatic cells. They contained transcription 
factors Oct3/4, Sox2, Klf4, L-myc, Lin28 and Shp53 (a combination optimised by 
Okita et al., 2011), to induce pluripotency in fibroblasts and late outgrowth 
endothelial cells from cord blood. A myriad of studies have sought to identify the 
combination of transcription factors for optimal reprogramming, with a variation of 
conclusions. As few as two factors (Sox and Oct) have been claimed to be sufficient 
for reprogramming in some cases (Rizzino et al., 2009). The 'Okita combination’ 
was decided upon as this report has influenced a large number of studies since its 
high impact publication. As expected, low efficiency of reprogramming was reported 
in all cell lines. It was marginally higher for cord blood-derived late endothelial 
outgrowth cells in comparison to fibroblasts. Though reprogramming efficiencies 
were low, this is a common finding in the field, indicating the complexity of the 
molecular changes which occur during the reprogramming process. All derived iPS 
cells were found to express cell surface pluripotency markers SSEA3 and SSEA4; 
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colonies were also stained positive for Oct3, Nanog and Sox2. As a test of true 
pluripotency, they could spontaneously differentiate into derivatives of all three 
primary germ layers, and at later passages were found to be mostly free from 
exogenous episomal plasmids. As previously reported, these are only required to 
induce pluripotency, not maintain it (Okita et al., 2011). Nuclear reprogramming was, 
however, unsuccessful in endothelial cells derived from peripheral blood or from 
vascular biopsies. This was unexpected, as there are reports in the literature that 
endothelial cells derived from blood can be reprogrammed, often with higher 
efficiencies than fibroblasts (Geti et al., 2012). The inability to reprogram peripheral 
blood EOCs, in comparison to cord blood-EOCs may indicate innate differences 
between the two cells types. Faster cell kinetics are associated with cord blood 
derived EOCs, and they typically survive a greater number of population doublings 
in culture (Ingram et al. 2004). It is possible that these characteristics render them 
more amenable to reprogramming than peripheral blood EOCs.   
 
Despite claims that episomal plasmids are the optimal vector for delivery of the 
transcription factors required for reprogramming (Hu, 2014), alternative methods of 
reprogramming endothelial cells from adult/peripheral blood and vasculature could 
be investigated in further experiments. For example, Warren et al. (2010) report 
relatively high efficiency of reprogramming (4.4%) using a synthetic mRNA cocktail 
containing Oct3/4, Sox2, Klf4, cMyc and Lin28, in the reprogramming of fibroblasts 
and keratinocytes. This is amongst the highest reprogramming efficiencies reported 
in the literature, so may be an interesting alternative to explore in the reprogramming 
of peripheral blood-derived endothelial cells.   
Though more replicates of these cellular reprogramming experiments are required to 
confirm the findings presented in this chapter, this work suggests that endothelial 
outgrowth cells from healthy cord blood reprogram with marginally greater 
efficiency than those from healthy peripheral blood or fibroblasts. Though it is 
unclear if this phenomenon is due to their progenitor or endothelial phenotype; it is 
likely that it may be the result of their progenitor cell type, as it has been reported 
that progenitor cells may be more amenable to reprogramming than mature cells 
(Eminli et al., 2008; Giorgetti et al., 2009). The fact that the more mature endothelial 
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cell types (derived from adult peripheral blood and vasculature) did not successfully 
reprogram supports this argument, that ‘younger’ endothelial cells derived from cord 
blood, which haven’t had time to accumulate DNA mutations (Bauman, 2009), are 
more easily reprogrammed.  
It is unfortunate that endothelial cells from sources other than cord blood were not 
reprogrammed, as this would be the ideal source for the routine generation of iPS 
cells of patients, a strategy for their study in vitro envisioned for the future. A simple 
blood sample is more easily obtained than a skin biopsy (from which fibroblasts are 
obtained), and not many people have cord blood stored. However, the relatively 
higher efficiency of reprogramming of endothelial cells derived from cord blood 
offers opportunities to study the properties of endothelial-derived iPS cells.  
 
6.2. Pro-angiogenic endothelial cells can be differentiated from human 
embryonic and induced pluripotent stem cells  
 
Endothelial differentiation from human embryonic and induced pluripotent stem cells 
is challenging with consistently low yields of functional endothelial cells generated 
from a range of differentiation protocols. Protocols which involved a 2D monolayer 
differentiation system with ‘differentiation medium’ did not yield big enough 
populations of cells expressing endothelial cell markers which were feasible for 
further culture following sorting. Despite reports of VEGF addition to differentiation 
media significantly enhancing CD31 expression (Ferreira et al., 2007), this did not 
enhance differentiation efficiency. The most efficient method of endothelial 
differentiation was a 3-dimensional embryoid body system, in which stem cell 
aggregates were exposed to a series of mesoderm-inducing cytokines and growth 
factors- members of the Wnt, TGF-beta and FGF families. Though the molecular 
mechanisms that control endothelial differentiation during embryogenesis are not 
completely understood, certain signalling pathways & their cytokines have been 
elucidated. The BMP and Wnt signal transduction pathways are known mediators of 
endothelial differentiation and function, interacting in such a way to target 
endothelial-specific genes for the induction of angiogenesis in vivo (La Bras et al., 
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2010). Extensive optimisation of the cytokines used in this endothelial differentiation 
protocol was carried out on ES cell lines H1 and H9 by the Univeristy of Glasgow. 
The ES and iPS cell lines used in these studies were indistinguishable in terms of 
their pluripotent characteristics, thus it was assumed that a protocol optimised for ES 
cells would work in a similar way for iPS cells. This was found to be the case. Upon 
disaggregation of the embryoid bodies and further culture, distinct populations of 
CD31+ cells were isolated from both ES and iPS differentiating populations. These 
appeared to have many similar features to control endothelial cell lines, ascertained 
through immunophenotyping experiments. In addition, the functions of these cells 
were investigated in vitro, which indicated that their angiogenic, proliferative and 
migratory properties were comparable to endothelial control lines. However, the 
stem cell derived endothelial cells differed from controls in a murine model of 
vascularisation in vivo, where they appeared pro-angiogenic. Whilst they increased 
vessel density, they did not incorporate into murine vasculature, suggesting that they 
are stimulating angiogenic processes through paracrine mechanisms. The 
morphological, phenotypic and functional endothelial characteristics of all stem cell 
derived CD31+ cells confirm that endothelial differentiation through this embryoid-
body protocol is successful, despite low efficiencies. The pro-angiogenic properties 
of these derived cells in vivo is an exciting finding, and it would be interesting to 
investigate further the mechanisms by which they appear to increase vessel density. 
In the future, this differentiation protocol could be applied for the study of 
endothelial cells from patient populations to elucidate mechanisms of endothelial 
dysfunction.  
 
There is not a great distinction between the phenotypes of progenitor and mature 
endothelial cell types. Indeed, the definition of an ‘endothelial progenitor cell’ is not 
clear, and whilst phenotypes have been suggested, there remains uncertainty 
regarding the identity and source of these cells (Ingram et al., 2005). Experiments 
within the laboratory (Tura et al., 2013) indicate that endothelial outgrowth cells 
from blood have very similar properties to human umbilical vein endothelial cells, a 
cell line widely used in cell culture research. However it is unclear if these cell types 
are inherently the same, or if their similar properties are a consequence of the 
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uniformity of cell culture conditions. The endothelium is widespread throughout the 
body, due to its functions which are fundamental to the survival of all tissues and 
organs. These functions vary to some extent depending on location and local tissue-
specific requirements, therefore subsets of endothelial cells vary slightly in 
phenotype. For example, fenestrated endothelium (containing pores 60-80nm in 
diameter) lines capillaries of organs that are involved in filtration or secretion of 
small molecules and proteins, such as the kidney (Satchell and Braet, 2009). In 
comparison, an uninterrupted lining is provided by a continuous layer of endothelial 
cells in arteries and veins; here the cells are held together by tight junctions which 
only allow diffusion of smaller molecules (Aird, 2007). However, the source of 
endothelial cell line is not often taken into account in their culture, with most 
laboratories often culturing endothelial cells in endothelial growth medium, or 
endothelial medium, as in this thesis. Whilst cells in culture are kept in physiological 
conditions in terms of temperature and gaseous exposure, in the absence of their 
physiological micro-environment and exposure to biochemical and mechanical 
stimuli, the characteristics which define sub-sets of endothelial cells may be altered 
or lost. This is an issue which must be considered in general when working with cells 
in culture. Therefore, though HUVEC and EOC provide a standard endothelial cell 
control, they may not completely represent endothelial cells in physiological 
conditions, as the subtleties in different phenotypes that exist between different 
endothelial populations may be lost in cell culture. Though this is a limitation of the 
system of cell culture itself, further experiments could look into the differentiation of 
specific types of endothelial cell. Rufaihah et al. (2013) demonstrate that endothelial 
cells derived from an embryoid body based differentiation protocol and purified 
based on their expression of CD31 can be differentiated to arterial endothelial cells 
when supplemented with 8-bromoadenosine-3’:5’-cyclic monophosphate sodium salt 
(8Br-cAMP); whereas without this supplement venous endothelial cells are derived 
(Rufaihah et al., 2013). In the presence of 8Br-cAMP higher levels of Ephrin B2 
were expressed, typical of arterial endothelial cells and involved in arteriogenesis 
(Korff et al., 2008). This heterogeneity may be something to consider for the 
refinement of the differentiation protocol in the future.  
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Exposure to shear stress is likely to more effectively mimic physiological conditions, 
and may increase efficiency of differentiation (Yamamoto et al., 2005). Reports 
indicate that cell culture of ES cells in standard ‘differentiation medium’ under shear 
stress (generated by fluid flow) induces expression of vascular endothelial cell 
markers VEGFR2, VE-cadherin and CD31 (Yamamoto et al., 2005). This was 
significantly greater than expression in cells in static conditions. Furthermore, shear 
stress-exposed cells were able to form tube-like structures in collagen gel at a faster 
rate than cells not exposed to shear stress.  The apparatus to study this was being 
established as this PhD work was coming to an end, so would be interesting to 
investigate in the near future.  
The most recognisable difference between stem cell derived endothelial cells and 
endothelial cell controls was their performance in the in vivo subcutaneous sponge 
assay, designed to assess the angiogenic effects of implanted cells. Upon 
quantification of this assay, it was found that implanted EC-ES and EC-iPS enhanced 
murine vessel density, whilst EOC or EOC conditioned media did not. Although 
stem cell derived endothelial cells did not incorporate into the neovasculature, the 
increase in vessel density suggests that they may be releasing factors to influence 
angiogenesis or vasculogenesis in a paracrine manner.  
 
6.3. Pro-angiogenic endothelial cells are generated more efficiently from 
iPS cells which derived from endothelial cells rather than fibroblasts 
Low efficiencies of endothelial differentiation from ES and fibroblast-derived iPS 
cells are overcome when carried out in iPS cells generated from late endothelial 
outgrowth cells: efficiency increases to 20.8%. This suggests that whilst different 
types of stem cell line can appear to be fully pluripotent, there may be underlying 
differences that cause differentiation bias: the propensity to differentiate towards a 
particular cell type. The mechanisms that underpin this phenomenon require 
elucidation; from comparison with other studies of iPS cell differentiation it appears 
likely that it is the result of residual epigenetic memory.  
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Being able to generate large numbers of cells in a short space of time (from efficient 
endothelial differentiation) means that cells are not in culture as long before use in 
analysis experiments or before cellular therapies. There are limitations of having to 
expand cells in culture: significant changes can occur such as alterations of activated 
state, karyotype, expression of cell surface antigens and growth kinetics (Staton et al., 
2004). Over time, endothelial cells become quiescent and senesce after a number of 
population doublings (for example, HUVEC can be kept in culture for up to 10 
passages). The generation of large numbers of endothelial cells from endothelial-
derived iPS cells will therefore shorten the time in culture required to expand the 
population to a reasonable size for analysis and in the future, therapeutic use. 
It would be interesting to determine if endothelial-derived iPS cells also efficiently 
differentiate into other mesodermal or cardiovascular lineages. Similarly, if their 
differentiation to cells types of other lineages (ectoderm and endoderm) is less 
efficient.  
 
6.4. Future directions 
 
6.4.1. Reproducibility 
Additional experiments would help confirm the reproducibility of the findings and 
conclusions suggested in this thesis. The reprogramming work would benefit from 
being reproduced in different cell types from one individual, to confirm or deny the 
suggestion that iPS cells are most efficiently generated from EOC from cord blood, 
over those from other sources, and over fibroblasts. This would give insight into the 
influence of genetic background on reprogramming efficiency.  
 
6.4.2. Epigenetics 
It will be important to elucidate the proposed epigenetic mechanisms that underpin 
the enhanced endothelial differentiation of eiPS over fiPS, to more fully understand 
the variations in reprogramming and differentiation that occur between different 
somatic cell types. DNA microarrays could be used to study gene expression and 
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chromatin structure of the cells at each stage of the process: before reprogramming, 
once they are iPS cells and once they are differentiated. Sample cDNA strands, 
stained with fluorescent nucleotides hybridise to synthetic DNA on a microarray 
plate, which have known sequences. From this, fluorescent dots correspond to the 
specific DNA sequences, from which the sample DNA can be sequenced. Methylated 
DNA immunoprecipitation can also give insight into the chromatin structure of the 
sample, by isolating and enriching methylated DNA sequences. These DNA 
sequences are then purified and correspond to methylated genes..If it were found to 
be the case that certain endothelial phenotype-associated genes remain active 
throughout the process, predisposing them to endothelial differentiation, it would be 
interesting to repeat differentiation with later passage eiPS. There are reports that 
extended passaging of iPS cells may ameliorate the effect of epigenetic memory 
(Chin et al., 2009), likely because pluripotency may be detected before complete 
resetting of the epigenome. In fact, Chin et al. (2009) describe differences between 
the gene expression profiles of early passage iPS cells and ES cells. ES signature 
genes were found to be expressed at lower levels in early passage iPS cells, but 
increase over time in culture to match ES cell levels.   
 
6.4.3. Patient studies 
The use of personalised iPS cell technology opens many avenues of research, for 
example the elucidation of causative mutations and the modelling of disease 
processes. The work presented in this thesis provides the foundation for the 
generation of iPS cells from patients with premature atherosclerosis due to a 
suspected hereditary component. As multiple genes could be the cause of 
atherosclerosis, iPS cell technology lends itself to a personalised approach for the 
study of endothelial dysfunction mechanisms, which could vary patient to patient. In 
the absence of typical environmental risk factors, it can be difficult to ascertain the 
cause of the disease in these patients due to the complex nature of the condition and 
multiple candidate genes. In a subpopulation of these patients, endothelial 
dysfunction may be predisposing them to the condition, decreasing the ability of their 
vessels to repair and regenerate following injury. Endothelial dysfunction is well 
established as one of the earliest events in the pathogenesis of atherosclerosis 
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(Davignon, 2004). iPS cells derived from premature atherosclerosis patients would 
provide novel opportunities for the study of disease mechanisms. Patient endothelial-
iPS could be compared to healthy age matched controls, to ascertain any differences 
in functionality. For example, wound healing ability, cytokinetic response to 
angiogenic factors or ability to align to shear stress could be tested.  
 
If a patients’ atherosclerosis has a hereditary component, this will likely be 
transferred to their iPS cells and derivatives. Envisioned for the future is the large 
scale, long term storage of patient specific iPS cells which could be genetically 
corrected, differentiated to endothelial cells and administered back to the patient to 
assist in the repair and regeneration of damaged endothelium. The use of iPS-
endotheilal cells in tissue engineering could be investigated as a therapeutic 
application. For example, experiments have shown that microvessels can be 
generated from the seeding of endothelial progenitor cells on biodegradable scaffolds 
(Wu et al., 2004). This group discovered that in combination with smooth muscle 
cells, seeding of endothelial progenitor cells formed capillary like structures 
throughout a biopolymeric construct. Though tissue engineering is beyond the scope 
of this thesis, this is an interesting concept for consideration of the use of iPS-derived 
endothelial cells for future experiments.     
 
These cells could also be used for the modelling of disease pathways and for the 
screening of novel therapeutics. The next step towards the translation of these cells to 
the clinic would be to make the reprogramming and differentiation processes Good 
Manufacturing Practise (GMP)-standard, by removing and replacing animal and non-
human products with synthetic alternatives. This would avoid potential immune 







The benefits of stem cell technology for the study of endothelial cell function are 
gradually being realised. Endothelial differentiation from embryonic and induced 
pluripotent stem cells is challenging, however, a distinct population of cells with 
endothelial properties can be generated from a differentiation protocol involving 
embryoid body formation in media containing mesoderm-inducing cytokines. 
Resulting endothelial cells were found to highly express CD31, CD146, CD105, 
vWF, and eNOS, demonstrated angiogenic capacity in vitro and recovered from a 
scratch assay in a similar way to endothelial cell controls. Low differentiation 
efficiencies found in both ES and iPS differentiation to an endothelial phenotype 
can be enhanced by using induced pluripotent stem cells derived from somatic 
cells of an endothelial lineage. The mechanisms that underpin this are unclear but 
it seems likely that whilst these cells can be reprogrammed to pluripotency, and 
have similar characteristics to ES cells, they may retain epigenetic factors that 
increase endothelial differentiation efficiency. Endothelial cells derived from 
both fibroblasts and endothelial sourced iPS cells promote angiogenesis in vivo, 
observed through increased vessel density of subcutaneous sponges in the murine 
model of vasculogenesis. These cells do not, however, incorporate into murine 
vasculature, unlike early passage endothelial cell controls. It is likely therefore, 
that stem cell derived endothelial cells act to increase vessel density through 
paracrine mechanisms. I propose that an endothelial-based iPS cell is the ideal 
source for the generation of endothelial cells for disease modelling and possibly 
vascular regenerative therapies in the future. It is hoped that applying iPS cell 
technology to the study of endothelial cells from patients with premature 
atherosclerosis will clarify the molecular mechanisms of endothelial dysfunction 
in its pathogenesis. iPS-derived endothelial cells have major potential for future 
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Appendix Figure 1: Complete genomic data set following SNP array of fiPS; one 





Appendix Figure 2: Complete genomic data set following SNP array of eiPS; 
normal karyotype.  
